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Summary
Porcine congenital splayleg (PCS) is the most important congenital condition of 
piglets, associated with lameness and immobility, of unknown aetiology and 
pathogenesis. The aim of this study is to investigate the cellular and molecular 
changes in skeletal muscles of PCS, thereby gaining new molecular insights into this 
clinical condition.
Based on immunohistochemistry and histological image analyses on 4 sets of 2-day- 
old splayleg piglets, each with a corresponding normal litter mate, a consistent 
discovery has been that PCS muscles [semitendinosus (ST), longissimiis dorsi (LD) 
and gastrocnemius (G)] showed extensive fibre atrophy without apparent tissue 
damage. At present, it is not certain if PCS-associated fibre atrophy is accompanied 
by fibre hypoplasia. Both normal and PCS muscle fibres showed similar widespread 
distribution of lipid- and oxidative-positive fibres. Although there was no significant 
difference in fibre type composition, several structural myosin heavy chain (MyHC) 
genes were significantly down-regulated in PCS affected muscles. Interestingly, 
MAFbx, a major atrophy marker, was highly up-regulated in almost all PCS muscles, 
when compared with controls from normal litter mates. In contrast, P311, a novel 8- 
kDa protein, was relatively down-regulated in all PCS muscles examined.
To further investigate the functional role o f P311 in skeletal muscle, its full-length 
cDNA was sequenced (Accession. N-. EF416570) and over-expressed in murine 
C2C12 muscle cells. P311 over-expression enhanced cell proliferation and reduced 
myotube formation in C2C12 cells. The over-expression of calcineurin, a key 
intracellular calcium-dependent signalling factor of muscle differentiation, down-
regulated P3Î1 expression. Reduced P311 expression in PCS piglets might contribute 
to atrophy through reduced myotube contribution.
To investigate the functional role of SPARCL~1, a matricellular secreted glycoprotein 
that belongs to SPARC family, its full-length cDNA was sequenced (Accession. N-. 
EF416571) and over-expressed in murine C2C12 muscle cells. SPARCL-1 over­
expression led to reduced cell proliferation and down-regulation of MyHC genes 
during late differentiation. SPARCL-1 might be associated as a negative regulator of 
skeletal muscle cell proliferation and cell differentiation. However, endogenous 
SPARCL-1 expression was similar between PCS and normal muscles. Hence, 
although SPARCL-1 could play a role in muscle development, it is unlikely to be a 
main factor in the development of PCS.
In summary, PCS is shown to be a condition characterised by extensive fibre atrophy 
and raised fibre density, and it is proposed that the combined differential expression 
of MAFbx and P311 is of potential value in the diagnosis of sub-clinical PCS.
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Chapter 1
Literature review
17
Preweaning mortality in piglets constitutes a major loss to the pig industry. The Meat 
and Livestock Commission, UK (2003) reported a preweaning mortality rate for 
liveborn piglets of 12.2% in indoor herds and 9.9% in outdoor herds (Cutler et al., 
2006). Congenital abnormalities account for a small but significant proportion of 
preweaning losses (Partlow et al., 1993). They have been reported more frequently in 
pigs than in any other domestic animal species (Priester et al., 1970). A number of 
abnormalities may be seen in newborn piglets or shortly after birth. Briefly, 
congenital conditions can be categorised as: (1) spontaneous developmental 
abnormalities, such as cystic lymph nodes, (2) heritable abnormalities such as 
congenital meningoencephalocoele, atresia ani, arthrogryposis, porcine congenital 
splayleg, (3) infectious agents such as congenital tremor type AI (myoclonia 
congenita), (4) nutritional deficiency or poisoning such as mulberry heart disease and 
(5) unknown causes such as bleeding navel syndrome (Taylor, 2006).
Cystic lymph nodes ean occur in ileal mesenteric lymph nodes, caecocolic lymph 
nodes and colonic lymph nodes and measure up to 2 cm in diameter. Congenital 
meningoencephalocoele, also known as cranioschisis is a heritable abnormality. 
Affected pigs have exposed meninges protruding through incomplete fusion of 
parietal or frontal bones and the mortality rate is high (Wijeratne et al., 1974). Atresia 
ani is a common condition in which the rectum fails to open to the exterior. A thin 
membrane or a band of fibrous tissue may be present at the anal opening. Male pigs 
usually have swollen abdomens and die within 3 weeks of birth, but in females the 
reetum may open into the vagina and the animals suivive in 50% of cases. 
Arthrogryposis is a condition of joints and/or limbs being fused together, affected 
piglets normally die after birth. Arthrogryposis is caused by arthrogryposis multiplex
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congenita {amc) recessive gene (Lomo, 1985). Porcine congenital splayleg is a 
clinical condition of newborn piglets, characterised by muscle weakness, resulting in 
inability to properly stand and walk (Thurley et al., 1967). Congenital tremor Type 
AI (myoclonia congenita) results from infection of the sow by classical swine fever 
(hog eholera) virus. Affected piglets show various degrees of muscular tremor, ataxia 
and inability to stand and suck (Harding et al., 1966). Mulberry heart disease is a 
syndrome related to vitamin E and selenium deficiency. Affected piglets have acute 
heart failm-e and sudden death may occur (Mortimer, 1983). The cause of bleeding 
navel syndrome is unknown. Affected piglets bleed to death as a result of failed 
closure of the umbilicus. Attendance at farrowings and ligation of the umbilical cord 
can reduce the mortality. Feeding of aseorbic acid to the sow also has been shown to 
prevent the syndrome (Sandholm et al., 1979).
1.1. Porcine congenital splayleg
Porcine congenital splayleg (PCS), also known as straddlers or myofibrillar 
hypoplasia (reduced numbers of myofibrils), is a clinical disease of newborn piglets. 
It is arguably the most important congenital defect of newborn piglets and causes 
significant economic impact to the industry. PCS is the inability of newborn pigs to 
stand and walk properly, often with their limbs extending forwards or sideways as a 
result of muscular weakness (Thurley et al., 1967).
In 1967, the clinical term was first reported by Thurley et al. (1967). Sinee then, 
reports from different countries regarding congenital splayleg were published 
(Dobson, 1968; Cunha, 1968; Olson and Prange, 1968; Bollwahn and Pfeiffer, 1969;
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Lax, 1971; Svendsen and Andereasson, 1980). Reports on the prevalence vary 
considerably. In the United Kingdom, Ward and Bradley (1980) estimated that about 
0.4% piglets were affected by splayleg, which caused an annual loss of £300,000 to 
the pig industry at that time. In another two studies by Dobson (1968, 1971), the 
overall average prevalence rates were reported at 11% and 13% respectively. A 
further study in Ontario indicated that PCS was the most common congenital defect 
with 0.87% piglets affected (Partlow et al., 1993).
1,1.1 Clinical signs
PCS can be found at or a few hours after birth. At birth, 2 to 3 piglets may be affected 
in each litter. It invariably affects the hindlimbs, but occasionally affects the 
forelimbs. Most of the affected piglets are unable to move around or stand, although 
some splayleg pigs may able to move around with difficulty. The affected limbs are 
abducted, splayed forward or in sideways position. Often, an affected piglet is found 
seated on its hindquarters (Fig. 1.1).
An affected piglet is often separate from its healthy litter mates. Its immobility means 
that it cannot gain sufficient nutrients from the sow, resulting in staiwation and 
hypothermia. Affected neonatal pigs become emaciated, weak and dirty. Abrasions 
and ulceration develop on the body due to long periods of lying on the floor. Splayleg 
pigs are more predisposed to arthritis, polyarthritis, pododermatitis and osteomyelitis 
of the digits due to secondary bacterial infections. The mortality rate of splayleg 
piglets can reach around 50%. The cause of death is either starvation or crushing by
20
the sow. However, if  supportive treatment and extra care can be provided, the 
affected piglet can recover after one week.
Figure 1.1. Porcine congenital splayleg. A 2-day-old piglet with PCS showing 
forward extension and abduction of hindlimbs as a consequence of muscle weakness.
1.1.2. Prevalence and incidence
The condition is particularly prevalent in Landrace and Large White breeds, which are 
heavily muscled (Dobson, 1968; Tomko, 1993; Vogt et al., 1984), although it is 
known to occur in virtually all commercial lines. Both male and female piglets are 
susceptible to PCS (Tomko, 1993; Thurley et al., 1967), however, some studies 
indicate that male offspring are more susceptible. In one o f the studies, male progeny 
are 1.74 times more likely than females to succumb to PCS (Vogt et al., 1984). 
Another study showed that about twice as many males were affected as females (Van
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Der Heyde et al., 1989). Presently, it is not clear whether PCS is related to birth 
weight or litter size. One study found that PCS occurs more frequently in large litters 
than in smaller ones (Van Der Heyde et al., 1989). However, another study suggested 
that the oceurrence of splayleg was significantly higher in small litters (Tomko, 1993).
1.1.3. Pathogenesis of PCS
The aetiology and pathogenesis of PCS are not known. It is considered to be a 
multifactorial condition. The factors that are involved are thought to include genetic 
and environmental factors like sow management, administration of various drugs and 
mycotoxins.
Treatment o f pregnant sows with glucocorticoids can induce a myopathy in the 
newborn which mimics PCS (Jirmanova, 1983). However, there were histological 
differences in muscle from glucocorticoid induced and naturally occurring PCS 
(Ducatelle et al., 1986). Dexamethasone is a synthetic glucocorticoid used primarily 
as an anti-inflammatory agent in various conditions, including allergic states. More 
recently, it was suggested that affected muscles have a reduced number of myofibrils 
and an increased aceumulation of glycogen when compared with the muscles of 
normal piglets. The investigation had concentrated on the activity of glucose-6- 
phosphatase (G-6-Pase), a liver enzyme that breaks down glycogen reserves 
(Antalikova et al., 1996). Another study suggested that the slippery floor in farrowing 
crates could predispose newborns to PCS problems (Dobson, 1971). However, this 
environmental factor is not likely to be a causal factor of splayleg (Van Der Heyde et 
al., 1989). Choline is a vitamin like compound which is essential for acetylcholine
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synthesis. Supplementation with 2.2 to 3.0 g of choline in the diet of pregnant sow 
until parturition was reported to reduce the incidence of PCS (Cunha, 1968). 
However, a subsequent study could not reproduce this finding (Dobson, 1971).
Consumption offusarium  F-2 toxin (zearalenone) contaminated grain by sows in late 
pregnancy, could lead to a higher incidence of PCS, a condition that can be 
experimentally reproduced by the administration of purified F-2 toxin to pregnant 
sows (Miller et al., 1973). Increased stillbirths and neonatal mortality were also 
recorded. However, F-2 induced PCS piglets did not show the typical 
histopathological lesions described by Thurley et al (1967).
Misuse of certain drugs in pregnant sows may lead to signs of PCS in newborn piglets. 
Administration of 3.6 mg/kg/day of pyrimethamine, an anthelmintic, to pregnant 
Goettingen minipigs raised the incidence of PCS to 74% of the newborn, while the 
control group had only an incidence of 5.6% (Ohnishi et al., 1989). Induction by 
prostaglandin before the 113^ *’ day of pregnancy could also lead to higher incidence of 
congenital myofibrillar hypoplasia (Bolcskei et a l, 1996).
1.1.4. Histopathology of PCS
A variety of lesions have been described as the underlying pathological changes in 
congenital splayleg. The most consistent change is the presence of so-called 
myofibrillar hypoplasia (MFH), interpreted as an immaturity of the muscle (Ducatelle 
et al., 1986; Thurley et a l, 1967). Myofibrillar hypoplasia ranges from a slight 
reduction of myofibrillar content to severe myofibrillar deficiency, vacuolisation,
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focal degeneration and necrosis. However, myofibrillar hypoplasia can also be found 
in clinically normal piglets. The term congenital myofibrillar hypoplasia may not 
therefore be the diagnostic description of PCS (Ducatelle et ah, 1986).
As pointed out earlier, the morphological findings of dexamethasone treatment 
suggest that PCS might represent a congenital form of glucocorticoid myopathy 
(Ducatelle et al., 1986). Another study on muscle ultrastructure of PCS piglet, also 
showed reduced numbers of myofibrils and an increase in glycogen accumulation in 
comparison with muscle of normal piglets (Antalikova et al., 1996). Other studies 
found differences between PCS piglets and piglets with experimentally-induced 
glucocorticoid myopathy. Naturally occurring PCS had glycogen-filled 
extramyofibrillar space (EMS), whereas dexamethasone splayleg had only limited 
glycogen in the EMS (Ducatelle et al., 1986).
There were no significant qualitative differences between normal pigs and splayleg 
pigs aged from birth to 1 week, hased on light microscopic and ultrastructural 
examinations (Bradley et al., 1980; Ward and Bradley, 1980). The progressive 
clinical improvement in splayleg during the first week of life was found to be 
accompanied by an increase in muscle cell size, a reduction in the number of nuclei, a 
reduction in the severity of MFH, a reduction in the size of the extra-myofibrillar 
space and an increase in intracellular lipid. However similar changes were also found 
in normal pigs. The results indicated that light microscopy or ultrastructural 
morphology were not useful to diagnose splayleg due to the failure to detect any 
significant differences (Ward and Bradley, 1980). However, both studies took the
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form of visual subjective assessments. Quantitative measurements were not 
performed.
Generally, hypoplasia refers to underdevelopment of an organ because of a decrease 
in the numbers. In contrast, atrophy refers to a decrease in the size of an organ caused 
by disease or disuse. There are uncertainties about the histopathology of PCS. To 
date, it is not clear if clinical splayleg is involved reduction of fibre size (atrophy), 
number (hypoplasia) or both. In addition, few histochemical and/or biochemical 
parameters have been detected which are unequivocally associated with congenital 
splayleg. Therefore, further detailed study is required to accurately characterise the 
cellular features of PCS. With recent advances in imaging technology, morphological 
analysis of PCS can now be carried out with greater accuracy. This could add 
valuable information to our understanding of the pathogenesis of the disease.
1.1.5. Control and treatment of PCS
Given the uncertain aetiology and pathogenesis of PCS, it is difficult to reduce its 
incidence. From the husbandry viewpoint, a dry and non-slippery floor should be 
provided for farrowing. In addition, neonatal piglets should be protected from injury 
by the sow, and provided with adequate opportunities to suckle. These could reduce 
the incidence or the severity of PCS. Selection of breeding stock may help to control 
the disease. Good farm breeding records can help to identify individuals that are 
predisposed to the production of affected offspring. In addition, affected piglets that 
recover should not be used for breeding. With supportive care, adequate warmth and 
nutrition, affected piglets can recover from the condition. However, nursing is labour
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consuming and may not be economical as a routine in herd health management. The 
common treatment method used is tying together the affected limbs, with a loose 
“figure of 8” just above the hock joint. It appears to help the piglet to recover and 
gain the ability to move around. Adhesive tape can be used to tie affected legs but 
care must be exercised to avoid occlusion of blood flow.
1.2. An overview of muscle fibres
PCS is a disease condition that is closely related to muscle weakness, which leads to 
lameness and immobility. Hence, it is essential to have some understanding of the 
basic biology of fibre types, their properties and distribution in skeletal muscle. In 
addition, to investigate PCS it is necessary to evaluate the condition in the context of 
molecular mechanisms, which could involve the processes of muscle hypertrophy or 
atrophy.
Each muscle fibre is formed by the fusion of a number of undifferentiated myoblasts 
into a single cylindrical, multinucleated cell. Both skeletal and cardiac muscles are 
striated muscles. The term striated muscle is derived from its feature of light and dark 
bands perpendicular to the long axis of the fibre when examined under light 
microscopy.
This banding pattern is derived from the overlap of thick and thin filaments into 
cylindrical bundles known as myofibrils. The thick and thin filaments are arranged in 
repeating patterns, one unit of this repeating pattern is known as a sarcomere (Fig. 1.2). 
The thick filaments are located in the middle of each sarcomere, where their orderly
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parallel arrangement produces a wide, dark band (A band). Each sarcomere contains 
two sets of thin filaments, one at each end anchored to a network of intercoimecting 
protein known as the Z line. The thick filaments are principally composed of the 
contractile protein myosin, while the thin filaments contain the contractile protein 
actin. During contraction, cross-bridges are formed between these myosin and actin 
filaments in a cyclical, ATP-dependent manner. The thin filaments are drawn in over 
the thick filaments, resulting in a shortening of the sarcomere and the generation of 
force.
The thin filaments also contain troponin and tropomyosin proteins, which play 
important roles in regulating contraction. Tropomyosins are rod-shape molecules, 
which are arranged end to end to form a chain along the thin actin filament. It 
partially covers the myosin-binding site, thereby preventing cross-bridge formation. 
Each tropomyosin is held in this position by a troponin complex. When calcium 
binds to specific binding sites on troponin, tropomyosin is dragged away from the 
myosin binding site which allows cross-bridge formation to take place.
27
Muscle fiber
n r :
Myofibril
Myofibnl
I band A band
Z line Z line
Sarcomere
Z line Z line
■ ■ ■ I
### n il
* * # ,# # # ;
n i l  I I
M'i l ■ ■
Cross bridge
# t i l l ■ I
t  ■ I
• ■ ■ I I I 
11 I I I I
Thick (myosin) filament Thin (actin) filament
Figure 1.2. Arrangement o f filam ents In a skeletal muscle m yofibril that produces the 
striated banding pattern. (Adapted from Vender et al, 2001, Human Physiology; the 
mechanism of body function, edition)
1.2.1. Muscle fibres types
All skeletal muscle fibres do not have the same mechanical and metabolic 
characteristics (Pette and Staron, 1990). Generally, fibre types are identified based on 
two specific characters: (1) fast or slow fibre (2) oxidative or/and glycolytic fibre.
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Fast and slow fibres are classified according to their ability to split adenosine 
triphosphate (ATP). Fast fibres possess myosin that hydrolyses ATP rapidly, and thus 
have a faster cross-link cycle and greater velocities and power output. The downside 
of this is in the increased demand for ATP and rapid onset of muscle fatigue. In 
contrast, slow fibres have a lower velocity of contraction and a lower power output 
but are fatigue resistant. As a result, it is more economical in ATP usage and capable 
of sustaining isometric force for a longer period of time.
Another way of determining skeletal muscle fibres is based on the type of enzymatic 
machinery available for synthesizing ATP. Oxidative fibres are characterised by their 
large lipid storage, numerous mitochondria and high oxidative enzyme content 
(Goldspink, 1996). Normally, oxidative fibres are surrounded by small blood vessels 
and contain large amounts of myoglobin. These features give the fibres a dark-red 
colour, and thus oxidative fibres are also known as red muscle fibres.
In contrast, glycolytic fibres contain high concentrations of glycolytic enzymes, 
relatively large storage of glycogen, few mitochondria, less myoglobin and low 
capillary density. These features impart a pale appearance to these fibres, which are 
also known as white muscle fibres. Oxidative metabolism is limited by the 
requirement for adequate perfusion of oxygen and nutrient from blood circulation. 
Glycolytic fibres generally have much large diameters than oxidative fibres, and 
generate greater strength. Oxidative metabolism is tailored for low intensity activity; 
it is less useful for high intensity exercise due to the limitation of oxygen and blood 
supply. Therefore, as the force requirement increases, glycolytic metabolism will he 
recruited for the generation of necessary strength and power (Goldspink, 1996).
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Based on the characteristics of (1) fast or slow fibre, and (2) oxidative or/and 
glycolytic fibre, skeletal muscle fibres can be distinguished into three major types, 
which are slow-oxidative (SO), fast oxidative-glycolytic (FOG), and fast-glycolytic 
(FG) (Brooke and Kaiser, 1970; Handel and Stickland, 1987).
1.2.2. Myosin heavy chain
Myosin is hoth a structural and regulatory protein, comprising about 25% of the total 
protein pool in striated muscle cells (Pette and Staron, 2000). It forms the backbone 
of contractile machinery and serves as the motor that drives muscular activity 
(Baldwin and Haddad, 2002). Myosin is a hexameric protein composed of myosin 
heavy chain (MyHC) and myosin light chain (MyLC). It is the MyHC component 
that is of most interest when considering muscle fibre type, since these proteins 
mediate both the myosin motor function and filament formation. Each MyHC is 
made up of two functional domains, a globular head domain subfragment 1 (SI) 
proteolysis fraction, and a long helical rod domain subfragment 2 (S2) and light 
meromyosin (LMM) proteolysis fractions (Fig. 1.3). Both SI and S2 are grouped as 
heavy meromyosin (HMM). The globular head SI contains the actin binding domain 
and ATPase, while the rod domain is required for filament formation.
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Figure 1.3. Myosin heavy chain d im er w ith  bound myosin ligh t chain. The HMM portion 
can divided into the S1 and S2 fragment. The shaded SI proteolytic fragment/myosin head 
domain contains the actin binding and ATPase sites. S2 and LMM proteolytic fragments both 
correspond to the alpha helical coiled rod domain. (Modified from W eiss and Leinwand, 
1996). 81= subfragment 1; 82= subfragment 2; LMM= light meromyosin; HMM= heavy 
meromyosin.
MyHCs are encoded by a highly conserved multi-gene family. To date, there are 
eight known MyHC isoforms expressed in mammalian muscle. These are the (1) 
embryonic, (2) perinatal, (3) I/slow/p, (4) 2a, (5) 2x, (6) 2b, (7) a, and (8) extra-ocular 
or mandibular or masticatory MyHCs (Baldwin and Haddad, 2001). The properties of 
actin binding, ATPase activity and the speed of filament cross-linking, are unique to 
each MyHC isoform. Recently, some researchers categorised MyHC 2x as MyHC 2c 
based on immunohistochemistry staining (Sutherland et al., 2006).
During the foetal and embryonic stage, the MyHC embryonic, MyHC perinatal and 
MyHC I/slow/p are the three isoforms that predominantly expressed. Shortly after 
birth, the MyHC I/slow/p, MyHC 2a and MyHC 2x isoforms are most important in 
post-natal skeletal muscle. MyHC 2b is expressed in the fast fibres of rodent and 
porcine muscles (Pette and Staron, 2000), but it is absent from many other 
mammalian species such as the cattle and horse (Chikuni et ah, 2004a; Chikuni et ah,
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2004b). The expression of MyHC 2b in humans is limited to extraocular and 
masseter muscles, with only mRNA detectable in the latter (Horton et ah, 2001). The 
presence of MyHC 2b in porcine muscle makes the pig distinctive among large 
animals. It has been suggested that the high expression of the MyHC 2b isoform in 
porcine muscle is related to intensive breeding for leaner meat (Chang et al., 2003).
The extraocular MyHC isoform is confined mainly to the eye, laryngeal and 
mandibular muscles of carnivores (Baldwin and Haddad, 2001). Based on the MyHC 
classification approach, the post-natal muscle fibres in mammals can be divided 
according to metabolic, biochemical and biophysical characteristics (Schiaffmo and 
Reggiani, 1996). A summary of MyHC properties differences are illustrated in Table 
1. 1.
MyHC I/slow/p 2 a 2x 2 b
Type Slow-oxidative Fast oxidative- 
glycolytic
Fast oxidative- 
glycolytic
Fast-glycolytic
Size ++ (++) (++) +++
Glycogen (+) (++) (++) +++
Lipids +++ ++ (+) (+)
Fatigue resistant intermediate intermediate sensitive
PSE* resistant intermediate intermediate prone
Table 1.1. The properties and m etabolic profiles o f MyHC fib re  types. * Pale, soft 
exudative meat quality, independent of ryanodine mutation. ( ) indicates variable levels.
The MyHC I/slow/p and MyHC 2b fibres, also known as slow oxidative (red) and fast 
glycolytic (white) respectively, represent 2 extreme metabolic profiles. The MyHC 
2a and MyHC 2x fibres are intermediate fast oxidative-glycolytic fibres. Fast MyHC
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2a fibres are more closely related to MyHC I/slow/p fibres, and fast MyHC 2x are 
more similar to fast MyHC 2b fibres. Besides the single MyHC isoform (pure fibre 
type), it should be noted that mixed expression of two or more MyHC isoforms can 
occur (hybrid fibre type). The combinations of hybrid fibre may range from MyHC 
I/slow/p with MyHC 2a, MyHC 2a with MyHC 2x to MyHC 2x with MyHC 2b 
isoforms (Schiaffino and Reggiani, 1994). The normal proportions of hybrid fibres in 
skeletal muscle are low, but their numbers may increase dramatically during MyHC 
fibre transition (Talmadge et al., 1999).
In general, each muscle is composed of different types of fibres. Fibre type 
distribution is largely dependant on their anatomical and functional roles. Postural 
muscles such as the soleus muscle, contain a high proportion of oxidative fibres and 
are activated continuously to produce slow and repetitive movements (Hnik et ah, 
1985). In contrast, the muscles used for intensive activities, like sprinting, are 
composed of FG or FOG fibres, with their greater capacity for force and strength 
generation, but lower resistance to fatigue.
1.2.3. Muscle fibre adaptation and transition
Muscle fibres are dynamic structures capable of altering their phenotype under 
various conditions, e.g. increasing or decreasing neuromuscular activity, mechanical 
loading or unloading, altering hormonal profiles (especially of thyroid hormones), and 
ageing (Pette and Staron, 2000). This allows muscles to adopt the most energy- 
efficient configuration for the demand at any given time. Fibre transition not only 
involves changes in MyHC expression, but includes alteration in the isoform profiles
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of a multitude of sarcomeric proteins. Changes in MyHC isoforms tend to follow a 
general scheme of sequential and reversible transitions from fast-to-slow and slow-to- 
fast. A summary of these factors and their effects on fibre expression of MyHC 
isoforms is shown (Fig. 1.4).
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Figure 1.4. Summary o f the factors influencing MyHC expression and fibre type.
(Modified from Fluck and Hoppeler, 2003).
1.2.3.1. Neuromuscular activity
Neuromuscular activity is an important factor for specific muscle fibre phenotype 
development and its subsequent maintenance (Pette and Vrbova, 1985). Cross­
reinnervation studies clearly demonstrated that neural activity could lead to switch in 
fibre phenotype (Buller, 1965). Reports from spinal cord injury and denervation
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experiments, also suggested that in the absence of innervation, muscle will undergo 
atrophy and switch in fibre phenotype from slow to fast (Pette and Staron, 2000). 
Fast fibres will turn to slow type when reinnervated by a slow nerve and vice versa 
(Pette and Vrbova, 1985).
Electrical activity is the main mechanism by which the nervous system exerts control 
over fibre phenotype. Based on the slow and fast motoneuron-specific firing patterns, 
electrical stimulation can be classified into two protocols. The chronic low-frequency 
stimulation (CLFS), which mimics the tonic low-frequency (10-20 Hz) impulse 
pattern is normally delivered to a slow-twitch muscle (Salmons and Vrbova, 1969). 
On the other hand, the short burst (phasic) of high-frequency (100-150 Hz) 
stimulation mimics the pattern that is normally delivered to a fast-twitch muscle 
(Lomo et ah, 1974). The use of CLFS as an experimental model to study 
neuromuscular activity has proved to be very fruitful (Pette and Vrbova, 1999).
Calcium (Ca^ "^ ) is an essential element in muscle function. It is required for the 
activation of muscle contraction through the troponin-tropomyosin complex, and for 
secondary roles such as regulation of ATP provision. The different concentrations of 
Ca^ "^  in cytosol also serve as indicators for the electrical activation pattern in skeletal 
muscle. Slow-type signalling pattern results in a sustained intracellular Ca^”^ 
concentration of 100 to 300 nM (Chin and Allen, 1996), while fast pattern results in 
short-lived Ca^^ elevations of up to 1 pM (Westerblad and Allen, 1991). Hence, the 
concentration of cytosolic calcium-ion is controlled by electrical stimulation, and is 
believed to be a major influence on MyHC isoform expression in muscle (Talmadge,
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2000). Increasing intracellular Ca^ "^  levels in myotube cultures has been shown to 
enhance the expression of MyHC slow (Kubis et ah, 1997).
I.2.3.2. Mechanical loading and unloading
When considering the role of mechanical loading, focus will be on; (1) functional 
overload, (2) resistance training and (3) endurance training. Conversely, to appreciate 
the effects of reduced weight bearing, focus will be on: (I) space flight, (2) hindlimb 
suspension and (3) spinal cord injury.
In events of functional overload, such as the surgical removal of targeted muscle 
synergists to induce functional overload, results indicate that in fast muscles such as 
plantaris muscle, the expression of MyHC 2x and MyHC 2b aie decreased, whereas 
both MyHC I and MyHC 2a expression are raised (Baldwin and Haddad, 2001). 
Similar results were observed in resistance training. In rodents, the expression of 
MyHC 2b shifted to the MyHC 2x isoform. As previously mentioned, MyHC 2b is 
hardly detectable in human muscle, therefore the major finding was the decreased 
expression of MyHC 2x and concomitant increase in MyHC 2a expression in a human 
model (CaiToll et al., 1998).
Unlike resistance training, endurance training appears to be both muscle specific and 
dose dependent. Only in mixed fast or fast muscles that undergo moderate to high 
endurance training, show a shift from MyHC 2b to MyHC 2x/MyHC 2a expression 
(Demirel et al., 1999). If the endurance training is extended to extreme, it is possible 
to induce MyHC I expression (Demirel et al., 1999). In human world-class marathon
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runners, a strong bias towards the expression of up to 80-90% of the slow type MyHC 
isoform was found (Andersen et ah, 1994).
On the other hand, when skeletal muscle is continuously unloaded, the opposite 
pattern of transformation occurs. The effects o f mechanical unloading have been 
studied using various models. Neonatal rats in a microgravity spaceflight 
environment showed significant reduction in muscle growth with a resulting MyHC 
pool biased towards fast MyHC 2b and 2x expression (Adams et ah, 2000). The 
findings indicated that weight bearing activity is essential for slow muscle isoform 
development and expression. In contrast, it is not essential for fast MyHC 2x and 
MyHC 2b development expression (Adams et ah, 2000). Muscles of rats subjected to 
hindlimb suspension showed a transition from slow-to-fast fibre phenotype switch 
(Haddad et ah, 1998).
Spinal cord injury in small animals (cats and rats) has been shown to cause 
transformation in MyHC expression that is qualitatively similar to those reported in 
spaceflight or hindlimb suspension experiments (Talmadge, 2000). There was a 
marked reduction in the expression of MyHC slow isoform, and an increase in the 
relative expression of all three fast MyHC isoforms (Talmadge, 2000). However, 
there is a difference between small animals and humans in response to spinal cord 
injury. In humans suffering from spinal cord injuries with lower extremity paralysis, 
there was considerable delay in the transformation of slow to fast MyHC profiles, 
unlike that seen in animal models (Talmadge, 2000; Andersen et ah, 1996).
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12.3.3. Hormones
Hormonal signalling has a major influence on skeletal muscle development and 
muscle fibre phenotype determination. Several notable hormones are involved in 
increasing muscle mass by promoting protein synthesis or by reducing protein 
degradation, such as anabolic hormones, which include growth hormone, insulin-like 
growth factors (IGFs) and testosterone. In contrast, catabolic hormones such as 
glucagon and glucocorticoids, increase protein metabolism and lead to reduced 
muscle mass. Among the hormones listed, thyroid hormone and IGFs also showed 
marked influence on the expression of specific MyHC isoforms.
Thyroid hormone consists of two iodine-containing amine hormones-thyroxine (T4) 
and triiodothyronine (T3). Of the two, T3 appears to have the greater effect on 
skeletal muscle fibre phenotype. In general, hypothyroidism causes fast-to-slow 
transition. The magnitude and specific isoform transition vary between different 
muscle types. The transition of MyHC 2a/2x to MyHC I was observed in slow 
muscle, whereas a shift from MyHC 2b/2x to MyHC 2a/I was detected in fast and 
mixed muscles (Caiozzo et al., 1998). In contrast, hyperthyroidism elicits a slow-to- 
fast transition. The transition involves repression of MyHC I expression and 
enhancement of fast MyHC 2x/2b isoform (Caiozzo et ah, 1998). T3 with clenbuterol 
also greatly enhances the slow to fast fibre type switch (Awede et ah, 2002). In 
addition to their impact on adult muscle fibre phenotype, thyroid hormone also plays 
an important role in muscle development and maturation. In a space flight study, 
results indicated that an intact thyroid gland was essential for down-regulation of 
neonatal isoform during muscle development (Adams et ah, 2000).
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IGFs (IGF-1 and IGF-2) are polypeptides with high sequence similarity to insulin. 
The IGFs stimulate both muscle cell proliferation and differentiation through 
interaction with the type 1 IGF receptor (IGFIR), insulin receptor exon 11- (IR-A) 
and insulin receptor exonl 1+ (IR-B), all of which are transmembrane tyrosine kinase 
receptors (Denley et al., 2005). The type 2 IGF receptor (IGF2R) (known also as 
mannose-6-phosphate receptor), has no intrinsic signalling transduction capability and 
serves to sequester IGF-2 from potential receptor interactions and to internalise and 
degrade IGF-2 (Denley et ah, 2005). The action of the IGFs are modulated by a 
family of six high-affinity IGF binding proteins (IGFBF 1-6). The IGFBPs act as 
carrier proteins for the IGFs in the circulation, protecting them from degradation and 
transporting them to specific tissues (Florini et ah, 1996). Both IGF hormones are 
secreted by the liver as a result of growth hormone (GH) stimulation. They are also 
synthesised locally in muscle tissues, acting in an autocrine/paracrine manner in 
response to damage, mechanical loading or stretching (Adams, 2002). Besides the 
major IGF-1 (IGF-lEa), a spliced variant with a carboxyl terminus different from 
IGF-lEa, named mechano growth factor (MGF), is rapidly inducible in skeletal 
muscle and appears to be an early trigger for satellite cell proliferation (Hill and 
Goldspink, 2003; Yang and Goldspink, 2002). The autocrine/paracrine muscle 
production of IGF-2 during muscle differentiation and regeneration was found to 
participate in a positive feedback loop to further enhance muscle differentiation 
(Erbay et ah, 2003; Wilson et ah, 2003) and regeneration (Kirk et ah, 2003). IGF-1 
has the additional effect of converting fibres to fast glycolytic, by raised expression of 
glycolytic enzymes in IGF-1-transfected C2C12 myotubes (Semsarian et ah, 1999a), 
by a modest rise in fast 2b fibres in transgenic mice carrying muscle IGF-1 isoform 
driven by a rat myosin light chain (MyLC)-1/3 promoter (Musaro et ah, 2001), and by
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raised type 2a and 2b fibres at the expense of slow fibres in IGF-1-treated dystrophic 
mice (Lynch et ah, 2001). The mechanism responsible for the slow to fast fibre type 
switch, however, remains elusive.
I.2.3.4. Ageing
Ageing is associated with structural and functional changes in skeletal muscle. 
Studies on slow and fast rat muscle indicated age-related changes in fibre type and 
MyHC isoform composition. It has been shown that ageing leads to fast-to-slow 
transition (Larsson and Ansved, 1995).
In fast muscles of rat, results showed decreases in the MyHC 2b/2x and increases in 
the slow myosin isoform with ageing (Skorjanc et al., 1998; Danieli-Betto et al., 
1995). A similar transition was observed in slow muscle, in which MyHC 2a was 
gradually replaced with MyHC I isoform (Larsson and Ansved, 1995). However, 
increases of MyHC I expression in ageing muscle do not necessarily lead to increase 
in fatigue resistance, as in endurance training athletes. In endurance runners, slow 
type fibres are rich with mitochondria, but the mitochondrial content in ageing fibres 
is reduced.
In addition, an age-related decline in protein synthesis rate of MyHC has been 
demonstrated (Lexell et ah, 1986; Balagopal et ah, 2001). The reduction of MyHC, 
the key protein in contractile apparatus, is likely to contribute to muscle weakness and 
reduced locomotion. The reduction in MyHC and mitochondrial protein production 
could be caused by decreases in mitochondrial DNA and messenger RNA (Nair,
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2005). To reduce the ageing effect, resistance training that could increase MyHC 
protein has shown to be beneficial (Balagopal et ah, 1997).
1.2.4. Muscle hypertrophy and atrophy
Skeletal muscle hypertrophy is characterised by an expansion of fibre sizes, either 
through enlargement or elongation that will lead to increase in muscle mass. In 
contrast, muscle atrophy refers to reduction in fibre size or fibre loss as a consequence 
of disease, age or muscle inactivity (Glass, 2003; Glass, 2005).
i.2.4.1. Hypertrophy and the PÏ3-K pathway
The IGF-activated PI3-K signalling pathway is widely regarded as the primary route 
to skeletal muscle hypertrophy (Glass, 2003; Glass, 2005). Phosphatidylinositol 3’- 
kinase (PI3-K) consists of two sub-miits, the SH2 domain containing regulatory unit 
(p85), and a catalytic sub-unit (pi 10) (Vivanco and Sawyers, 2002). PI3-K catalyses 
the phosphorylation of membrane-bound phosphatidylinositol (4,5)-biphosphate (PIP2) 
to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 subsequently serves as a 
docking station for Aktl (also known as protein kinase B) and phosphatidylinositol- 
dependent protein kinase 1 (PDKl). Aktl is phosphorylated by PDKl, and once 
activated Aktl phosphorylates a number of substrates that are responsible for a range 
of growth processes, which include protein synthesis, glycogen synthesis, muscle 
differentiation and cell proliferation. A key target of activated Aktl is the 
phosphorylation of mTOR (mammalian target of rapamycin), a serine/threonine
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kinase, which in turn activates a number of downstream effectors including ribosomal 
protein S6 kinase (p70S6K) and eIF-4E, both of which mediate translation initiation 
and appear to play important roles in muscle hypertrophy.
1.2.4.2. Atrophy and the ubiquitin-proteasome proteolysis pathway
It has been shown that protein degradation is elevated during muscle atrophy which 
leads to a reduction in muscle mass (DeMartino and Ordway, 1998). Among all 
MyHC isoforms in skeletal muscle, MyHC I was the primary target for protein 
degradation as a consequence of mechanical unloading (Baldwin and Haddad, 2002). 
The pathways of protein degradation are poorly understood, but studies have 
implicated the involvement of the ubiquitin-proteasome proteolysis pathway, which 
degraded the contractile proteins that lead to muscle atrophy (Glass, 2005; Solomon 
and Goldberg, 1996; Solomon et al., 1998).
In this pathway, proteins are targeted for degradation by covalent ligation to ubiquitin 
(Ub), a 76-amino-acid residue protein. Ubiquitin protein ligation requires sequential 
action of three enzymes. Firstly, the ubiquitin is activated by an ubiquitin-activating 
enzyme (El family). Secondly the activated ubiquitin is conjugated to substrate 
proteins by an ubiquitin-conjugating enzyme (E2 family). Finally, degradation of the 
substrate proteins with ubiquitin protein ligase (E3 ligase family) (Hershko and 
Ciechanover, 1998). There is a single E l, but there are many species of E2s and 
multiple families of E3s or E3 multiprotein complexes. Specific E3s appear to be 
responsible mainly for the selectivity of ubiquitin-protein ligation and protein 
degradation (Hershko and Ciechanover, 1998).
42
Studies in different catabolic situations (fasting, diabetics, uraemia and tumour 
conditions) with cDNA microarrays, found that genes encoding the Ub-proteasome 
pathway (E2 and E3 family) were up-regulated (Lecker et ah, 2004). Among the up- 
regulated genes, two E3 ligase family members were consistently highly up-regulated 
in all four conditions. There were the MuRFl (muscle ring finger 1) and MAFbx 
(muscle atrophy F-box or atrogin-1), and were identified as mediators of muscle 
atrophy (Lecker et ah, 2004). This result has strengthened the previous finding, in 
which genetically modified null mice that were deficient in either MuRFl or MAFbx 
showed resistance toward atrophy (Bodine et ah, 2001b). The same research group 
also demonstrated that these two genes were up-regulated in other atrophy conditions 
(denervation, immobilization or un-weighting) and over-expression of MAFbx lead to 
myotube atrophy in C2C12 cell culture (Bodine et al., 2001b).
MuRFl comprises 3 domains: a RING-fmger domain, required for ubiquitin activity, 
a B-box of unclear function, and a coil-coil domain, which may be required for the 
formation of heterodimer with a related protein MuRF2 (Glass, 2005). Over­
expression of MuRF-1 has been shown to disrupt the titin subdomain (an important 
element for sarcomere formation) (McElhinny et ah, 2002). On the other hand, 
MAFbx contains an F-box domain, a characteristic of E3 ubiquitin ligase family. F- 
box E3 ligases usually bind to a substrate that is post-translationally modified, for 
example by phosphorylation (Glass, 2005).
Decreased activity of the PI3-K/Aktl signalling pathway can lead to muscle atrophy 
(Bodine et ah, 2001a). Conversely, activation of Aktl in rat muscle can prevent
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denervation atrophy (Bodine et ah, 2001a). Recent studies demonstrated that 
reduction the PI3-K/Aktl signalling pathway in myotube atrophy condition, can lead 
to activation of FOXO transcription factors and MAFbx induction (Sandri et ah, 
2004). FOXO protein is a subgroup of the Forkhead family of transcription factors, it 
is one of the downstream targets of the PI3-K/Aktl pathway that could mediate IGF-1. 
Mammalian cells contain three members of this family, which are FOXO 1 (FKHR), 
FOXO 3 (FKHRLl) and FOXO 4 (AFX). By inhibition of FOXO function through 
the use of a RNAi construct in vivo (fasting mouse) and dominant negative construct 
in vitro (cultured myotube treated with glucocorticoids), activation of MAFbx is 
prevented (Sandri et ah, 2004). Moreover, over-expression of F0X 03 leads to a 
dramatic atrophy of myotube and muscle fibres. In contrast, the MAFbx mRNA level 
was reduced in F0X 03 over-expressed cells with IGF-1 added (Sandri et ah, 2004). 
Therefore, inhibition of FOXO factors seems to prevent muscle atrophy.
1.2.5. Calcineurin
Calcineurin (Cn) is an enzyme complex that comprises three subunits: calcineurin A 
(CnA) catalytic subunit, calcineurin B (CnB) regulatory subunit and calcium-binding 
protein calmodulin (Schulz and Yutzey, 2004), There are three major isoforms of 
CnA (a, p and y) and two gene isoforms of CnB (1 and 2). Only CnAa, CnAp (Aa 
more abundant than Ap) and CnBl are expressed in skeletal muscle (Parsons et ah, 
2004). Cn is a calcium dependent serine-thieonine phosphatase that is widely 
distributed throughout the body. It has been implicated in a wide variety of biological 
responses including T-lymphocyte activation, neuronal and cardiac development, and 
skeletal muscle development (Crabtree, 2001; Bassel-Duby and Olson, 2003). In
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skeletal muscle, Cn is required for the muscle development process. It is involved in 
muscle differentiation and conversion of fast-to slow muscle phenotypes (Chin et ah, 
1998; Dumi et ah, 1999). It has been shown that inhibition of Cn activity in primary 
cell culture can prevent cell differentiation, whereas over-expression of Cn has been 
shown to enhance differentiation (Belling et ah, 2000; Friday et ah, 2000).
It has been reported that activated calcineurin mediates the hypertrophic effect of 
IGF-1 (Musaro and Rosenthal, 1999; Semsarian et ah, 1999b). However, there is 
compelling evidence, including transgenic and knock-out data, to indicate that Cn has 
no direct effect on muscle hypertrophy (Rommel et ah, 2001; Pallafacchina et ah, 
2002; Parsons et ah, 2003). In contrast, IGF-1-induced hypertrophy is mediated by 
the phosphatidylinositol-3 kinase PI3-K/Aktl pathway as detailed earlier (Rommel et 
ah, 2001; Pallafacchina et ah, 2002; Parsons et ah, 2003).
1.3. Candidate genes of PCS
PCS is a multifactorial disorder with intermediate heritability. It is a complex 
condition where pathogenesis is likely to be mediated by at least several genes, 
loosely termed as candidate genes. Candidate genes are genes that may be involved 
in the development or pathogenesis of a specific disease/condition. They may not 
necessarily be the cause of the disease.
Nine differentially expressed sequence tags (ESTs) were isolated between the biceps 
femoris of normal and of splayleg piglets (Maak et ah, 2001). EST is a unique stretch 
of DNA usually at the 3’end region of a gene that is useful for identifying full-length
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genes and sei-ves as a landmark for mapping. By homology comparison, nine porcine 
homologues to human genes were identified: (i) TATA box binding protein
associated factor B (TAFIB), (ii) B-cell CLL/lymphoma (7B BCL7B), (iii) pyruvate 
dehydrogenase kinase, isoenzyme 4 PDK4, (iv) SPARC-like 1 (SPARCL-l), (v) 
ribosomal protein SIO (RPSIO), (vi) epithelial protein lost in neoplasm (EPLIN), (vii) 
N-myc downstream-regulated gene 2 (NDRG2), (viii) pleiomorphic adenoma gene 
like 2 (PLAGL2) and (ix) BCL-2 associated transcription factor short form {BTFS).
TAFIB has RNA polymerase I transcription factor activity, which could be involved 
in transcription from Pol I promoter and Pol II promoter (Comai et al., 2000). The 
function of BCL7B has not been determined, but it could be involved in cell 
differentiation and congenital Williams syndrome (a neuro developmental disorder) 
(Meng et ah, 1998). PDK4 expression is suppressed by insulin in porcine skeletal 
muscles (Kim et al., 2006). SPARCL-1, is down-regulated in many types of cancer 
cells and may serve as a negative regulator of cell growth and proliferation (Bendik et 
ah, 1998). EPLIN  is a cytoskeleton-associated protein that inhibits actin filament 
depolymerization (Chang et ah, 1998). NDRG2 is a cytoplasmic protein that may 
play a role in neurite outgrowth and may be involved in glioblastoma carcinogenesis 
(Deng et ah, 2003), PLAGL2 might induce the expression of a proapoptotic protein 
Nip3, leading to cellular apoptosis (Mizutani et ah, 2002). Not much is known about 
BTFS.
In another recent differential display study, cyclin-dependent protein kinase inhibitor 
3 (CDKN3) was identified as a potential candidate gene by differential display (Maak 
et ah, 2003). CDKN3 belongs to a family of dual-specificity protein phosphatases.
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Over-expression of wild type CDKN3 could delay cell cycle progression (Gyuris et a l, 
1993). However, the quantitative analysis of expression by real-time PGR showed no 
significant difference between normal and affected pigs (Maak et al., 2003).
Of the list of candidate genes for PCS highlighted (Maak et al., 2001; Maak et al., 
2003), the association of SPARCL-1 with PCS is particularly interesting to explore. 
The putative anti-proliferative property of SPARCL-1 could play a role in PCS 
pathogenesis.
1.3.1. SPARC
SPARC (secreted protein acidic and rich in cysteine), also termed osteonectin, BM-40, 
is a 32-kDa protein. It was first identified as a major non-collagenous protein of bone 
matrix (Termine et al., 1981). It is a member of matricellular glycoprotein, a group of 
non homologous macromolecules that is involved in cell-matrix interactions which do 
not serve primarily structural roles (Lane and Sage, 1994). Other members of this 
group of proteins include the thrombospondins (TSP) 1 and 2, osteopontin (OPN), 
tenascins (TN)-C and X (Brekken and Sage, 2000). Although their structures are 
different, they appear to perform related functions, e.g. they exhibit counter-adhesive 
effects that lead to cell rounding and changes in cell shape which result in the 
disruption of cell-matrix interactions. These proteins are also expressed when tissue 
undergoes changes in cell shape and motility, e.g. tissue renewal, tissue remodelling 
and embryonic development (Bornstein, 1995). Therefore, the matricellular proteins 
are different from the traditional adhesive proteins such as fibronectin, laminin,
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fibrillar collagens and vitronectin, all of which contribute to the structural stability of 
the extracellular matrix.
SPARC contains modular domains that can function independently to bind cells and 
matrix components (Engel et al., 1987). Based on sequence analysis, four putative 
domains (Fig. 1.5), I to IV were distinguished in the protein sequence. Domain III 
and IV are also termed as Extracellular calcium binding domain (EC domain).
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Figure 1.5. M odular s tructure o f human SPARC. The ribbon diagram derived from 
crystallographic data indicates three structural modules. The follistatin-like domain, aa 
53/137, is shown in red except for peptide 2.1, aa 55/74, and the K GHK angiogenic peptide, 
aa 114/130, which are shown in green and black, respectively. The EC-module aa 138/286 
is shown in blue except for peptide 4.2, aa 255/274, which is shown in yellow. (Adapted from 
Hohenester et al. 1996 and the Brookhaven Protein database, accession number 1BM0)
The N-terminal domain I is highly acidic in character, it binds to several calcium ions 
with low affinity (Maurer et al., 1992). This N-terminal domain exhibits the most
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divergent sequence among the family of SPARC-like proteins. Therefore, antibodies 
against a particular SPARC have not been found to cross react with other SPARC-like 
proteins (Yan et al., 1998). The second domain (Domain II) is the Cys-rich, 
follistatin-like (FS) domain, in which all the Cys residues are disulfide-bonded, and 
with an N-linked complex carbohydrate. Domain II is homologous to a follistatin 
(FS)-domain and Kazal type protease inhibitors (Maurer et al., 1995). Follistatin (FS) 
is an activin-binding protein, which inliibits the action of activin, and thereby inhibits 
the release of follicle stimulating hormone. Kazal inhibitors, which inhibit a number 
of serine proteases (such as trypsin and elastase), belong to the family of proteins that 
includes pancreatic secretory trypsin inhibitor; avian ovomucoid; acrosin inhibitor; 
and elastase inhibitor. Domain III (EC domain) is largely a-helical and is responsible 
for the binding site for collagen IV (Mayer et al., 1991). The C-terminal domain, 
Domain IV contains the EF-hand motif with a high-affinity calcium binding site 
(Pottgiesser et a l, 1994). Domains III and IV were not independent but represent one 
domain (hence termed the EC domain) binding both calcium and collagens 
(Pottgiesser et a l, 1994).
SPARC could; (a) disrupt cell adhesion through dissolution of the focal adhesion 
complex (Lane and Sage, 1994), (b) promote changes in cell shape, an effect of 
counter-adhesive function (Lane and Sage, 1994), (c) regulate cell differentiation in 
lens epithelial cells (Bassuk et a l, 1999), (d) be anti-proliferative by inactivating 
cellular responses to certain growth factors induced by platelet-derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) (Yan and Sage, 1999), (f) be involved in angiogenesis and
tumorigenesis via interaction with PDGF, VEGF and bFGF (Yan and Sage, 1999), (g)
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promote wound healing, by influencing the activity of transforming growth factor- 
beta (TGF-P), a growth factor that associated with rapid remodelling of coimective 
tissue (Yan and Sage, 1999).
The anti-proliferative property of SPARC has been verified on cells derived fi-om 
SPARC-null mice. Fibroblast, mesangial cells, and smooth muscle cells isolated from 
SPARC-null mice exhibited a higher rate of proliferation relative to their wild-type 
counterparts. Null cells were also more sensitive to the inhibition of cell cycle 
progression induced by recombinant SPARC (Bradshaw et al., 1999).
SPARC also inhibits progression of cells from G1 to S phase or prolongs G1 phase of 
the cell cycle (Claeskens et al., 2000). If cell cycle progression is inhibited by 
SPARC, it is likely that SPARC functions in cell differentiation also. In fact, SPARC 
has exhibited prominent expression during the terminal differentiation of cultured 
human kératinocytes and in terminally differentiated retinal ganglion cells in vivo 
(Yan et ai., 1998). Moreover, SPARC is believed to regulate terminal differentiation 
of lens epithelial cells, because disruption of the SPARC locus in mice resulted in the 
abnormal differentiation of lens fibres (Bassuk et al., 1999). In vitro, SPARC is 
secreted into the medium of a variety of cell types. In normal tissues, SPARC protein 
is detected intracellularly, except in bone matrix (Termine et al., 1981).
1.3.1.1. SPARC and related proteins
To date, four SPARC related proteins are known. They are: (a) quail retina protein 
QRl (Guermah et al., 1991); (b) TSC-36/FPR, a TGF-P-induced, follistatin related
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protein secreted by glioma cells (Shibanuma et al., 1993); (c) testican, a proteoglycan 
found in human testis (Alliel et al., 1993) and (d) SPARCL-1, a putative ECM 
glycoprotein which was found in rat brain (Johnston et al., 1990). All the members in 
this group have an EC domain (extracellular calcium binding domain), followed by a 
Follistatin (FS) like domain. However, the acidic Domain I exhibits considerably less 
identity within this group (Fig. 1.6 ).
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Figure 1.6. SPARC and related proteins. Three prominent modules are shown. The N- 
termlnal domains I of each protein exhibit considerably reduced Identity, although all are 
acidic. A folllstatln-llke, Cys-contalning module (FS) Is followed by the extracellular calclum- 
blndlng domain (EC). TY designates a thyroglobulln-llke domain In testican. Triangles 
represent characterized modules In testican and tsc36/FRP. (Quote from Yan et al., 1999; 
Modified from Maurer et al., 1995.)
Among the related proteins, SPARCL-1 displays the highest amino acid similarity 
with SPARC, sharing 55.6% identity at FS domain and 61.4% identity at EC domain. 
The structure differences between SPARC and SPARCL-1 was at domain I, 
SPARCL-1 has a longer domain I sequence compare to SPARC. Although SPARCL- 
1 and SPARC share a similar pattern of tissue distribution, they are not found in the
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same structures within organs (Soderling et al., 1997). SPARCL-1 was expressed in 
medium and large vessels of the kidney, whereas SPARC was expressed in glomeruli 
and vasculature of the kidney. However, another cell adhesion study has shown that 
these two proteins exhibit similar functions with respect to the inhibition of 
attachment and spreading of endothelial cells in culture (Girard and Springer, 1996).
1.3,2. SPARCL-1
The matricellular protein SPARC like-1 (SPARCL-1), also known as 
MAST9/hevin/SCl, is a member of the SPARC family. SPARCL-1 contains a 
follistatin-like domain (FS) and an extracellular calcium binding domain (ES), which 
are the hallmarks of the SPARC family.
SPARCL-1 (as SCI) was originally cloned from a rat brain expression library by 
screening with a polyclonal antibody raised against a synaptic junction glycoprotein 
(Johnston et al., 1990). Its mRNA was expressed widely tln'oughout the brain and 
could be detected in many types of neurons (Johnston et al., 1990). MAST9, was 
identified in human non-small cell lung carcinomas (Schiaml et al., 1994). Hevin, its 
human homologue, isolated from a specialised postcapillary vascular structure called 
high endothelial venules, was found in the tonsils (Girard and Springer, 1995). 
MAST9/Hevin gene encoded a glycoprotein, which exhibit 62% identity in its 
carboxy terminus to the extracellular matrix protein SPARC, therefore, 
MAST9/Hevin was renamed to SPARC-like 1 (SPARCL-1) (Isler et al., 2000).
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SPARCL-1 mRNA is expressed in many normal human tissues including heart, 
kidney, prostate, ovary, small intestine, colon, and lymph nodes (Bendik et al., 1998). 
It has been shown to be a negative regulator of cell proliferation (Claeskens et al., 
2000). It inhibits progression of cells from G1 to S phase or prolongs G1 phase 
(Claeskens et al., 2000). SPARCL-1 is down-regulated in many types of cancer cells 
and may serve as a negative regulator of cell growth and proliferation (Bendik et al., 
1998).
PCS is suspected to be caused by a delayed maturation of limb muscles. SPARCL-1 
was highlighted in PCS skeletal muscle and could be a candidate gene involved in the 
development of myofibrillar hypoplasia (Maak et al., 2001).
1.3.3. P311
P311 is another candidate gene identified for its possible association with PCS. P311 
was found to be highly expressed during dietary restriction in skeletal muscle of 
young pigs (da Costa et al., 2004). This finding suggests that P311 could play an 
important role in the differentiation and growth of skeletal muscle. No direct 
evidence was obtained of its relationship with PCS. Down regulation of P311 
expression is hypothesised to be involved in the development of muscular weakness 
in PCS directly or indirectly.
P311, also referred as PTZ17 (pentylenetetrazol), is an 8-kDa intracytoplasmic protein 
originally found in the developing mouse brain (Studler et al., 1993). P311 is
characterized by the presence of a conserved PEST domain (sequence rich in Pro, Glu,
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Ser, and Tin’). P311 has three PEST like domains, only the domain located at the N- 
terminus, shows similarity within human, mouse and chicken species. To date, little 
is known about the function of the PEST domain, and little is known about the 
suggested function of P311. PEST domains are: (a) putative targets for degradation 
by the ubiquitin/proteasome system, which degrades proteins by covalently linking 
ubiquitin to lysine residues of the protein, thereby allowing recognition and 
degradation of the protein by the proteasome. (Varshavsky, 1997); (b) candidate sites 
for protein-protein binding (Ghose et al., 2001); (c) targets for degradation by calpains 
(Noguchi et al., 1997) and (d) thought to be involved in phenotypic changes 
consistent with myofibroblast transformation (Pan et al., 2002). Myofibroblasts are 
cells with features intermediate between fibroblasts and smooth muscle cells that play 
a main role in tissue repair.
With the presence of PEST domain, P311 protein was subjected to extremely rapid 
degradation by the ubiquitin/proteasome system. To detect the presence of P311 
protein, different approaches were used. The PEST domain was deleted during 
plasmid construction (Paliwal et al., 2004) or by adding proteasome inhibitor to 
reduce the degradation of P 3 Î1 protein (Taylor et al., 2000). Lactacystin was selected 
but did not block decay of the protein effectively. In addition, pulse-chase 
experiments were performed in which cells were treated with lactacystin in 
combination with a series of protease inhibitors including o-phenanthroline, pepstatin, 
leupeptin, and aprotinin. Only the combination of lactacystin and the metalloprotease 
inhibitor, o-phenanthroline, was able to block degradation of P311 (Taylor et al., 
2000). The data suggested that P311 was subject to rapid degradation by both the 
ubiquitin/proteasome system and an unknown metalloprotease.
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1.4. Aims
PCS is a classic example of a multifactorial disorder with intermediate heritability. 
Histological examination of affected muscle reveals the presence of “myofibrillar 
hypoplasia”. However, the cellular changes, including biochemical and fibre type 
changes, associated with PCS remain poorly described. Hardly any information is 
available on the molecular changes that occur in the muscles in PCS. Therefore, the 
aims of this thesis are to undertake: (1) cellular and molecular characterisation of PCS 
and (2) functional studies of PCS candidate genes.
1.4.1. Cellular and molecular eharacterisation of PCS
The aim is to undertake a detailed cellular and molecular characterisation of the 
morphological, metabolic and fibre type changes in PCS affected muscles. The 
investigations will incorporate the use of immunohistochemistry and histochemistry 
coupled with detailed image analysis. TaqMan quantitative real-time RT-PCR will be 
used to investigate the expression of MyHC genes in PCS. Findings would aid in 
diagnosis and understanding of the pathogenesis of PCS.
1.4.2. Functional studies of PCS candidate genes
P311 and SPARCL-1 are 2 novel genes identified from the literature as candidates for 
PCS investigation. To investigate the functional role of these candidate genes, their
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full-length cDNAs will be over-expressed in murine C2C12 muscle cells by 
adenovirus infection and stable transfection. Quantitative changes in cell proliferation 
rate (BrdU), myotube formation (fusion index) and expression of MyHC genes 
(TaqMan quantitative real-time RT-PCR) will be determined.
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Chapter 2
Materials and Methods
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2.1. Introduction
The general materials and methods used throughout the project are described in this 
Chapter. More specialised protocols are listed in the relevant sections. Most of the 
general materials and methods described in this Chapter are derived from standard 
materials and methods that can be found in common laboratory manuals e.g. Maniatis, 
(1989).
2.2. Porcine congenital splayleg
2.2.1. PCS piglets and muscle selection
PCS is a condition in newborn piglets that show inability to stand and walk properly, 
the limbs extending forwards or sideways as a result of muscular weakness. In this 
study, 2-day-old PCS affected piglets with both hind limbs extended were selected, 
along with a normal litter mate. The selected normal litter mates were active and did 
not have lameness problems.
PCS is closely associated with muscle weakness. Among the muscles examined, the 
most seriously affected are the semitendinosus (ST) in the hindlimb, the longissimus 
dorsi (LD) in the lumbar region and the triceps in the forelimbs (Thurley et al., 1967). 
However, some researchers believed that the adductor and sartorius are more 
seriously affected because they are the major muscles concerned with upper hindlimb 
adduction (Bradley et al., 1980). In a more recent study, the LD muscle and biceps 
femoris were found to show less number of myofibrils (Antalikova et al., 1996). Thus, 
a wide range of muscles can be affected by PCS. In this study, the ST, LD and
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gastrocnemius (G) muscles were selected for cellular and molecular analyses from 
those described above. The gastrocnemius muscle was selected in this study because 
it is a hindlimb muscle and might be involved in PCS. The selected muscles were 
removed from four 2-day-old splayleg male piglets, along with 4 corresponding 
normal litter mates (commercial hybrid stock, Large White x Landrace). Piglets were 
put down by captive bolt. The selected skeletal tissue samples were quickly dissected 
out, a complete cross section was taken from the mid-belly of the muscles. Two sets 
of selected muscle samples were prepared. The first set of muscle samples were 
rapidly frozen in isopentane cooled in liquid nitrogen. They were then wrapped in 
aluminium foil and stored in liquid nitrogen until required for immunohistochemistry 
and histochemistry (Section 2.2.2). The second set of muscle samples were placed in 
cryotubes and immediately snap-frozen in liquid nitrogen until required for total RNA 
extraction (Section 2.7.1.1).
2.2.2. Immunohistochemistry and histochemistry
A SLEE cryostat (CM3050, Leica) was used to section all muscle samples. Each 
muscle sample was transferred to a cryostat chuck, then tissue embedding compound 
(OCT compound, Sakura) and cryo spray agent (Cellpath) were applied until a mould 
was formed. The sample was then placed in the cryostat where it was left to warm to 
the cryostat temperature of -20°C before sectioning. The cryostat section thickness 
was set at 10 pm. Each tissue block was trimmed to a satisfactory muscle depth. 
Each section was picked up with pre-3-aminopropyltriethoxysilane (2 % in acetone) 
coated microscope slide, and held for few seconds to allow the section to melt onto 
the slide. Each slide was air dried for 30 min before storage in -70°C. The remaining
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tissue was brushed in an upward direction, and the process was repeated to generate 
more sections. When the sectioning was completed, the muscle block was wrapped in 
cellophane and aluminium foil, and stored at -70°C.
Muscles were immunostained for: (a) p-dystroglycan at 1:200 dilution
(VisionBiosystems) to outline individual muscle fibres, (b) slow myosin heavy chain 
(MyHC) at 1:50 dilution (cat. N-. M8421, Sigma) for slow muscle fibres and (c) fast 
MyHC at 1:50 dilution (cat. N-. M4276, Sigma) for fast muscle fibres. The slow 
MyHC antibody is a human monoclonal antibody that shows specificity only for slow 
fibres. The fast MyHC antibody is a rabbit monoclonal antibody that shows 
specificity to all three porcine fast MyHC fibres (2a, 2x and 2b) (Chang et al., 2003). 
Histochemical staining was performed with: (a) Sudan Black B (SBB) staining to 
detect the presence of lipids and (b) succinate dehydrogenase (SDH) staining as an 
indicator of muscle fibre oxidative capacity.
Upon commencing staining, slides were removed from the freezer and left at room 
temperature for 30 min. The sections were ringed using a ‘pap’ pen 
(DakoCytomation) and placed in 10 mM Tris Buffer Tween (TbT), pH 7.5, for 5 min. 
The sections were stained using the EnVision+ system, Peroxidase (DAB kit K4007, 
DakoCytomation) according to the manufacturer’s instructions. Briefly, the sections 
were first removed from the wash buffer and laid out in a humidified chamber where 
the endogenous peroxidase activity was quenched by application of a peroxidase 
block for 5 min. Next, the slides were washed in TbT for 5 min before application of 
the primary antibody (P-dystroglycan, MyHC slow or MyHC fast antibody) in 10 mM 
Tris Buffer Saline (TBS), pH 7.5, for 1 hour at room temperature. After incubation.
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the slides were washed in TbT for 5 min, and incubated with polymer-horseradish 
peroxidase (HRP) anti-mouse antibody for 30 min. Subsequently, the sections were 
rinsed in TbT for 5 min, followed by two 5 min rinses in deionised water. The 
staining was visualised with a 5 min incubation in 3, 3-diaminobenzidine (DAB)+ 
substrate-cliromogen that resulted in brown coloured staining at the antigen site. 
Following the DAB staining, the slides were washed in deionised water. The sections 
were counterstained with Gill’s haematoxylin (Sigma), a specially formulated high 
contrast stain solution used as a biological nuclear stain. Next, the slides were washed 
in tap water, dehydrated tlirough an ethanol gradient and were cleared in Histo-clear 
solution (BDH, UK), a xylene substitute. DPX mountant for microscopy (BDH, UK) 
was used to mount the cover-slip before examination by light microscopy (Carl Zeiss 
Ltd).
Prior to histochemical staining, slides were left to dry at room temperature for 30 min. 
For SBB staining, the sections were ringed using a ‘pap’ pen and rinsed in 70% 
ethanol (Fisher Scientific, UK). The sections were stained using saturated SBB in 
70% ethanol for 2 hours. After the incubation period, the slides were rinsed with 70% 
ethanol followed by deionised water. The sections were counterstained with Gill’s 
haematoxylin, a specially formulated high contrast nuclear stain solution. For SDH 
(Nachlas et al., 1957), slides were incubated in IM of sodium succinate with 
tétrazolium solution (nitro blue tétrazolium, 2M Tris-HCl and IM MgCU) at 37°C for 
1 hour. They were then incubated in formal saline [4% formaldehyde (Fisher 
Scientific, UK) in normal saline] for 10 min. After incubation, the slides were gently 
rinsed with deionised water for 2 min. Subsequently, the sections were counterstained 
with Meyer’s carmalum (2g of carmine in 100 ml of 5% ammomium alum) for 5 min
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to highlight muscle fibre membranes. For both stains, the same rinsing protocol was 
used. Slides were rinsed in tap water, dehydrated through an ethanol gradient and 
were cleared in Histo-clear solution (BDH, UK). Finally, DPX (BDH, UK) was used 
to mount the cover-slip.
2.2.3. Image analysis
Processed slides were examined under an image capturing light microscope (Carl 
Zeiss Ltd). For each muscle sample, 6 fields with at least 500 fibres each were 
randomly selected for morphometric analysis under magnification X200 using the 
KS300 image analysis software (Carl Zeiss Ltd). There are superficial and deep 
layers in Semitendinosus muscle (Handel and Stickland, 1987), the superficial layer 
was selected for study in this project. The parameters that were determined were fibre 
type, size and number (Figs. 2.1 and 2.2). Two teclmicai problems encountered in the 
image analysis work. The first was connected to muscle fibre density. An adult 
muscle cross-section has an average of about 200-300 fibres within one field under a 
magnification of X I00. However, in 2 day-old muscles there were about 800-1400 
fibres per field under the same magnification. This number of fibres was too large to 
manage effectively. Hence a magnification of X200 was used. The use of this 
magnification resulted in the second technical problem. This coneerned the usage of 
the in-house computer macro for the KS 300.3.0 software programme, which was for 
use at only X I00. As a result, each mask prepared from a field viewed at X200, had 
to have each fibre outlined manually which was a time consuming process (2 
hours/mask). In contrast, with the help of the software, each adult muscle only took 
15 min to complete.
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Figure 2.1. Image analysis. (A) Typical field of 
normal LD muscle immunostained for dystroglycan, 
captured under X200 magnification. (B) Manually 
drawn mask of image A. (C) Computer annotated 
fibres based on mask from B. (D) Overlay of 
images C and A. (E) Enlargement of part (red 
border) of image D.
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Figure 2.2. identification o f MyHC fast and 
MyHC slow  fibres. (A) Typical field of normal 
LD muscle immunostained for dystroglycan, 
captured under X200 magnification. (B) and (C) 
are serial muscle cross-sections immunostained 
with MyHC fast and MyHC slow antibody, 
respectively. Both images were used to identify 
the numbers of fast and slow fibres located within 
the field. Blue arrows indicate positive MyHC fast 
fibres. Red arrows indicate positive MyHC slow 
fibres. Green lines are for orientation of the 
images.
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2.3. Recombinant DNA techniques
2.3.1. Transformation of bacteria with plasmid DNA
2.3.1.1. Transformation of commercially available ultracompetent cells
Plasmids were maintained in Escherichia coli commercially available. XL2-Blue 
MRF’ and XL 10-Gold ultracompetent cells supplied by Stratagene were used in most 
of the transformations. Plasmid DNA transformation was carried out following the 
manufacturer’s guidelines, summarised as follows. Competent cells were thawed on 
ice, 4 pi of p-mercaptoethanol (Stratagene) was added to 100 pi of competent cell in a 
prechilled 15 ml Falcon 2059 polypropylene tubes (BD Biosciences), mixed gently 
and incubated on ice for 10 min. Plasmid DNA was then added to the cells, at a 
concentration of 0.1 to 50 ng of DNA per 100 pi of competent cells. The mixtures 
were incubated on ice for 30 min, then heat-shocked for 30 s at 42°C in a water bath, 
followed by incubation on ice for 2 min. At the same time, NZY broth (per litre, 5 g 
NaCl, 2 g MgS0 4 . 7H2O, 5 g of yeast extract and 10 g of NZ amine) was pre-heated 
at 42°C and 900 pi of the pre-heated NZY broth was then added to the mixtures. 
Subsequently, the tube was incubated at 37°C for 1 hour in an orbital shaker (S I50, 
Stuart) at 225-250 rpm. With a sterile spreader, 200 pi of the transformation reaction 
was plated on Luria-Beitani agar (LB agar per litre, 10 g of NaCl, 10 g of tryptone, 5 
g of yeast extract and 20 g of agar) plates containing 1 units/ml kanamycin.
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2.3.I.2. Topo- TA cloning
The TOPO-TA system is a specialised cloning kit (Invitrogen) specifically designed 
for the cloning of PCR products (Section 2.4), taking advantage of non-template 
terminal transferase activity of Taq polymerase that leaves a single deoxyadenosine 
residue overhang on PCR products. The linearised vector in the kit possesses a single 
deoxythymidine residue overhang, allowing any PCR product to be ligated into the 
vector.
The supplier’s protocol was followed. Four pi of PCR product were added to 1 pi 
Topo-TA vector, mixed gently and left at room temperature for 5 min. Next, the 
mixture was added into the aliquot of “One-Shot” cells, mixed and incubated in ice 
for 30 min. The cells were heat-shocked for 30 s at 42°C in a water bath. The tube 
was immediately transferred back to ice and further incubated for another 2 min. Two 
hundred and fifty pi of SOC medium (per litre, 0.5 g of NaCl, 20 g of tryptone, 5 g of 
yeast extract and 20 mM glucose) at room temperature were added into the tube. 
Then, the cells were incubated at 37°C for 1 hour in an orbital shaker at 200 rpm. At 
the end of incubation, 50 pi of the transformed cells were plated onto LB agar 
supplemented with either ampicillin or kanamycin antibiotics, and incubated 
overnight at 37°C.
2.3.2 Isolation of plasmid DNA
Isolation of plasmid DNA was earned out in all instances by a modified version of the 
alkaline lysis technique (Birnboim and Doly, 1979).
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2.3.2.I. Small scale plasmid preparations
Cells picked from single colonies were grown in 5 ml LB, overnight at 37°C in an 
orbital shaker. For each overnight culture, 1.5 ml of cells were spun down in a 
microcentrifuge tube at 10,000 x g for 1 min and the supernatant was discarded. Then, 
another 1.5 ml of culture were added to the pellet and the centrifugation step repeated, 
for a total of 3 ml of culture processed per overnight culture. The final pellet was 
spun again briefly, remove the remaining LB medium by pipette.
Plasmid DNA minipreps were prepared using the Spin Miniprep Kit (Qiagen). The 
supplier’s protocol was used, briefly as follows. Each selected cell pellet was 
thoroughly resuspended in 250 pi Buffer PI by pipetting. Cell suspensions were 
lysed by the addition of 250 pi Buffer P2, mixed by inversion. Three hundred and 
fifty pi Buffer N3 solution were added and mixed thoroughly to precipitate the protein. 
The resulting precipitate was centrifuged for 10 min at 10,000 x and then the 
supernatants were applied to Qiaprep spin columns. The columns were centrifuged at
10,000 X g for 1 min and the flow through was discarded. The DNA was bound to the 
column after it had been spun down. Each column was washed with 500 pi Buffer PB 
to remove trace nuclease activity. Each column was further washed by spinning with 
750 pi Buffer PE. Centrifugation was repeated to remove any residual ethanol from 
the last washing step. Subsequently, the column was transferred to a clean 1.5 ml 
microcentrifuge tube, and plasmid DNA was eluted fi'om the column by adding 50 pi 
of 10 mM Tris-Cl, pH 8.0. The columns were left to stand for 1 min, then centrifuged
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at 10,000 X g for 1min. The column was discarded and the plasmid DNA was stored 
at -20°C until required.
2.3.2,2. Large scale plasmid preparations
Cells picked from single colonies were grown in 5 ml LB, overnight at 37°C in an 
orbital shaker. Two ml of overnight culture were inoculated into 400 ml LB medium, 
supplemented with either ampicillin or kanamycin antibiotics in a one litre conical 
flask. The medium was cultured overnight in a shaking incubator. At this level of 
aeration, the cells were approximately mid-log phase when harvested the following 
morning. The bacterial broth was centrifuged at 6,000 x g for 15 min at 4°C.
The Maxiprep Kit (Qiagen) was used to isolate the plasmid DNA. The 
manufacturer’s protocol was used, re-stated briefly as follows. The cell pellets were 
each resuspended in 10 ml Buffer PI. The cells were then lysed with the addition of 
10 ml Buffer P2 by mixing vigorously by inversion, followed by incubation at room 
temperature for 5 min. Ten ml of prechilled buffer P3 was added, mixed thoroughly 
and spun at 10,000 x g for 40 min at 4°C. While waiting for the centrifugation, 
Qiagen maxiprep columns were equilibrated with 10 ml Buffer QBT. The 
supernatant from the centrifugation step was applied to the column by pouring 
thi'ough a 0.2 pm cell strainer (Qiagen) to remove residual particulate matter. 
Columns were washed twice, each time with 30 ml Buffer QC. All flow-thi'ough was 
discarded.
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Plasmid DNA was eluted with 15 ml Buffer QF into a 30 ml clear centrifuge tube (BD 
Biosciences). 10.5 ml isopropanol (AnalaR®, UK) was added and mixed by inversion 
to precipitate the DNA. The tube was centrifuged at 15,000 x g for 30 min at 4°C. 
The supernatant was carefully discarded and the pellet was then carefully washed with 
5 ml of 70% ethanol, prechilled to -20°C, and spun again at 15,000 x g for 15 min at 
4°C. Supernatant was removed and the pellet was left to air-dry. The plasmid DNA 
was resuspended in 200 pi 10 mM Tris Cl, pH 8.0 and stored at -20°C until required.
2.3.2.3. Determination of DNA concentration by spectrophotometry
The concentration of DNA preparations, principally from large scale plasmid 
preparations, was determined spectrophotometrically (DU-65 spectrophotometer, 
Beckman) with optical density measurements at 260 and 280 mn against a distilled- 
water blank. Each plasmid sample was diluted 1:200 in millipore-pure water 
(Millipore) to a total volume of 800 pi, and transferred to a quartz, optical cuvette 
(LCM, LA). An OD260 measurement of 1.0 was taken to indicate a double-stranded, 
plasmid DNA concentration of 10 pg/pl. The OD ratio of 260/280 nm was used to 
estimate the purity of the DNA preparation, with a ratio approaching 1.8 as being the 
ideal (Hirschman and Felsenfeld, 1966).
2,3.3. Restriction endonuclease digestion
For most restriction digests, between 1 and 2 pg of DNA was digested in 20 pi of 
reaction mix containing 5 to 10 units of appropriate restriction enzyme, such as EcdK
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I, Xho I, BamR  I, Xba I and others (Invitrogen), and the required enzyme buffer 
(Buffers A, B, L, M and H) (Invitrogen). Generally, all the reactions were incubated 
for a minimum of two hours at 37”C.
2,3.4. DNA electrophoresis
2.3.4.I. Agarose gel electrophoresis
The molecular weight of the DNA samples was determined in 0.8% agarose gels. 
Two grams of agarose powder (Biogene, UK) was added into 250 ml TAB buffer (40 
mM Tris acetate, 1 mM EDTA) in a 1 litre conical flask. The agarose was melted in a 
microwave, and allowed to cool to around 55”C. Ethidium bromide (Fisher Scientific, 
UK) of 75 pg/ml concentration was then added, and the whole gel mix was poured 
into a casting plate (Pharmacia Biotech) with appropriate gel comb inserted. The 
casting comb was carefully removed once the gel had set. The gel was stored at 4“C 
until needed. DNA samples were prepared for loading by adding the appropriate 
volume of 10 X loading buffer [0.25% bromophenol blue (Sigma), 0.25% xylene 
cyanol FF (USB Corp, Ohio) and 30% glycerol (Fisher Scientific, UK) in water], 
together with a known molecular size standard DNA as a marker, typically a 1 kb 
DNA Ladder® (Invitrogen). After loading the samples, depending on DNA sizes, the 
gels were run for 60-90 minutes under 70 volts (GNA-200, Pharmacia Biotech). 
Examination of the gel was done under a UV transilluminator (UVP Inc), the 
molecular size of the DNA was determined by comparison with the standard marker.
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2.3.4.2. Excision of DNA bands
Enzymatic digestion was performed as described in Section 2.3.3 to obtain DNA 
fragments of a particular size. The agarose containing DNA was visualized under a 
UV transilluminator and the desired band excised quickly from the gel using a scalpel. 
DNA was recovered from the gel slice using the QIAquick Gel Extraction Kit 
(Qiagen). The kit protocol is summarised as follows. Each gel slice was transferred 
to a 1.5 ml micro centrifuge tube and weighed. For each gel slice, three volumes of 
Buffer QG were added to every volume of gel sample. Samples were then heated for 
10 min in a 50°C water bath. Once the gel slice was completed dissolved, one gel 
volume of absolute isopropanol was added. The mixture was transferred to a 
Qiaquick spin column/collection tube assembly. The column assembly was spun at
10,000 X g for 1 min. Flow through was discarded and 750 pi of PE buffer was added 
to the column. The column was spun again at 10,000 x g for another 1 min, and the 
flow thi'ough discarded. To remove all traces of ethanol present, the centrifugation 
step was repeated. After that, the column was transferred to a clean 1.5 ml 
microcentrifuge tube. Thirty pi of 10 mM Tris Cl, pH 8.5 were added to the column 
and left stand for 1 min. Finally, the column was spun again at 10,000 x g for 1 min. 
The column was discarded and the eluted products stored at -20°C until required.
2.3.5. DNA ligation
T4 DNA ligase (Promega) was used for most of the cloning strategies. The multiple 
cloning site of the relevant plasmid vector was cut with the appropriate restriction 
enzymes (Section 2.3.3) and treated with calf alkaline phosphate (Roche) for one hour 
at 37°C. Vector DNA (50-100 ng) was mixed with the target insert, at a molar ratio
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of 1:5, together with an appropriate volume of ligation buffer and 4.5 units of T4 
DNA ligase (Promega), to make up a final volume of 10-20 pi. The reactions were 
left overnight at 14°C, before proceeding to the transformation step, described in 
Section 2.3.1.
2.4. Polymerase chain reaction
The polymerase chain reaction (PCR), a means of amplifying small amounts of 
specific DNA template from a complex mixture, is reviewed extensively by Innis and 
Gelfand, (1990). The general guideline of how the method was applied to DNA 
amplification throughout the project is described below. The details of more specific 
PCR experiments are provided in the relevant Chapters where necessary.
2.4.1. PCR primer design
Custom oligonucleotide syntheses were provided by MWG Biotech. Most of the 
oligonucleotide primers were between 20 to 30 deoxynucloetide residues in length, 
with a base comparison of 50-60% guanine (G) or cytosine (C) where possible. 
Primer pairs with complementary sequences were avoided, and both primers were 
designed (Primer 3 software, US) so as to have matching annealing temperatures (Tm).
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2.4.2. PCR conditions
PCR reagents were supplied by Promega. Amplification reactions were typically set 
up in a reaction mixture of the following: 200 pM of dNTP, PCR buffer (50 mM KCl, 
10 mM Tris-HCl, pH 9.0, 0.1% Triton® X-100 and 1.5 mM MgClz) and 2.5 units of 
Taq DNA polymerase. The appropriate amount of DNA or cDNA template varied 
between PCR reactions, but was generally between 10 to 100 ng. Thermal cycling 
was carried out on a thermocycler machine (Mastercycler® gradient, Eppendorf). For 
standard PCR, the template was denatured firstly for 3 min at 95°C, followed by 30 s 
at 95°C denaturing step, 30 s at 60°C annealing steps and 90 s at 72°C extension steps. 
The above process was repeated for 34 cycles, and a final 72°C for 2 min, before 
holding at 4°C. The PCR amplification products were stored at -20°C until needed. 
Amplification products were visualised by agarose gel electrophoresis, as mentioned 
in Section 2.3.4.1. Up to 10 pi of the PCR reaction were loaded into each well for 
electrophoresis.
2.5. DNA sequence analysis
All sequence data were obtained using ABI sequencing kits (Applied Biosystems), 
based on the chain termination method (Sanger et al., 1977) with cycle sequencing 
modification as previously described (Innis et al., 1988). Version 3.0 ABI thermal 
cycle system (Applied Biosystems) was used in this project.
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2.5.1. Sequencing primer design
Custom oligonucleotides for cycle sequencing were supplied by MWG Biotech. Most 
of the oligonucleotide primers were 20 to 25 oligonucleotides in length, with a base 
comparison of 50-60% guanine (G) or cytosine (C) where possible. The last (3’) 
bases of either adenosine (A) or thymidine (T) was avoided, with a 3’ stretch of 4-5 
guanine (G) or cytosine (C) residues preferred.
2.5,2. Reaction conditions for cycle sequencing
The majority of the templates used for sequencing in this project were plasmid DNA 
derived from small scale (Section 2.3.2.1) or large scale (Section 2.3.2.2) preparations. 
The supplier’s guidelines (Applied Biosystems) were followed. Briefly, the cycle- 
sequencing reaction mixture consisted of ABI PRISM® Big Dye reagent mixture 
(Applied Bio systems) and appropriate sequencing buffer, together with 200 to 500 ng 
of DNA template and 1.6 pmol/pl of each sequencing primer, made up to 20 pi with 
millipore-pure water. Cycle sequencing was carried out on a thermocycler machine 
(Mastercycler® gradient, Eppendorf), using the following programme. The template 
was denatured for 2 min at 96°C, followed by 10 s at 96°C (denaturing), 10 s at 50°C 
(annealing) and 4 min at 60°C (extension) . The last 3 steps of the above process 
were repeated for 24 cycles, with a final hold at 4°C. The cycle sequencing products 
were stored at -20°C until needed.
Performa CTR gel filtration cartridges (Edge Biosystems) were used to clean the 
cycle-sequencing reaction product. The cartridge effectively removed dye terminators,
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dNTP s, and other low molecular weight materials from sequencing reactions. The 
manufacturer’s protocol for the cleaning process is summarised as follows. Firstly, 
the Performa Gel Filtration Cartridges were centrifuged for 3 min at 750 x g. Then, 
the cartridges were transferred to clean 1.5 ml micro centrifuge tubes. The sequencing 
products were added to the packed columns, and centrifuged for another 3 min at 750 
X g. The eluted volume which contained the clean sequencing products was retained. 
These samples were then freeze-dried for 1 hour by vacuum desiccation (VR-1, 
Hetovac). The sequencing products were resuspended in 25 pi Hi-Di formamide 
(Applied Biosystems). Twenty pi of the resuspended samples were loaded into each 
of the 96-well-plate. Then, the plate was loaded in to the ABI PRISM® 3100 Genetic 
Analyzer (Applied Biosystems), a 16-capillary instrument. Data were analysed using 
Chi’omas version 2.2.3 software packages (Technelysium Pty Ltd, US). Sequence 
pileups and comparisons were carried out by Blast (NCBI) and AliBee Multiple 
Alignment (GeneBee).
2.6. Cell culture
2.6.1. C2C12 cell culture
Most of the cell culture work was performed with C2C12 cells (cat. N~. CRT-1772, 
ATCC), a subclone of a mouse myoblast cell line. C2C12 cells differentiate readily to 
form contractile myotubes. C2C12 cells have several advantages over the usage of 
primary cultme. Firstly, they are effectively a homogenous population of myoblasts 
without the other contaminating cell types. Secondly, C2C12 cells are robust and 
amenable to laboratory manipulation. All C2C12 cells were grown in proliferation
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medium (PM) [10% foetal bovine serum (BioWest, France) in Dulbecco’s modified 
Eagle medium (DMEM) (Gibco®) with 100 units/ml penicillin, 100 pg/ml 
streptomycin (Invitrogen) and 10 pg/ml ciproxine (Bayer)]. At 80% confluence, PM 
was replaced by differentiation medium (DM) [4% horse serum (BioWest, France) in 
DMEM with penicillin and streptomycin] to promote myotube formation.
2.6.1.1. Cell passaging
C2C12 cells were routinely passaged when they reached about 80% confluence. 
During passage, culture medium was carefully removed and discarded. The cells 
were washed twice with phosphate buffered saline (PBS) (Gibco®). Trypsin (0.05%) 
and EDTA (0.53 mM) (Invitrogen) were added to detach the cells and incubated at 
37°C for 5 min. After the incubation, the flask was gently tapped to dislodge the cell 
monolayer. Five times the volume of serum containing medium was added to 
inactivate the enzyme, and the mixture was transferred to a 50 ml Falcon tube and 
centrifuged at 1200 x g for 5 min. The supernatant was discarded and the cell pellet 
was resuspended in fresh PM.
2.6.I.2. Cell storage
Cells cannot be maintained indefinitely in culture and therefore must be stored in 
liquid nitrogen for long term usage. Cells that required storage were washed and 
trypsinised as mentioned in the above section. The cells were resuspended In 100% 
foetal calf serum with 10% DMSO (Ambion), and transferred into cryovials
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(Invitrogen). Cryovials were pre-chilled in the ice. With help of an isopropanol-filled 
freezing container “Mr. Frosty” (cat. N~. 5100, Nalgene®), the cryovials were frozen 
at a controlled rate (l°C/min) at -70°C freezer overnight. The following day, the vials 
were transferred to -196°C liquid nitrogen storage.
When removing cells from cryostorage, the vials were thawed quickly in a water bath 
at 37°C, without the tubes being submerged into the water bath. Ten ml of PM were 
added and the mixture was centrifuged at 1200 x g for 5 min. The supernatant which 
contained cytotoxic DMSO was discarded. The cell pellet was resuspended in fresh 
cultured medium and transferred to a culture flask.
2.6.I.3. Surface coating
Some culture flasks, multi-well plates and chambered slides were coated with gelatin 
to modify the culture of C2C12 cells. Gelatin 2% stock solutions (Sigma) were 
preheated at 37°C for 30 min. Sterilised and millipore-pure water was used to prepare 
0.1% gelatin solution. One day prior to plating, sufficient 0.1% gelatin was placed 
into each well or chamber, to cover the entire surface. After 15 min, the gelatine 
solution was aspirated away. Each well or chamber was then rinsed with water and 
left to air-dry. Coated culture dishes were kept at room temperature.
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2.6.2. AD293 cell culture
AD293 ceils (cat. N-. 240085, Stratagene) were used for the production and 
amplification of recombinant adenoviruses. The AD293 cell line is a modified human 
embryonic kidney 293 (HEK293) cell line, with improved cell adherence and plaque 
formation properties. HEK293 cells are human embryonic kidney cells transformed 
by sheared adenovirus type 5 DNA. AD293 cells have similar properties to HEK293 
cells, which produce the adenovirus E l gene in trans, allowing the production of 
infectious virus particles when cells are transfected with El-deleted adenovirus 
vectors. Standard HEK293 cells do not adhere well to tissue culture dishes.
AD293 cells were cultured in DMEM supplemented 10% PCS for growth purpose, 
together with standard antibiotics supplementation of 100 units/ml penicillin, 100 
pg/ml streptomycin (Invitrogen) and 10 pg/ml ciproxine (Bayer). The passage and 
storage of the AD293 cells were similar to that of C2C12 cells as described previously 
in Sections 2.6.1.2 and 2.6.1.3.
2.6.3. Lipofectin transfection
The introduction of foreign DNA into mammalian cell culture was typically 
performed through liposome-mediated transfection, using Lipofectin (Life 
Technology™). The guidelines from the suppliers are briefly restated. Transfection in 
a 25 cm^ culture flask was performed when cells were 40% confluent. Two solutions 
were prepared, solution A (60 pi of Lipofectin reagent with 900 pi of Optimem 
medium was allowed to stand at room temperature for 30-45 min) and solution B (10
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pi or 6.0 pg of DNA with 900 pi of Optimem medium). The two solutions were 
mixed and incubated at room temperature for 20 min to allow the formation of DNA- 
liposome complexes. At the same time, PM was removed from the cell culture, and it 
was rinsed twice with 5 ml Optimem solution. Four ml of serum-free PM were added 
into each tube containing the DNA-liposome mixture, and the whole solution was 
overlaid onto the cells. The cells were incubated for 5 to 6 hours at 37°C in a 00% 
incubator (Gallenkamp, UK). Following this, the DNA containing medium was 
replaced with 5mi of 10% DMEM and incubated for a further day.
In order to produce an enriched population of modified cells, a selection system must 
be used to remove untransfected cells. Geneticin (G418) (Gibco®) was used as a 
selectable marker. G418 is a type of aminoglycoside phosphotransferase which 
blocks protein synthesis by interfering ribosomal function. G418 (2000 pg/ml) was 
used in stable selection for at least 7 days. To monitor the effectiveness of the 
selection process, a control population of untransfected cells was maintained in 
identical conditions. After 7 days, the surviving transfected cells were switched to 
1000 pg/ml of G418, to maintain the selection pressure.
To obtain larger populations of transfected cells, the transfection flasks were passaged 
from 25 cm^ culture flasks to bigger 75 cm^ culture flasks (Costar®, USA). Care was 
exercised to keep the passage number low. Cells were periodically stored in liquid 
nitrogen for future use. Cells derived from stable transfections were used for the 
proliferation assay and fusion index experiments, described in later sections. All 
subsequent experiments on stably transfected cells were conducted in the absence of 
G418.
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2.6.4. Recombinant adenovirus production
As a complement to stable transfection, infectious recombinant adenoviruses were 
generated to carry the genes of interest. BD Adeno-X^" Expression System 2 (BD 
Biosciences) was used to produce recombinant adenoviruses. The protocol involved 
the transfer of the gene of interest from a BD Creator Donor Vector to a BD Adeno-X 
Acceptor Vector, by the use of ere recombinase. The manufacturer’s protocol is 
summarised as follows.
2.6.4.I. Adenovirus vector cloning
The starting plasmid vector pDNR-CMV for the insertion of the gene of interest 
housed an expression cassette that was derived from the plasmid pAAV-IRES-hrGFP 
(Stratagene) which comprised a multiple cloning site for the creation of a 3’-end 
FLAG fusion gene and a GFP reporter gene, with an internal ribosomal entry site 
(1RES) between the two (Fig. 2.3).
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Figure 2.3. Plasmid vector pDNR-CMV. It comprises a multiple cloning site for the 
creation of a 3’-end FLAG fusion gene and a GFP reporter gene (which derived from pAAV- 
IRES-hrGFP vector). Amp= ampicillin resistance gene; Cm= chloramphenicol resistance 
gene; CMV= cytomegalovirus; IRES= internal ribosome entry site; MCS= multiple cloning 
site; SacB= sucrase gene from B.subtillis. BamH I, EcoR I & Xho I are vector restriction 
sites.
The following reagents were prepared for the creator reaction, which included: 1 pi 
(200 ng) of recombinant donor vector, 1 pi of Cre Recombinase and 18 pi of reaction 
mix (pLP-Adeno-X-CMV acceptor vector, Cre rection buffer and bovine serum 
albumin). The mixture was left at room temperature for 15 min. After incubation, the 
reaction was terminated at 70°C for 5 min. The recombinase enzyme binds to the 
loxP sites on both the donor vector and acceptor vector, and undertakes DNA cleaving
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and ligation. As a result, the gene of interest was transferred in the appropriate 
orientation to the acceptor vector (Fig. 2.4).
Four pi of reaction was withdrawn and added into to XL 10-Gold ultracompetent cells 
(Stratagene). The procedure for ultracompetent cell transformation was described in 
Section 2.3.1.1. The next day, a minimum of 10 bacterial colonies were individually 
picked into 30 pi of deinonised H2O. The colony was resuspended by gentle 
voilexing. Twenty pi of bacterial suspension were transferred into 5 ml of LB broth 
containing 100 pg/ml ampicillin and 30 pg/ml chloramphenicol. The medium was 
cultured for 5-6 hour at 37°C in a shaking incubator (S I50, Stuart). The remaining 10 
pi was analysed by PCR to identify positive clones. Each reaction was set up as 
follows. Ten pi double-distilled water, 10 pi of bacterial suspension, 2.5 pi of lOX 
Taq PCR buffer, 1 pi each of primer mix and dNTP mix, and 0.5 pi of Taq polymerase. 
Thermal cycling was carried out on a thermocycler machine (Mastercycler® gradient, 
Eppendorf). The template was firstly denatured for 2 min at 95°C, followed by 15 s 
at 94°C, 30 s at 64°C and 30 s at 68°C. The last 3 steps of the above process were 
repeated for 20 cycles. Amplification products were visualised by agarose gel 
electrophoresis, as described in Section 2.3.4.1. The predicted band size for a 
successful recombination was 660 bp.
Once a positive clone was identified by PCR, the clone was amplified by maxiprep 
DNA preparation as described in Section 2.3.2.2 by using the previous 20 pi of 
bacterial suspension inoculated into the 5 ml LB broth.
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Figure 2.4. Overview o f recom binant adenovirus production. (Diagram modified 
from BD-Adeno-X expression systems 2 User Manual, BD Bioscience)
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2.6.4.2. Pac I digestion of recombinant Adeno-X DNA for transfection
Before the Adeno-X DNA could be packaged, the recombinant plasmid was linearised 
with Pac I to expose the inverted terminal repeats (ITRs) which were located at either 
end of the genome (Fig. 2.4). The ITRs contained the origins of adenovirus DNA 
replication and must be positioned at the terminal of the linear adenovirus DNA 
molecule to support the formation of the replication complex. A mixture of the 
following reagents were prepared in a sterile 1.5 ml microcentrifuge tube: 20 pi of 
deinonised H2O, 5 pg/pl of recombinant plasmid DNA from the above section, 4 pi of 
10 X Pac I digestion buffer, 4 pi of 10 X BSA and 2 pi of Pac I restriction enzyme. 
The contents were incubated at 37°C for 2 hour. After the incubation period, 60 pi of 
IX TE buffer (pH 8.0) and 100 pi of phenol: chloroform: isoamyl alcohol (25:24:1) 
(Sigma) were added to the reaction. The tube was mixed gently, and was spun at
10,000 X g for 5 min at 4°C to separate the phases.
The top aqueous layer was transferred to a clean sterile 1.5 ml microcentrifuge tube. 
Four hundred pi of 95% of ethanol and 1/10 volume of 3M sodium acetate (NaOAc) 
were added to the tube and was mixed gently. The mixture was spun at 10,000 x g at 
4°C for 5 min, and the supernatant was discarded. Three hundred pi of 70% ethanol 
were added to wash the pellet and the tube was centrifuged again at 10,000 x g for 2 
min. Subsequently, supernatant was removed and the pellet was left to air-dry at 
room temperature. The DNA was resuspended in 10 pi sterile IX TE buffer pH 8.0 
and used for transfection.
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2.6.4.3. Transfecting AD293 cells with Pac I digested Adeno-X DNA
The transfection protocol was similar to lipofection transfection (Section 2,6.3). 
However, Lipofectamine (Life Technology™) was selected in this protocol instead of 
Lipofectin (Life Technology""), because of the need for higher transfection efficiency 
(Ciccarone et al., 1999). Transfection was performed in a 25 cm^ culture flask.
Following transfection, AD293 cells were regularly checked for cytopathic effects 
(CPE), which were manifested as rounded and detached cells. It could take up to two 
weeks for full CPE to develop. Cells were transferred to a 50 ml tube. No trypsin 
was used. The cells were spun at 1,500 x g for 5 min at room temperature. The 
supernatant was removed and the pellet was resuspended in 500 pi of sterile PBS. 
Then, the cells were lysed with three consecutive freeze-thaw cycles. Each time the 
cells were frozen in dry ice for 5 min and thawed for 5 min in 37°C with vigorous 
mixing. After the third cycle, the cells were spun at 10,000 x g for 10 min. The 
lysate was transferred to a clean, sterile microcentrifuge tube and stored at -70°C.
For amplification of the recombinant adenovirus, the lysate from a 25 cm^ culture 
flask was used to infect a larger 75 cm^ culture flask. After CPE was fully established, 
cell lysate was haiwested after 3 freeze-thaw cycles as before. To obtain a higher 
quantity of high-titre adenovirus, lysate from the first amplification was used to infect 
a series of 162 cm^ culture flasks. Cell lysate and culture medium were pooled for 
virus purification.
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2.6.4.4. Purification of recombinant adenoviruses
BD Adeno-X virus purification kits (BD Biosciences) were used to purify and 
concentrate adenoviruses (Fig. 2.5). All the procedures were performed in a Class II 
biosafety hood. Combined lysate and culture medium from the earlier steps described 
above were clarified with a filter disc in the filter unit bottle, connected to a vacuum 
source. Once the process was completed, the vacuum line was disconnected and the 
filtrate was transferred into a sterile filter bottle. Ten units of Benzonase nuclease 
(BD Biosciences) per ml were added to the filtrate to remove contaminating cellular 
DNA, and the mixture was incubated at 37°C for 30 min. An equal volume of IX 
dilution Buffer was added to the filtrate.
Next, the tube assembly was placed in the virus containing filtrate. The supernatant 
was loaded into the syringe and the content pushed through the virus-affmity filter at 
-20 ml/min. The inlet tubing was transferred to a holding vessel containing IX wash 
buffer. Then, the wash buffer was pulled into the syringe through the tubing, and 
wash buffer was pushed tlirough the filter at -20 ml/min. Next, the filter was 
removed from the tubing assembly. To elute the adenovirus, the BD luer-lok tip 
syringe was filled with 3 ml of IX elution buffer. It was attached to the filter 
cartridge and 1 ml of the elution buffer was pushed through the filter into a sterile 15 
ml conical tube. The filter was incubated at room temperature for 5 min before 
pushing the remaining elution buffer through the filter. The purified adenovirus was 
aliquoted in sterile 1.5 ml microcentrifuge tubes and stored at -70°C.
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Pre-Filter Disc
Holding vessel
1. Detach the holding vessel
2. Treat with Benzonase Nuclease
3. Add dilution buffer
Adeno-X Purification Filter
Tubing Assembly
A im i|riii[|rtirn
Syringe
1. Filter
2. Rinse with 1x wash buffer
1. Elute with 1x elution buffer
2. aliquot
3. Stored at -70°C
Figure 2.5. Overview o f the BD-Adeno-X v irus purification protocol. (Diagram 
modified from BD-Adeno-X Virus Purification User Manual, BD Bioscience)
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2.6.5. Cell cytotoxicity assay
Cells cytotoxicity assay was performed with the Cell Titer-Blue kit (Promega), which 
uses the indicator dye resazurin to measure the metabolic capacity of cells as an 
indicator of cell viability. Viable cells retained the ability to reduce resazurin into 
resorufin, which is highly fluorescent. Non-viable cells do not reduce the indicator 
dye, and thus do not generate a fluorescent signal. Fifteen thousand C2C12 cells were 
plated into each well of a 96 well plate. For time course studies, infections with genes 
of interest were used at a multiplicity of infection (MOI) of 5. Cells were infected in 
PM for 3 days (31), followed by 3 days in DM (31 3D), or by 6 days in DM (31 6D), or 
10 days in DM (31 lOD). Stably transfected cells were grown in PM for 3 days (PM), 
followed by 3 days in DM (DM 3D), or 6 days in DM (DM 6D), or 10 days in DM 
(DM lOD). At the above selected time points, cells were incubated in 20 pi of 
CellTiter-Blue Reagent at 37°C for 2 horns. The plate was then examined under 
fluorescence at 560 nm excitation and 590 nm emission wave lengths. The dye 
solution was removed and the wells were washed 3X with PBS. Cell lysate were 
harvested from the wells using the protocol described in Section 2.6.10. Fluorescence 
results were normalised to unit weight of protein (mg/ml).
2.6.6, Ceil proliferation assays
Proliferation assays were performed in stably transfected C2C12 cells by quantifying 
cell number with a Neubauer haemocytometer. The haemocytometer is a thick glass 
slide with a ruled area etched on it, and the ruled square 3 mm by 3 mm. This square 
is further divided into nine squares, each 1 mm by 1 mm. The space between the top 
of the platform and the coverglass is 0.1 mm (Fig. 2.6). When the haemocytometer is
loaded properly, the volume of cell suspension that will occupy one primary square is 
0.1 mm^ (1.0 mm^ x 0.1 mm) or 1.0 x lO'"* ml. All outside edges of the nine large 
squares of the haemocytometer are bounded by triple lines.
1 mm
^  Cover ghw
^Courting \  
chambeis
Cover gle#s laowtmg
Sangle iitioductionpoirt
. ^ 0.1 nun Minple 
\  dqofh
Figure 2.6. Neubauer haemocytometer. It contains nine squares, each 1 mm by 1 mm, 
and the space between the top of the platform and the cover-slip is 0.1 mm.
Thirty thousand cells were plated on each 25 cm^ flask (three flasks each for 
individual DNA construct). The C2C12 cells were allowed to grow up to 5 days. The 
cells were trypsinized and spun down at 1200 x g for 5 min. Cells were resuspended 
in 1 ml of fresh PM. Fifty pi of the resuspended cells were added to 50 pi of Trypan 
Blue, and mixed well. The cover-slip was gently placed on top of the 
haemocytometer and 15 pi of the mixture was carefully pipetted into each side of the 
haemocytometer.
With the X200 magnification of the microscope, all the cells that were located within 
the upper left corner of the primary square were counted, and counting was repeated 
for the other three comers. The same procedure was used to count the cells on the 
other side of the haemocytometer. Eight readings were obtained from the counting.
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The cell concentration in the original suspension (in cells/ml) was determined by the 
formula:
Cells/ml = total count x 1000 x dilution factor
A dilution factor of two was used as 50 pi of the resuspended cells had been mixed 
with an equal volume of Trypan Blue. The results were statistically analysed as 
detailed in Section 2.9.
2.6.7. Fusion index assay
Fusion index is defined as the number of nuclei within myotubes in a given field 
divided by the total number of nuclei in the same field. It was performed to determine 
whether different constructs in transfected cells conferred differences in fibre fusion. 
Thirty thousand C2C12 cells stably transfected with different DNA constructs were 
plated on 24 well plates in PM for 3 days, followed by DM for a further 9 days. 
During differentiation, DM was replaced every other day.
After 9 days in DM, cells were fixed in 50% methanol/50% acetone (Fisher Scientific, 
UK) for 15 min. The cells was washed 3X with PBS and permeabilized by PBS 
containing 0.25% Triton for 20 min. After washing, the cells were incubated for 1 
hour in blocking buffer (0.1% Triton/5% sheep serum in PBS). Next, cells were 
incubated with a primary antibody [anti-desmin 1:200, (Dako), anti-MyHC slow or 
anti-MyHC fast 1:200, (Sigma)] at 4°C overnight. The next day, the cells were 
washed three times in PBS, and stained with a secondary FITC conjugated sheep anti­
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mouse antibody at 1:200 dilution (Sigma). After washing, it was mounted using 
Vectashield® hard set mounting medium with DAPI (Vector). The stained cells were 
examined under an inverted fluorescence microscope (Leitz, Labovert). Images were 
captured by a CCD camera (C4742, Hamamatsu). Fusion rates were analysed using 
Adobe® Photoshop software (Adobe®). Five fields were randomly chosen for 
counting captured at X200 magnification (Fig. 2.7). Three independent experiments 
were conducted. The collected data was statistically analysed as detailed in Section
2.9.
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Figure 2.7. Fusion index determ ination. Stably transfected C2C12 myotubes (differentiated for 9 
days) were immunostained for (A) desmin, along with (B) DAPI nuclei staining, captured under X200 
magnification. (C) Overlaid image A and image B. (D) The number of nuclei within myotubes as 
well as the overall total number of nuclei were determined (fusion index). With the aid of Adobe® 
Photoshop software, line dot was plotted on every nucleus within the myotubes.
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2.6.8. BrdU assay
BrdU, also known as 5-bromo-2-deoxyuridine, is a common chemical used in the 
detection of proliferating cells. It works by substituting for thymidine during DNA 
replication (being a base analog of thymidine) and incorporating itself into the newly 
synthesized DNA. Antibodies specific for BrdU (linked to a fluorescent molecule) 
are used to detect the incorporated chemical. In this study, BrdU assay was used to 
measure the proliferation rate of recombinant adenovirus infected cells and stably 
transfected cells.
Fifteen thousand C2C12 cells were plated into each well of a 24 well plate. Cells 
were infected the following day with concentrated adenovirus. At day 3 of infection, 
cells were exposed to BrdU (40 pg/ml) for 2 hour prior to fixation. Five hundred pi 
of 100% pre-chilled methanol were added into each well for 10 min to fix and 
permeabilise cells. After a brief washing step with PBS, cells were fixed by 500 pi 
0.2% paraformaldehyde for 1 min. The washing step was repeated, and cells were 
incubated with 500 pi 0.07 M NaOH for 10 min. This denatured the DNA to allow 
the antibody to access the BrdU molecules that had been incorporated into the 
replicating DNA. The washing step was repeated, cells were blocked with 5% sheep 
serum in 0.1% Triton X for 1 hour. Next, 200 pi anti-BrdU antibody at 1:300 (Sigma) 
in blocking buffer were incubated into the cells at 4°C overnight. The following day, 
the wells were rinsed, and secondary antibody (Texas Red conjugated goat anti-mouse 
IgG from Southern Biotech at 1:200) were applied for 1 hour. It was mounted using 
Vectashield® hard set mounting medium with DAPI (Vector). Images were captured 
by a CCD camera mounted on an inverted fluorescence microscope (Leitz, Labovert).
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Images were analysed with Adobe® photoshop software. For each construct, 5 
random fields were chosen under magnification X200. BrdU assay, was quantified as 
number of BrdU positive stained nuclei in a given field divided by the total number of 
nuclei (DAPI stained) in the same field. For each construct, three independent 
experiments were conducted. The data was statistically analysed as detailed in 
Section 2.9.
2.6.9. Immunofluorescence
Thirty thousand C2C12 cells, infected with the gene of interest or GFP control 
adenovirus, were grown for 3 days in PM, followed by 8 days in DM on each well of 
a 12 well plate. The procedures were similar to other immunofluorescence protocols 
(Section 2.6.8), the major differences being that the cells were fixed in 4% 
paraformaldehyde instead of methanol, and NP40 was used to permeabilise cells 
instead of Triton X.
Cells were incubated in blocking buffer [5% goat serum (BioWest, France) in PBS] 
for 1 hour. Subsequently, the cells were incubated with primary anti-FLAG M2 
monoclonal antibody at 1: 2000 dilution (Sigma), overnight at 4°C. Next day, they 
were washed thiee times in PBS. A goat anti-mouse-TRITC (Tetramethyl Rhodamine 
Iso-Thiocyanate) at 1:200 dilution (Southern Biotech) was used as the secondary 
antibody in a 45 minute incubation at 37°C. The washing steps were repeated. Next, 
it was mounted using Vectashield® hard set mounting medium with DAPI (Vector). 
Images were captured by a CCD camera mounted on an inverted fluorescence 
microscope (Leitz, Labovert).
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2.6.10. Protein extraction
Cells were grown at 37°C until they reached the required confluence level or 
differentiation state. First of all, cells were rinsed twice with PBS. Then, RIPA 
buffer (0.6 ml) (Santa Cruz Biotechnology) containing 6 pi of phenylmethylsulfonyl 
fluoride (PMSF), 6 pi of sodium orthovanadate and 6 pi of protease inhibitor were 
added into a 100 mm cell culture dish. The cells were incubated for 15 min at 4°C. 
After incubation, cells were scraped off with a cell scraper. The scrape lysate was 
transferred to a microcentrifuge tube. The dish was washed with a further 0.3 ml 
RIPA buffer to remove any remaining adherent cells. The solution was combined 
with the first lysate and, together incubated on ice for 30 min. The cells were spun at
10,000 X g for 10 min at 4°C. The supernatant was transferred to a sterile 
micro centrifuge tube and stored at -20°C.
2.6.11. Determination of protein concentration
Spectrophotometry (DU-65 spectrophotometer, Beckman) at OD562 was used to 
determine protein concentration. The BCA™ protein Assay kit (Pierce) was used. It 
is a detergent-compatible formulation based on bicinchoninic acid (BCA) for the 
colorimetric detection and quantitation of total protein. The supplier’s procedure is 
summarised below. A set of diluted albumin protein standards (0.05 mg/ml, 0.1 
mg/ml, 0.2 mg/ml, 0.4 mg/ml, 0.6 mg/ml) was prepared. Fifty parts of reagent A with
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1 part reagent B (50:1, Reagent A:B) were mixed together. For convenience, 20 ml of 
reagent A and 400 pi of reagent B were prepared in bulk.
Each protein sample was diluted 1:10 in millipore-pure water to a total volume of 50 
pi. Fifty pi of each standard and protein samples were loaded into microcentriftige 
tubes. One ml of the mixture (reagent A and B) was added into each tube, and 
incubated at 37°C for 30 min. Next, each sample was transferred to an optical cuvette. 
Its optical density was determined at 562 nm. A standard curve was plotted with the 
albumin protein standards, and then used to determine the protein concentration of the 
sample.
2.7. Quantitative Real-Time RT-PCR
Quantitative real-time revers e-transcription polymerase chain reaction (real-time RT- 
PCR), was used to measure an accumulating PCR product in real time by using an 
internal fluorogenic TaqMan oligonucleotide probe that was activated by the 
endogenous 5’->3’ nuclease activity of Taq polymerase (Freeman et al., 1999). Real­
time RT-PCR is a combination of two separated techniques. The first technique 
involved is reverse transcription, the conversion of mRNA to cDNA. The second 
technique is the actual real-time PCR. The probes used in this study were based on 
TaqMan, or fluorogenic 5’ nuclease, chemistry (Roche). In this method, the probe 
was labelled with a 5’ fiuorochiome and 3’ quencher. As the DNA polymerase 
encountered the annealed probe, its 5’ nuclease activity cleaved it and separated 
fluorochrome from quencher. This resulted in an increase in fluorescence that serves
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as an indicator of the PCR reaction progress. The reaction was characterised by the 
point at which the level of fluorescence, and hence the PCR amplification, crossed a 
set thi'eshold. The higher the target’s copy number, the sooner this threshold would 
be reached. The samples were quantified relative to an endogenous control, typically 
a house-keeping gene. In this project work, p-actin was selected as the house-keeping 
for normalisation.
2.7.1. Total RNA extraction
2.7.1.1. Extraction of total RNA from cells
The RNeasy® Mini kit (Qiagen) was used to extract total RNA from cultured cells. 
The manufacturer’s protocol was used, re-stated briefly as follows. Ten pi of 14.3 M 
P-mercaptoethanol (Phiobio, UK) were added to 1 ml of Buffer RLT. Buffer RLT 
was added to disrupt the cells, approximately 600 pi of Buffer RLT was used for each 
cell pellet containing 5 xlO^ to 1 x 10  ^ numbers. With a rotor-stator homogenizer 
(Ultra-Turrax® T8, IK A), each samples was homogenised for 30 s. Next, 600 pi of 
70% ethanol was added to the homogenized lysate and mixed well. The mixture was 
added to an RNeasy mini column placed in a 2 ml collection tube, and centrifuged for 
15 s at 8,000 X g. The flow-tlirough was discarded, 700 pi Buffer RWl were added 
and centrifuged for 15 s at 8,000 x g. The RNeasy column was transferred to a new 2 
ml collection tube and 500 pi Buffer RPE were added into the RNeasy column. The 
tube was closed gently, and centrifuged for 15 s at 8,000 x g. Another 500 pi Buffer 
RPE were added, and centrifuged at 8,000 x g for 2 min to dry the RNeasy silica-gel 
membrane. The tube was spun again at 10,000 x g for 1 min. Next, the column was
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transferred to a clean 1.5 ml collection tube, and 40 p,l of double-distilled water were 
added directly onto the silica-gel membrane. The column was spun for the last time at
8,000 X g for 1 min. The column was discarded and the total RNA was stored at - 
20°C.
2.7.I.2. Extraction of total RNA from splayleg skeletal muscles
Promptly after the piglets were put down by captive bolt, the selected skeletal tissues 
were dissected out. These tissue samples were placed in cryotubes and immediately 
snap-frozen in liquid nitrogen.
RNeasy® Mini kit (Qiagen) was used to extract total RNA from splayleg piglets. The 
supplier’s protocol was used, summarised as follows. Tissues were removed from 
liquid nitrogen storage and kept on dry ice. Thirty mg of tissue were ground using a 
mortar and pestle, pre-chilled with liquid nitrogen. The muscle fragments were 
collected into a micro centrifuge tube with a fine spatula, and 300 pi of Buffer RLT 
with P-mercaptoethanol (Phiobio, UK) were added to the tube. With a rotor-stator 
homogenize!' (Ultra-Turrax® T8, IK A), the samples were homogenised for 30 s. Next, 
590 pi of double-distilled water were added to the homogenate, followed by 10 pi of 
20 mg/ml Proteinase K solution (cat. N-.19131, QIAGEN). The mixture was 
incubated at 55°C for 10 min. After incubation, the tube was spun at 10,000 x g for 3 
min. The supernatant was pipetted into a new tube, and 450 pi of 100% ethanol were 
added to the cleared lysate. The mixture was added to an RNeasy mini column placed 
in a 2 ml collection tube, and centrifuged for 15 s at 8,000 x g. Thi'ee hundred and 
fifty pi Buffer RWl were added to the RNeasy column and centrifuged for 15 s at
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8,000 X g. DNase I mixture (70 pi of Buffer RDD with 10 pi DNase I stock solution) 
(Qiagen) were added directly onto the RNeasy silica-gel membrane, and incubated foi­
ls min. Next, another 350 pi Buffer RWl were added into the column, and 
centrifuged for 15 s at 8,000 x g. The remaining RNA extraction steps are identical to 
those described in the previous Section 2.7.1.1.
2.7.2. Total RNA quality and quantity determination
RNA 6000 Nano Labchip® kit (Agilent Technologies) was used to measure the 
quality and quantity of the total RNA extracted. The manufacturer’s protocol is 
summarised below. RNA 6000 Nano gel matrix was filtered in advance before use. 
One pi of dye was added to 65 pi aliquot of filtered gel, vortexed and spun down at
10,000 X g for 10 min. At the same time, the chip priming station was set up (Fig 2.8). 
A RNA Nano chip was placed on the station, and 9.0 pi of the gel-dye mix were 
pipetted into the well marked “H”. The plunger on the station was set at 1 ml. The 
station was closed and the plunger was pressed until held in place by the syringe clip. 
The plunger was released after 30 s and pulled back to the 1 ml position after 5 s. 
After the station was open, 9.0 pi of gel-dye mix were added to further two wells 
marked with “G”s. For all other wells on the chip, 5.0 pi of RNA 6000 Nano marker 
were added. Samples and the RNA 6000 ladder were preheated for 2 min at 70°C to 
minimise secondary structure. One pi of each sample was loaded into each of the 12 
sample wells. Another 1 pi of ladder was loaded into the well marked with a ladder. 
Subsequently, the chip was vortexed for 1 min in an adapter vortex mixer (MS2-S8,
99
IK A) at 2400 rpm. The chip with samples was read in an Agilent 2100 bioanalyser 
(Agilent Technologies).
o o o o o o o o o o o o
RNA Labchip
Plunger 
Syringe clip
Syringe
Station
Figure 2.8. A RNA 6000 Nano labchlps and a chip prim ing sta tion w ith  piunger. The
well marked "G” is highlighted.
2.7.3. Reverse transcription
The Reverse Transcription System kit (Promega) was used to synthesise cDNA from 
total RNA template. The supplier’s procedure is summarised below. The extracted 
total RNA was incubated at 70°C for 10 min in a water bath. The following reagents 
were prepared for a 1 pg o f RNA sample: 4pl o f 25 mM MgCh, 2 pi o f 10 X reaction 
buffer (100 mM Tris-HCl, pH 9.0, 500 mM KCl, 1% Triton® X-100), 2 pi o f 10 mM 
dNTP mixture, 0.5 pi o f recombinant RNasin® ribonuclease inhibitor, 15 u/pl or 0.63 
pi o f AMV reverse transcriptase and 0.5 pg or 1 pi of random primer. One pg o f total 
RNA and double-distilled water were added to make up to a final volume o f 20 pi in 
each tube.
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The mixture was incubated for 10 min at room temperature to allow primer extension. 
Then, the tube was transferred to a water bath for an hour at 42°C. Subsequently, the 
tube was placed at 99°C for 5 min in a heating block to inactivate the reverse 
transcriptase. Samples were stored at -20°C until needed. All the cDNA samples 
were diluted 100 fold in advance of real-time RT-PCR experiments.
2.7.4. Real-time PCR primer and probe design
Probe and primer sequences were designed using the Primer Express v 2.0 software 
(Applied Biosystems). Typically the probe and primer sequences were between 20 to 
30 deoxynucloetide residues in length, with a base comparison of 50-60% guanine (G) 
or cytosine (C) where possible and the repeats of long nucleotides were avoided. The 
annealing temperature (T„i) was typically around 70°C for probes and 60°C for 
primers. Probes designed were based on TaqMan chemistry (ftuorogenic 5’ nuclease 
chemistry, Roche).
2.7.5. Taqman reaction conditions
Reactions were set up in 96 well optical plates (Applied Biosystems), with the 
following reaction mixture in each sample well: 1 x Universal Master Mix (AmpliTaq 
Gold DNA polymerase, dNTP mix and MgCE, Applied Biosystems), 100 fold diluted 
cDNA template with the appropriate concentration of primers and probe, that made up 
to 25 pi per well. Triplicate analysis of each target gene was performed on the 96
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well optical plates. The ABÏ PRISM® 7700 sequence Detection System with software 
version 1.6 (Applied Biosystems) was used to quantify the cDNA samples. The real­
time RT-PCR cycles were as below. The template was firstly denatured for 2 min at 
50°C, followed by a 10 min denature step at 95°C, 15 s at 95°C annealing steps and 1 
min at 60°C extension steps. The processes were repeated for 39 cycles.
2.7.6. Real-time PCR data analysis
The data obtained from ABI PRISM® 7700 sequencer was normalised against the 
endogenous reference, (3-actin, to account for variation between cDNA samples, 
caused by differences in the efficiency of the total RNA extraction, in reverse 
transcription or in sample loading.
For each sample, an amplification plot was generated. An increase in the reporter dye 
fluorescence with each PCR cycle was displayed. From it, a threshold cycle (Cj) 
value was calculated, which was the PCR cycle number at which fluorescence was 
detected above threshold, based on the variability of baseline data in the first 15 
cycles. Each Ct value was determined from the mean of three separate real-time PCR 
reactions. The relative standard curve for each gene was plotted as Ct (y-axis) vs log 
[cDNA diluted 10-fold sequentially] (x-axis). The slope (m) of the standard curve 
describes the efficiency of PCR, and is defined by the equation
Ct = m (log Q) 4-C
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Where C t is the threshold cycle, Q is the initial amount, and c is the intercept on the 
y-axis. When PCR amplification is maximally efficient and resulting in a doubling of 
product in every cycle, the slope will be -3.3 (Medhurst et ah, 2000). For example, 
the relative standard curve for porcine SPARCL-l cDNA was plotted based on a series 
of 10 fold dilution (Fig. 2.9). The slope is -3.255 and the Y-intercept is 14.19.
Standard  curve
35
-3.2552X+ 14.189K30
R = 0.9964
25
20
-5.00 -4.00 -3.00 
Log ng cDNA
- 2.00 - 1.00 0.00- 6.00
Figure 2.9. Standard curve fo r real-time RT-PCR.
2.8. Western blot analysis
Western blot is an electro-blotting method in which proteins are transferred from a gel 
to a membrane and detected by binding of labelled antibody. It can be divided into 5 
steps: sample preparation, gel electrophoresis, nitrocellulose transfer, antibody 
binding, visualising results.
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2.8.1. Preparation of protein samples
Two hundred and forty pi of 3x sample buffer [0.1875 M Tris-HCl, pH 6.8, 6% 
sodium do decy 1-sulphate (SDS) (USB Corp, Ohio), 30% glycerol, 0.03% 
bromophenol blue] were added to 30 pi IM dithiothreitol (DTT) (Invitrogen) (in 0.5 
ml tube) and vortexed thoroughly to mix, to prepare a SB/DTT master mix. 
Appropriate volumes of water and protein were added to a 1.5 ml microcentriflige 
tube, followed by 6 pi SB/DTT, to make up a final volume of 18 pi. The samples 
were vortexed and spun briefly at 6,000 x g for 8 s, incubated at 90°C for 4 min, and 
stored at -20°C until needed.
2.8.2. Protein electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate denatured proteins according to their molecular weight (Laemmli, 1970). 
Model mini-V8-10 Vertical Gel electrophoresis System (Life Technology ") was used 
(Fig. 2.10). The gel plates, comb and spacer were assembled, and a distance of 1 cm 
below base of comb was marked. The following reagents were used for a 10% 
resolving gel: 0.1 ml of 10% ammonium persulphate (APS) (Sigma), 4 ml millipore- 
pure water, 2.5 ml Resolving Buffer (1.5 M Tris-HCl, pH 8.8), 3.3 ml acrylamide 
(Sigma) [29% (w/v) acrylamide, 1% (w/v) bisacrylamide in millipore-pure water], 0.1 
ml of 10% SDS and 0.01 ml of tetramethyl-1-, 2-diaminomethane (TEMED) 
(Aldrich). The solution was gently syringed between the glass plates to a level just 
above that marked, the plates was tapped on bench to release any trapped air bubbles.
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The resolving gel was overlaid with approximately 0.5 ml of 0.1% SDS, to ensure a 
smooth, flat, bubble free surface. The 0.1 % SDS was washed with millipore-pure 
water, and the loading comb placed between the glass plates. The stacking gel mix of 
2.5 ml Stacking Buffer (0.5 M Tris-HCl, pH 6.8), 1.3 ml acrylamide [29% (w/v) 
acrylamide, 1% (w/v) bisacrylamide in millipore-pure water], 0.1 ml of 10% APS, 0.1 
ml of 10% SDS, 0.01 ml TEMED and 6 ml millipore-pure water, was applied over the 
resolving gel, and left for 20 min to polymerise. The comb was removed and the 
wells were flushed with Running Buffer (0.25 M Tris Base, 1.92 M glycine, 1% SDS).
Power cords
Upper electrode 
Ledge
Buffer tank
Safety lid
Gel wedge block
Lower Gel supportelectrode frame
Rim
Figure 2.10. Gel E lectrophoresis system. A mini-V8-10 Vertical model, which contains 
buffer tank, gel support frame, gel wedge block and safety lid. Two long and short glass 
plates with gel holder are not illustrated here.
Six hundred ml running buffer were poured into the running tank, polymerised gel 
was removed from its blue moulds and place in the rmming tank. Samples prepared 
by the method described in the previous Section 2.8.1 were warmed at 55°C to ensure 
that the SDS went into solution before being loaded into the gel. A colour protein
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ladder marker (SeeBlue® Plus2 Pre-Stained standard, Invitrogen) was loaded along 
with the protein samples. Gels were run at 200 volts for approximately 1 hour or until 
the dye front reached the bottom of the glass plate.
2.8.3. Transfer onto PVDF membranes
At this stage, the protein in the gel was transferred onto a membrane made of 
polyvinylidine difluoride (PVDF). The membrane binds proteins non-specifically. 
Binding is based on hydrophobic interactions as well as charges between the 
membrane and protein. One sheet of filter paper (3MM, Whatman®) was soaked in 
anode buffer I [0.3 M Tris pH 10.4, 10% (v/v) methanol], two in anode buffer II [25 
mM Tris, pH 10.4, 10% (v/v) methanol] and three in cathode buffer [25 mM Tris pH
10.4, 40 mM glycine, 10% (v/v) methanol]. PVDF membrane was rehydrated in 
methanol for 10 seconds, followed by water for 5 min, and then in Anode Buffer II 
until required. After gel electrophoresis, the gel was immersed in cathode buffer for 5 
min. Thi’ee sheets of filter paper (one from anode buffer I and two from anode buffer 
II) were placed on the base of the transfer unit. Next, the PVDF was placed on top, 
followed by the gel onto the membrane. Thi'ce sets of cathode buffer pre-soaked filter 
papers were placed on top of the gel (Fig. 2.11). When the transfer unit was 
assembled, it was run at a constant current of 1.3 mA/cm^ for 1 hour. After one hour, 
the power supply was switched off, and with the PVDF membrane still in place, a 
pencil was used to label the membrane. To assess the transferred proteins, the 
membrane was immersed in Ponceau S [0.5 g Ponceau S (Sigma), 25 ml acetic acid] 
for 1 min and washed with millipore-pure water. After visual assessment, the
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membrane was washed with TBS/S [0.5 M Tris pH 7.4, 1.5 M NaCl, 0.1% tween 
(Invitrogen)] before antibody binding.
(-) Cathode plate
3 filter papers (cathode buffer) 
Gel
PVDF membrane 
2 filter papers (anode buffer II) 
1 filter paper (anode buffer I)
(+) Anode plate
Figure 2.11. The com plete transfer unit assembled. The gel and PVDF were sandwiched 
with three filter papers on either side. The current path from cathode to anode transferred the 
protein from the gel to the PVDF membrane.
2.8.4. Antibody binding
After transfer, the PVDF membrane was incubated in blocking buffer [5% skimmed 
milk (Marvel) in TBS/T] for 45 min on a rocker. Next, the membrane was incubated 
overnight with primary antibody in blocking buffer at 4°C. The membrane was 
washed three times in TBS/T, 30 min each. Subsequently, peroxidase conjugated 
secondary antibody (anti-mouse IgG, Dako) 1:5000 was applied to the blocking buffer 
and left to incubate for 1 hour. The washing step was repeated as before.
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2.8.5. Use of ECL reporting
The presence of conjugated secondary antibody was detected by enhanced 
chemiluminescence (ECL Amersham, GE Healthcare). A secondary antibody 
conjugated with horseradish peroxidase (HRP), catalysed the oxidation of luininol by 
hydrogen peroxide in a light-emitting maimer. Chemiluminescence was increased by 
a chemical enhancer, to the point where it was detectable by autoradiography thiough 
blue-light sensitive film. Its use was as described in the manufacturer’s protocol. 
One ml each of ECL solutions A and B was mixed in a small, shallow dish. PVDF 
membrane was coated evenly in the mixture for one min, dried with filter paper and 
wrapped in cling film. The membrane was transferred into an X-ray cassette. A 
range of exposure time (seconds to min) was used. Finally, the film was processed in 
an X-ray processor (Compact X4, Xograph imaging system), and protein molecular 
weights were marked on the film.
2.9. Statistical analyses
SAS software (SAS Mixed Procedure, SAS Institute) was used to analyse most of the 
data.
Mean fibre size data were analyzed by mixed model variance analysis (SAS Mixed 
Procedure, SAS Institute) using muscle types (ST, LD, G), disease status (normal, 
splayleg) as fixed effects, experiments and replicates as random effects. The standard 
error of the difference between sample means was calculated using the error mean
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square from the ANOVA. Differences between pair-wise combinations of the least 
square means were tested for significance (P<0.05).
Fibre density data were analyzed by mixed model variance analysis (SAS Mixed 
Procedure, SAS Institute) using muscle types (ST, LD, G), disease status (normal, 
splayleg) as fixed effects, experiments and replicates as random effects. The standard 
error of the difference between sample means was calculated using the error mean 
square from the ANOVA. Differences between pair-wise combinations of the least 
square means were tested for significance (P<0.05).
Percentage of slow and fast data were analyzed by mixed model variance analysis 
(SAS Mixed Procedure, SAS Institute) using muscle types (ST, LD, G), disease status 
(normal, splayleg) as fixed effects, experiments and replicates as random effects. The 
standard error of the difference between sample means was calculated using the error 
mean square from the ANOVA. Differences between pair-wise combinations of the 
least square means were tested for significance (P<0.05).
Proliferation assay data were analyzed by mixed model variance analysis (SAS Mixed 
Procedure, SAS Institute) using treatments {SPARCL-l, P311, vector) and 
experiments as fixed effects. In contrast, flasks (3 flasks from each treatment) and 
replicates (4 counts from each flask) were used as random effects. As the data were 
not normally distributed, log 10 transformation was used. The standard enor of the 
difference between sample means was calculated using the error mean square from 
the ANOVA. Differences between pair-wise combinations of the least square means 
were tested for significance (P<0.05).
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BrDU assay results were analyzed by mixed model variance analysis (SAS Mixed 
Procedure, SAS Institute) using treatments {SPARCL-l, P311, vector) and 
experiments as fixed effects. In contrast, wells (2 well from each treatment), 
replicates (4 counts from each well) were used as random effects. The standard error 
of the difference between sample means was calculated using the error mean square 
from the ANOVA. Differences between pair-wise combinations of the least square 
means were tested for significance (P<0.05).
Fusion index assay data were analyzed by mixed model variance analysis (SAS 
Mixed Procedure, SAS Institute) using treatments {SPARCL-l, P311, vector), 
immuno-stainings (desmin, MyHC fast, MyHC slow) as fixed effects and experiments 
as a random effect. The standard error of the difference between sample means was 
calculated using the error mean square from the ANOVA. Differences between pair­
wise combinations of the least square means were tested for significance (P<0.05).
Real time PCR data for PCS muscle were analyzed by mixed model variance analysis 
(SAS Mixed Procedure, SAS Institute) using muscle types (ST, LD, G), disease status 
(normal, splayleg) as fixed effects, litters and replicates as random effects. The 
standard error of the difference between sample means was calculated using the error 
mean square from the ANOVA. Differences between pair-wise combinations of the 
least square means were tested for significance (P<0.05).
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Unless specifically stated, quantitative real-time RT-PCR data for gene over­
expression studies were expressed as mean ± standard deviation from triplicate 
samples within the same experiment.
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Chapter 3
Cellular and molecular 
characterisation of PCS
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3.1. Introduction
Porcine congenital splayleg (PCS) is a clinical condition of newborn piglets, 
characterised by muscle weakness, resulting in the inability to properly stand and 
walk, with affected limbs extended sideways or forwards (Thurley et ah, 1967). It is 
arguably the most important congenital defect of commercial piglets and causes 
significant economic loss to pig farmers (Partlow et ah, 1993). The prevalence of 
PCS can range from less than 1% in most farms to over 8% in some establishments 
(Ward and Bradley, 1980).
A range of pathological lesions has been described for PCS, the most common feature 
being the presence of myofibrillar hypoplasia, often interpreted as an immaturity of 
the muscle (Thurley et ah, 1967; Ducatelle et ah, 1986). However, myofibrillar 
hypoplasia is not exclusive to PCS as the condition is also found in clinically normal 
piglets. The descriptive finding of myofibrillar hypoplasia is therefore not diagnostic 
of PCS (Ducatelle et ah, 1986), In this study, the condition of myofibre hypoplasia 
(reduced numbers of myolibres) in PCS was examined. In general, hypoplasia refers 
to underdevelopment of an organ because of a decrease in numbers. If the description 
is correct, there would be fewer fibres in affected piglets compared with normal 
piglets. To date, no such quantitative measurements have been performed to verify 
the described term. It is possible that clinical splayleg is due to a reduction of fibre 
size (atrophy), number (hypoplasia) or both.
With recent advances in imaging technology and quantitative PCR, morphological 
analysis and relative muscle gene expression can now be conducted with greater 
precision. The aim of this Chapter is to investigate the cellular and molecular
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pathology of PCS, which included the results obtained by immunohistochemistry, 
histochemistry and the relative muscle gene expression levels of PCS.
3.2. Materials and methods
3.2.1. Immunohistochemical and histochemical staining
The procedures of muscle selection, immunohistochemical and histochemical staining 
followed by image analysis were previously described in the Materials and Methods 
Chapter (Section 2.2).
3.2.2. Total muscle fibre number measurement in PCS
Selected semitendinosus (ST), longissimus dorsi (LD) and gastrocnemius (G) muscles 
were removed from four 2-day-old splayleg male piglets, along with 4 corresponding 
normal litter mates. Besides the determination of mean fibre size and fibre density as 
described in Section 2.2., attempts were made to measure the total muscle fibre 
number of each muscle.
To obtain such measurements, images were captured under an image capturing light 
microscope (Carl Zeiss Ltd) at a magnification of X12.5. Firstly, the total cross- 
sectional area of the muscle was measured and analysed using KS300 image software 
(Carl Zeiss Ltd), as described in Figure. 3.1. Secondly, several random fields were 
selected for measurements as described in Section 2.2.3. The number of fibres 
counted represented at least 3-5% of the total number present. Then, estimations of
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total muscle fibre number were calculated, based on the following mathematical 
equation:
Total muscle fibre number -  fibre number in selected field X total cross-sectional area
area of selected field
3.2.3. Quantitative real-time RT-PCR
Total RNA was isolated from porcine muscles as described in the Section 2.7.1.2. 
Two pg of total RNA were used for each cDNA conversion. Four sets of cDNA 
samples from PCS and normal piglets were prepared (litters 1 to litters 4). For pre­
natal muscles, LD was pooled from 3 Pietrain-based pig foetuses from gestation stage 
of 35, 49, 63, 77 and 91 days (da Costa et ah, 2003). Additionally, pooled whole 14- 
day embryos and 21-day embryos derived from the same uterine horn were used (da 
Costa et ah, 2003). The pre-natal and embryo samples were used to assess the 
developmental expression of MAFbx and P31L
TaqMan quantitative real-time RT-PCR (Applied Biosystems) was performed on a 
number of porcine genes: MyHC slow, MyHC 2a, MyHC 2x, MyHC 2b, Myf5, MyHC 
embryonic, MyHC perinatal, a-actin, j3-actin, MAFbx, P311 and SPARCL-L All the 
primers and probes sequences are shown in Table 3.1. The design of MAFbx, P311 
and SPARCL-l primers and probes will be discussed in Chapters 4 and 5. A relative 
standard curve method, normalised to (3-actin as described in Section 2.7.6 was used 
in the quantification of expression. The primer concentration and the value for the 
standard cui*ve are shown in Table 3.2.
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Figure 3.1. Total cross-sectional area 
measurement. (A) Typical field of normal ST 
muscle immunostained for dystroglycan, captured 
at X12.5 magnification. Green lines are for 
orientation of the images. (B) The images were 
captured and superimposed to form the whole 
muscle. (C) By the aid of KS300 software, 
manually drawn masks of image B were made. 
(D) Computer annotated fibres based on masks 
from C were overlaid on image B. (E) Actual 
semitendinosus muscle on slide.
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Table 3.1. Sequences of porcine primers and TaqMan probes.
G ene P rim er Sequence 5 ’—^  3 ’
MyHC slow S GGC CCC TTC CAG CTT GA
A TGG CTG CGC CTT GGT XT
P CCT CTT TCT TCT CCC AGG GAC A TT CGA
MyHC 2a S TTA A A A  AGC TCC AAG  A A C  TGT TTC A
A CCA TXT CCT GGT CGG A A C  TC
P TTC CAG GCT GCA TCT TCT CAC TTG CTA AG
MyHC 2x S AGC TTC AAG  TTC TGC CCC ACT
A GGC TGC GGG TTA TTG ATG G
P AGC CCA GTC A A A  GAC CCT TTG A G A  TGC A
MyHC 2b S CAC TXT A AG  TAG TTG TCT GCC TTG AG
A GGC AGC AGG GCA CTA GAT GT
P TGC CAC CGT CTT CAT CTG GTA A C A  TAA  GAG G
MyHC embryonie S CCC GGC TXT GGT CTG ATT T
A GGT GTC GGC TGA GAG TCA
P TGC TGC TGT CTG CTG TCC TCT GCG
MyHC perinatal S CGA GCC CTC CTG CTT TAT CTC
A TGC CAG ATG  A A A  ATG CAG GTT
P CCA AGA GCC CAG AGT GTT AGG CAC TTC C
skeletal a-actin S CCA GCA CCA TGA A G A  TCA A G A  TC
A ACA  TCT GCT GGA AGG TGG A CA
P CCC CGC CGG AGC GCA AGT
p-actin S CTC CTT CCT GGG CAT GGA G
A CGC ACT TCA TGA TCG AGT TGA
P CCT GCG GCA TCC ACG A G A  CCA C
M AFbx S AAG  CGC TTC CTG GAT GAG A A
A GGC CGC A AC  ATC A TA  GTT CA
P AGC GAC CTC AGC AGT TAG TGC A A C  AAG G
S, sense; A, antisense; P, TaqMan probe. A ll probes were 5 ’ labelled with 6-carboxyfluorescein (FAM ), 
and 3 ’ labelled with 6-carboxytetramethylrhodamine(TAM RA).
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Table 3.2. Porcine RT-PCR primer concentration and value of standard curve.
G ene P rim er concentration  o f  
5 ’ :3’(pm ol/pl)
S tand ard  curve value
M yHC slow 900:900 T: 0.027
S: -3.912
Y: 13.934
M yHC 2a 900:900 T: 0.013
S: -3.780
Y: 12.190
MyHC 2x 50:50 T: 0.007
S: -3.720
Y: 13.889
MyHC 2b 50:50 T: 0.017
S : -3.988
Y: 9.624
MyHC embryonic 900:900 T: 0.012
S: -3.645
Y; 14.885
MyHC perinatal 900:900 T: 0.014
S : -3.410
Y: 10.311
skeletal a-actin 900:900 T: 0.031
S: -3.675
Y: 14.434
p-actin 300:300 T: 0.011
S: -3.673
Y: 13.201
M AFbx 900:900 T: 0.011
S: -3.867
Y: 14.636
T, threshold; S, slope; Y , y-intercept.
Besides the relative standard curve methods, comparative C t method was used in 
MyHC composition profile in Section 3.3.4. This method makes use of the arithmetic 
formula 2 to quantify a target gene, where A C t = C t of the target less C t of the 
reference, and where A A C t = A C t of the target gene less A C t of the calibrator (ABI 
Prism 7700 Sequence Detection System User Bulletin #2).
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3.3. Results
3.3.1. Muscle fibre atrophy in PCS muscles
Morphological and fibre type analyses were conducted on 4 sets of muscles from 4 
separate litters of pigs (3 muscles per pig: ST, LD and G); each set comprised one 2- 
day-old affected PCS piglet and a normal litter mate. Histological examination of all 
PCS muscles showed no evidence of apparent inflammatory change. PCS fibres were 
clearly smaller than those in the normal counterpart. These features were more 
prominent in ST and LD muscles (Fig. 3.2). Based on results from image analysis, 
the average fibre cross-sectional area of affected PCS piglets was consistently 
significantly smaller than their normal counterparts in all 3 muscles (Fig. 3.3). 
Consequently, fibre density (fibre number per unit area) from affected individuals was 
higher in the 3 muscles (Fig. 3.3).
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Figure 3.2. Morphological com parisons between m uscles of PCS and normal piglets. (A) Typical 
muscle fields of normal and PCS (ST, LD and G muscles) were immunostained for dystroglycan to outline 
individual muscle fibres, captured at X200 magnification. PCS fibres were clearly smaller than those in the 
normal counterpart. Red arrows highlight relatively large slow muscle fibres. ST= semitendinosus', LD= 
longissimus dorsi, G= gastrocnemius] Norm= normal; PCS= porcine congenital splayleg.
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Figure 3.3. Mean fib re  size and fib re  density o f fo u r sets o f 2-day-old PCS piglets and 
corresponding normal litte r mates. Fibre cross-sectional area was determined in PCS and normal 
muscles. PCS piglets showed smaller fibre size and higher fibre density in all three muscles. Differences 
between pair-wise combinations of the least square means were tested for significance (*p<0.05). 
Asterisks indicated statistical significance between normal and PCS muscle. The error bars indicate 
standard error. Norm= normal; PCS= porcine congenital splayleg.
PCS piglets also showed higher distribution of fibre number in the smaller fibre range 
than normal piglets (Fig. 3.4). The contrast in fibre size distribution was particularly 
evident in the ST and LD of PCS piglets, which showed a narrow and steep 
distribution pattern of smaller fibres (Fig. 3.4). In ST muscles, more than 50% of 
PCS fibres were less than 100 pm^, compared with normal fibres where only 35% 
were less than 100 pm^. In LD muscles, more than 50% of PCS fibres were less than 
75 pm^; compared with normal fibres only about 35% were less than 75 pm^. The 
degree of atrophy may vary between the muscles, with the ST and LD muscles more 
severely affected than the G muscle. Hence fibre atrophy was a feature of PCS 
muscles.
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Figure 3.4. D istribution o f muscle fibre cross-sectional areas o f fou r sets o f 2-day-old PCS 
piglets and corresponding normal litte r mates. At least 10,000 fibres were measured per muscle 
section and grouped by size in 25 increments. ST and LD muscles of PCS piglets showed a narrow 
and steep pattern of distribution. G muscles of PCS piglets showed a similar but smaller fibre size 
distribution than their normal litter mates.
122
% Slow fibre % Fast fibre
Norm PCS
Figure 3.5. Com position o f s low  and fast fibres of fou r sets o f 2-day-oid PCS piglets and corresponding 
normal litte r mates. No significant difference in slow or fast fibre types was found between normal and affected 
muscles. Differences between pair-wise combinations of the least square means were tested for significance 
(*p<0.05). Asterisks indicated statistical significance between normal and PCS muscle. The error bars indicate 
standard error. Norm= normal; PCS= porcine congenital splayleg.
Based on immunostaining for MyHC slow and MyHC fast fibres, no significant 
difference was found in fibre type composition between normal and affected muscles 
(Fig. 3.5). Previously, Hanzlikova (1980) has showed higher number of slow muscle 
fibre in normal muscles compare to PCS muscles. The failure of detection significant 
differences in fibre type composition may be due to limitation of sample numbers 
and/or the level of P value tested.
Histochemical staining with Sudan Black B (SBB) and succinate dehydrogenase 
(SDH) are shown in Figures 3.6 and 3.7. The staining protocols were described in 
Section 2.2.2. SBB staining was used to detect the presence of lipids and SDH 
staining is an indicator of oxidative fibre capacity. Attempts were made to analyse 
the percentage of SBB and SDH positive in PCS affected and normal muscles. 
Widespread distributions of lipid positive fibres were found in PCS affected and 
normal muscles. Similarly, both PCS affected and normal muscles showed
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widespread distribution of highly oxidative fibres. There was little difference in the 
distribution of lipid positive and oxidative fibre between PCS affected and normal 
piglets (Figs. 3.6 and 3.7).
Total muscle fibre number measurement could not be reliably determined, due to 
technical difficulty in obtaining complete cryostat cross-sections representative of 
total muscle areas. As such, it is not certain if PCS-associated fibre atrophy is also 
accompanied by fibre hypoplasia.
3.3.2. Selective reduction of MyHC expression in PCS muscles
Assessment of the phenotypic differences between muscles of normal and PCS piglets 
by TaqMan quantitative real-time PCR was performed on the muscles from the 4 sets 
of litter mates to determine the relative mRNA expression levels of MyHC embryonic, 
MyHC perinatal, MyHC slow, MyHC 2a, MyHC 2x, MyHC 2b and a~actin. No 
significant difference was found between normal and PCS piglets for MyHC 
embryonic, MyHC perinatal, MyHC 2a and a-actin (Fig. 3.8). PCS piglets, however, 
showed significantly lower expression of MyHC slow in LD and G muscles (Fig. 3.8). 
Expression of MyHC 2x and MyHC 2b in ST muscle was also statistically lower in 
PCS piglets (Fig. 3.8).
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Figure 3.6. Widespread distribution of lipid positive fibres (stained as black pigments). Typical 
muscle fields of normal and PCS (ST, LD and G muscles) were immunostained for SBB, captured at X200 
magnification. Both PCS affected and normal muscles were rich in intra fibre lipids. ST= semitendinosus, 
LD= longissimus dorsi] G= gastrocnemius] Norm= normal; PCS= porcine congenital splayleg.
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Figure 3.7. Widespread distribution of oxidative fibres (stained as dark purple pigment). (A) Typical 
muscle fields of normal and PCS (ST, LD and G muscles) were immunostained for SDH, captured at 
X200 magnification. Both PCS affected and normal muscles were highly oxidative. ST= semitendinosus, 
LD= longissimus dorsi] G= gastrocnemius] Norm= normal; PCS= porcine congenital splayleg.
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Figure 3.8. Comparison of muscle gene expression between PCS affected and normal muscles.
Quantitative expression of MyHC isoforms and a-actin in ST, LD and G muscles, presented as combined 
results of 4 sets of 2-day-old PCS piglets. Differences between pair-wise combinations of the least square 
m eans were tested for significance (*p<0.05). PCS piglets showed significantly lower expression of 
MyHC slow in LD and G muscles, and lower expression of MyHC 2x and MyHC 2b in ST muscles. 
Asterisks indicate statistical significance between normal and PCS muscles. Error bars indicate standard 
error. Norm= normal; PCS= porcine congenital splayleg.
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3.3.3. Relative expression of MyHC isoforms within muscles
In general, ST, LD and G muscles selected in this study are considered as fast type 
muscles. More than 85% fibres were fast fibre type based on immunohistochemistry 
(Fig. 3.5). A comparative Ct method, described in Section 3.2.3, was used to profile 
the relative expressions within each muscle of the different MyHC isoforms. There 
were no significant differences in the relative expression of MyHC isoforms 
expression between PCS affected and normal muscles (Fig. 3.9). The MyHC 2x was 
the most abundant isoform in all muscles, followed by MyHC 2a, MyHC slow, MyHC 
embryonic and MyHC 2b (Fig. 3.9). The relative abundance of the three fast post­
natal MyHC isoforms was in the order of 2x >2a >2b.
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Figure 3.9. Relative mRNA levels of MyHC Isoforms within PCS affected and normal muscles.
There were no significant differences in patterns of MyHC  isoforms expression within PCS affected and 
normal muscles. MyHC 2x mRNA was most abundant in all muscles, followed by MyHC 2a. The relative 
abundance of the three fast post natal MyHC  isoforms were in the order of 2x>2a>2b. Expression levels 
are relative to the lowest expressing isoform within each muscle which is the MyHC perinatal. ST= 
semitendinosus] LD= longissimus dorsi] G= gastrocnemius] emb= embryonic; per= perinatal; Norm= 
normal; PCS= porcine congenital splayleg.
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3.3.4. Up-regulation of MAFbx and down-regulation of P311 in PCS muscles
The ubiquitin-proteasome proteolysis pathway is a principal route of muscle atrophy 
in which MAFbx, an E3 ubiquitin ligase, was found to be consistently up-regulated in 
a variety of muscle atrophic conditions (Bodine et al., 2001b; Lecker et al., 2004). 
Because of the close association of MAFbx expression with muscle atrophy, the 
relative expression of porcine MAFbx in normal and PCS muscles was determined 
(Fig. 3.10.A). In almost all muscle samples examined, with the exception of ST 
muscle in litter 2, MAFbx expression was clearly found up-regulated in PCS piglets 
(Fig. 3.10.A). Another growth-related gene associated with muscle atrophy, PSl l ,  is 
a novel gene reported to be down-regulated in a number of muscle atrophic conditions 
(Lecker et al., 2004) but up-regulated under moderate dietary restriction (da Costa et 
al., 2004). In contrast to MAFbx, P311 expression in PCS muscles was consistently 
down-regulated in comparison with normal controls (Fig. 3.10.B). It is worthy to note 
that the significant differences in MAFbx and P311 expression between normal and 
affected muscles of litter 2 were not as great as in the other 3 litters, which might be a 
reflection of differing gradation of the disease process (Fig. 3.10). Moreover, the 
wide variation in expression levels of MAFbx and P311 between litters, were not 
entirely surprising. Endogenous gene expression is known to vary widely between 
individual pigs of the same genetic background and age, reared under identical 
husbandry conditions (Chang et al., 2003).
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Figure 3.10. (A) Quantitative PCR performed fo r MAFbx expression. With the exception of ST 
muscles in litter 2, MAFbx was more highly expressed in all PCS muscle samples compared with the 
corresponding normal muscles. Results of each litter are expressed as mean ± standard deviation from 
triplicate samples within the same experiment. Combined results of 4 sets of PCS piglets also tested for 
significance (*p<0.05) in differences between pair-wise combinations of the least square means. Norm= 
normal; PCS= porcine congenital splayleg.
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Figure 3.10. (B) Quantitative PCR performed fo r P311 expression. In contrast to MAFbx, P311 
expression was down-regulated in all PCS muscle samples. Results of each litter are expressed as mean 
± standard deviation from triplicate samples within the same experiment. Combined results of 4 sets of 
PCS piglets also tested for significance (*p<0.05) in differences between pair-wise combinations of the 
least square means. Norm= normal; PCS= porcine congenital splayleg.
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As little is known about the normal developmental expression pattern of MAFbx and 
P311, their embryonic and muscle foetal expression at different stages of gestation, 
and their expression in adult muscle was examined (Fig. 3.11). Real-time PCR results 
showed that MAFbx expression remained at basal levels throughout gestation and in 
adult muscle (Fig. 3.11.A). In relation to normal muscles, MAFbx expression in PCS 
LD muscles was significantly elevated (Fig. 3.11.A). Real-time PCR results showed 
that P311 expression in normal animals increased with gestation and remained raised 
in newborn and adult muscles. However, the expression of P311 in 2-day-old PCS 
piglets was considerably down-regulated (Fig. 3.1 l.B).
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Figure 3.11. Developmental expression o f MAFbx and P311. Expression of (A) MAFbx and (B) P311 
at different stages of embryonic/foetal development (14, 21, 35, 49, 63, 77 and 91 days of gestation), in 
24-week-old (adult) pigs, in 2-day-old PCS piglets and corresponding normal litter mates (Norm) were 
determined. Embryonic/foetal and adult cDNAs were pooled samples from 3 individuals. PCS and Norm 
cDNAs were pooled from the LD muscles of the 4 sets of litter mates. Expression of MAFbx was detected 
at basal levels throughout gestation and into adulthood but was elevated in PCS muscles. P311 
expression showed rising levels throughout development. However, its expression in PCS piglets was 
much reduced. Results expressed as mean ± standard deviation from triplicate samples within the same 
experiment. Norm= normal; PCS= porcine congenital splayleg.
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3.4. Discussion
3.4.1. PCS is associated with extensive muscle fibre atrophy
PCS is a well-recognised, commercially important clinical congenital condition of 
piglets. However, woefully little is known about its aetiology, pathogenesis or 
pathology. In this study, fibre atrophy with concomitant increase in fibre density was 
consistently found in PCS muscles (LD, ST and G) (Figs. 3.2 and 3.3). It appears that 
PCS is an extensive muscle condition that affects several muscle groups. Indeed, 
previous work has shown that PCS affects different muscles (Thurley et al., 1967; 
Bradley et al., 1980). ST and LD muscles were more severely affected than the G 
muscle (Fig. 3.4). PCS associated atrophy was not accompanied by significant 
changes in fibre type composition (Fig.3.5), but some affected muscles showed 
significant reduction in the expression of MyHC slow, MyHC 2x and MyHC 2b genes 
(Fig. 3.8). Hence PCS is a condition associated with muscle fibre atrophy ostensibly 
connected to reduced protein accretion, and is associated with reduction in the 
expression of structural muscle genes. At present, it is unclear if the atrophic fibre 
change observed in PCS muscles is a primary pathology of the condition or is a 
secondary outcome of disuse atrophy.
In the present work, due to technical difficulty in obtaining complete cryostat cross- 
sections representative of total muscle areas, the total muscle fibre number of each 
muscle could not be reliably determined. At present, it is not certain if PCS- 
associated fibre atrophy is also accompanied by fibre hypoplasia. For future work, to 
overcome this technical difficulty, accurate determination of the mid-belly 
circumference of each muscle is essential (Wigmore and Stickland, 1983; Rehfeldt et
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al., 2001). The standard protocol for total muscle fibre number measurement is 
summarised as follows (Wigmore and Stickland, 1983; Stickland and Handel, 1986; 
Dwyer et al., 1994). Firstly, the total cross-sectional muscle area was determined 
from circumference measurement. Secondly, mean number of fibres per unit area was 
measured using a Seescan image analysis system. Finally, total muscle fibre number 
was estimated by the mean number of fibres per unit area and total cross-sectional 
area. Up to 3-5% of the total muscle fibre number in randomly selected areas was 
counted.
Owing to the mamier in which PCS piglets were sourced, the weight of every animal 
in a litter was not obtained. Although body weight measurement was not taken, all 
PCS piglets appeared smaller in size compared with its normal counterparts. It had 
been shown that the smallest littermates developed fewer muscle fibres in their 
muscle compared with the largest littermate (Wigmore and Stickland, 1983; Stickland 
and Handel, 1986). PCS piglets thi'ough immobility could fail to gain sufficient 
nutrient from the sow, resulting in starvation and hypothermia. Post-mortem on PCS 
affected piglets revealed empty stomachs. In this study, the body weight differences 
observed in the 2-day-old PCS piglets might be the result of starvation. Equally, PCS 
associated with muscle fibre atrophy could contribute to the reduced body weight and 
immobility. Although only fibre atrophy has been demonstrated in this study, PCS 
could be caused by atrophy and hypoplasia. It has been suggested that muscle fibre 
number is an important determinant of postnatal growth such that pig littermates with 
a high fibre number tend to grow faster and more efficiently than littermate with a 
lower fibre number (Dwyer et al., 1993).
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3.4.2. Widespread distribution of lipid and oxidative fibres in PCS muscles
SBB and SDH staining showed widespread distribution of lipid and oxidative positive 
fibres in PCS affected and normal muscles. The pattern of distribution was similar 
between PCS affected and normal muscles (Figs. 3.6 and 3.7). Relative expression of 
MyHC isoforms within muscles showed that MyHC 2x and MyHC 2a were the two 
most abundant isoforms in all muscles (Fig. 3.9). Both MyHC 2a and MyHC 2x are 
characterised as fast oxidative-glycolytic fibres, which are highly oxidative with 
corresponding lipid content.
3.4.3. PCS is associated with muscle wasting
MAFbx, an E3 ubiquitin ligase enzyme, was identified as an early marker of atrophy 
through differential expression screening studies in multiple models of skeletal 
muscle atrophy (Lecker et a l, 2004; Bodine et a l, 2001b). E3 ubiquitin ligase is one 
of three enzymatic components of the ubiquitin-proteasome pathway (Hershko and 
Ciechanover, 1998), a major protein degradation route known to be responsible for 
skeletal muscle atrophy (Mitch and Goldberg, 1996). High levels of MAFbx mRNA 
in all 4 atrophic PCS piglets from 4 litters were demonstrated (presented as individual 
and combined litters) (Fig. 3.10.A), in contrast with basal levels found in normal 
muscles pre- and post-natally (Fig. 3.11.A). The elevated expression of MAFbx 
would suggest that the PCS muscles were subjected to a process of muscle wasting, 
possibly as a consequence of disuse atrophy. It remains possible that PCS is primary 
condition of gestational muscle under development.
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MAFbx atrophy marker was used in this study to exemplify atrophy in PCS. Besides 
MAFbx, muscle ring finger 1 (MuRFl) also is another well-known atrophy marker 
(Bodine et ak, 2001b). Only MAFbx atrophy marker could be used to assess the 
condition because of the limited availability of porcine gene sequences.
3.4.4. Down-regulation of P311 in PCS muscles
Rising levels o f P311 expression were found thioughout gestation, and this rise was 
maintained in post-natal normal muscles (Fig. 3.11 B). By contrast, in PCS muscles, 
P311 was detected at much reduced levels (Figs. 3.10.B and 3.1 l.B). Expression of 
P311 was previously repoited to be down-regulated in atrophic murine muscles 
(Lecker et al., 2004). In conditions of muscle wasting, arising from denervation or 
disuse, the process of protein degradation exceeds the rate of protein synthesis, 
resulting in net protein loss (Lecker et al., 2004). In PCS muscles, reduced P311 
expression could be a consequence of net protein loss. On the other hand, given that 
P311 promoted cell proliferation (Figs. 4.12.A and B), it may have an active role in 
promoting muscle growth through raised myoblast number.
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Chapter 4
Functional studies o f  P 3 11
139
4.1. Introduction
P311, first identified in murine embryonic neurons (Studler et al., 1993), is a small 8- 
kDa 68-amino acid protein with a short half-life of around 5 minutes (Taylor et al., 
2000). It is characterised by the presence of a conserved PEST domain (sequences 
rich in proline, glutamic acid, serine and tlireonine), a target site for degradation by 
the ubiquitin-proteasome system (Paliwal et ak, 2004).
The results obtained and discussed in Chapter 3, P311 expression was much reduced 
in PCS muscle. P 311 has been reported to be down-regulated in atrophic conditions 
(Lecker et ak, 2004). P311 does not belong to any known family of proteins, and its 
cellular function remains largely unclear. There are several reports about the cellular 
effects of P31Î on different cell types. Elevated expression o f P311 was found to 
associate with smooth muscle differentiation, and transformation of fibroblasts into 
myofibroblasts (Pan et ak, 2002; Taylor et ak, 2000). P311 was reported to be 
involved in glioblastoma cell migration and fibroblast cell proliferation (Pan et ak, 
2002; Mariani et ak, 2001; Taylor et ak, 2000). In addition, differentiation of neural 
cells was related to loss o f PS 11 expression (Taylor et ak, 2000). To investigate the 
function of P311 in skeletal muscle, it would be necessary to study its effects on 
muscle cell proliferation, differentiation and phenotype determination. The aims of 
this study were to first characterise the full-length P311 cDNA clone, and then to 
apply it to over-expression functional studies.
140
4.2. M aterials and methods
All the commonly used techniques in this section have been previously described in 
the Materials and Methods Chapter (Sections 2.3, 2.4, 2.5 and 2.6).
4.2.1. P311 cDNA cloning and sequencing
The cDNA of porcine P311 gene was previously isolated in the Molecular Medicine 
Laboratory, Faculty of Veterinary Medicine, University of Glasgow. The P311 
cDNA was housed in a pBK-CMV vector (Stratagene) (Fig. 4.1.A). A series of 
restriction digestions (Section 2.3.3), followed by DNA electrophoresis (Section 2.2.4) 
were performed to determine the insert size o f P311. After restriction mapping, the 
P311 cDNA insert was sub-cloned as 2 fragments and sequenced (Section 4.3.1. for 
details). pBK-CMV vector (Stratagene) and pBluescript II SK(+) vector (Stratagene) 
(Fig. 4 .l.B) were used for the sub-cloning. Sequencing was performed on P311 
cDNA with primers T3 (5’ ATT AAC CCT CAC TAA AG 3’) and T7 (5’ TAA 
TAC GAC TCA CTA TAG GG 3’) as described in Section 2.5.
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F1 origin
neo/kan
pBK-CMV
4 5 1 8  bp
.Vma 7(1025) 
5ma 7(1027) 
X b a l{ \0 5 1 )  
7(1069) 
7/W  777 (1075) 
£co7?7(1084) 
5am/77(1093) 
Pst I  i \ \ \ 5 )
} MCS
CMV promoter
pUC origin
B
Amp
F1 (+) origin
pBluescript II SK(+)
2 9 6 1  bp
Xho I  (669) \
77/W777(690) 
£co7?7(702)
P s t l { l \ 2 )
X m a l i l X A )
Sma 7 (716)
gam/7 7 (720)
X b a I (732)
pUC origin
Figure 4.1. Plasmid vector (A) pBK-CMV and (B) pB luescript II SK (+). Both of 
the vectors comprise a multiple cloning sites and T3/T7 polymerase promoters, 
neo/kan =neomycin/kanamycin resistance; Amp = ampicillin resistance gene; CMV 
= cytomegalovirus; MCS = multiple cloning site.
} MCS
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open reading frame finder (ORF finder, NCBI) was used to locate the possible 
starting codon and stop codon within P311. To amplify the coding region of P311 
without the stop codon, the following set o f P311 PCR primers was used. An EcoK I 
and a Xho I restriction digestion site were engineered into the 5’ and 3’ primers 
respectively. The primers are shown below, with the highlighted restriction digestion 
sites.
P311 PCR 5’ (sense primer)
5’ AA fcAA TTClCCC AAC ACT TCA CGC TGA G 3’
EcoK I
P311 PCR 3’ (anti-sense primer)
5’ AA tT C  GACj AAA AGA GCG GAG GTA ACT GAT 3’ 
Xho I
Amplification of the ORF was carried out as in Section 2.4. Next, the PCR products 
were cloned into TOPO- TA cloning vector (Invitrogen) (Fig.4.2) as in Section
2.3.1.2. The resulting colonies were selected for DNA miniprep preparation as 
described in Section 2.3.2.1. The insert size of P311 was confirmed by digestion with 
EcoK I and Xho I. The correct DNA band was excised and directionally cloned into 
pDNR-CMV for recombinant adenovirus production as described in Section 2.6.4.
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pUC origin
TOPO binding site
r ^ \
EcoR I (3963) \  ^ X h o I ( 4 \ )
f1 origin
TOPO
3973 bp
Kan
Figure 4.2. TOPO vector. It is designed to receive RT-PCR products. The PCR 
ll-TOPO vector is 4.0 kb in size. Kan= kanamycin resistance; Amp= ampicillin 
resistance gene; MCS= multiple cloning site.
4.2.2. P311 cell cultures, transfections and recombinant adenovirus production
C2C12 cells were grown in PM, and replaced by DM when cells reached 80% 
confluence. The C2C12 cell culture methods were described in Section 2.6.1. For 
stable transfections, C2C12 cells at 40% confluence in T25 culture flasks were 
transfected with 6.0 pg P311 pBK-CMV plasmid, by the use of lipofectamine and 
Opti-MEM, according to manufacturer’s instructions (Invitrogen) as detailed in 
Section 2.6.3. Coding region of porcine P311 cDNA and a constitutively active 
murine calcineurin A (Cn) (kindly supplied by Dr. S. Williams, University of Texas) 
were separately cloned into an adenovirus vector, using the Adeno-X Expression
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System 2 (BD Biosciences) as described in Section 2.6.4. Both P311 and Cn 
adenovirus constructs were cloned as fusion protein, which comprised a FLAG 
epitope at the carboxyl-end (Section 2.6.4.1). For time course studies, infection with 
P311 and Cn-adenovirus constructs were used at a multiplicity of infection (MOI) of 
5. Cells were infected in PM for 3 days (31), followed by 3 days in DM (31 3D), or by 
6 days in DM (31 6D). Stably transfected cells were grown in PM for 3 days (PM), 
followed by 3 days in DM (DM 3D), or 6 days in DM (DM 6D).
4.2.3. P311 immunofluorescence, cell cytotoxicity and Western blotting
C2C12 cells upon infection with P311 or GFP control adenovirus, were grown for 3 
days in PM, followed by 8 days in DM. To improve P3I1 stability, o-phenantliroline 
(cat. N-. P9375, Sigma) and lactacystin (cat. N-. L6785, Sigma) were added to the 
DM, at final concentrations of 1.26 mM and 10 mM respectively, 2 hours prior to 
fixation. The combination of proteasome inhibitor, lactacystin and the 
metalloprotease inhibitor, o-phenanthroline, was able to block degradation o f P311 
(Taylor et al., 2000). The immunofluorescence procedure was described in Section 
2.6.9. For cell cytotoxicity assay, a resazurin-based reduction assay that measures the 
metabolic capacity of cells, was performed according to manufacturer’s protocol as in 
Section 2.6.5. Western blotting was performed as in Section 2.8 with the use of 
primary anti-FLAG M2 monoclonal antibody (Sigma).
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4.2.4. P311 cell proliferation, fusion index and BrdU assay
Thirty thousand C2C12 cells were plated on each 25 cm^ flask (three flasks for each 
P311-pBK-CMV plasmid and pBK-CMV empty plasmid as control), and were grown 
for up to 5 days in PM. The cell proliferation assay was based on stably transfected 
cells as described in Section 2.6.6. For fusion index assays, after 9 days in DM, 
transfected cells were fixed and stained as detailed in Section 2.6.7. BrdU assays on 
C2C12 cells, infected with 7 7-adenovirus and stably transfected with P311 plasmid
construct, were performed as previously described (Section 2.6.8).
4.2.5. P311 quantitative real-time RT-PCR
TaqMan quantitative real-time RT-PCR (Applied Biosystems) was performed on a 
number of murine genes: MyHC slow, MyHC 2a, MyHC 2x, MyHC 2b, MyfS, MyHC 
embryonic, MyHC perinatal, a-actin, p-actin, and P31L All the primer and probe 
sequences are shown in Table 4.1. A relative standard curve method, normalised to p- 
actin, was used in the quantification of expression. The primer concentration used 
and the values of the standard curve calculations are shown in Table 4.2.
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Table 4.1. Sequences of primers and TaqMan probes.
G ene P rim er Sequence 5 ’->  3 ’
Porcine P 3 11 S GAG GGA AGG CCT A AG  GG
A CGG TCT CGC CAT CCT TCT T
P ACT TCC CAT CCC A A A  GGA A G T GAA CCG
Murine M yHC slow S GCC TGG GCT TAC CTC TCT ATC AC
A CTT CTC A G A  CTT CCG CAG GAA
P CGT TTG A G A  ATC CAA GGC TCA
Murine M yHC 2a S CAG CTG CAC CTT CTC GTT TG
A CCC G A A  A AC  GGC CAT CT
P TGA GTT CAG CAG TCA TGA G
Murine M yHC 2x S GGA CCC ACG GTC GAA GTT G
A GGC TGC GGG CTA TTG GTT
P CTA A AG  GCA GGC TCT CTC ACT GGG CTG
Murine M yHC 2b S CAA TCA GGA ACC TTC GGA A C A  C
A GTC CTG GCC TCT GAG AGC AT
P TGC TGA AGG A C A  CAC AGC TGC ACC T
Murine M yf5 S CAG CCC CAC CTC C AA  CTG
A GCA GCA CAT GCA TTT GAT A C A  TC
P TGT CTG GTC CCG A A A  G A A  CAG CAG CTT
Murine M yHC embryonic S TCC GAC A A C  GCC TAC CAG TT
A CCC GGA TTC TCC GGT GAT
P ATG CTG ACT GAT CGT GAG A A C  CAG TCT ATC CT
Murine M yHC perinatal S GG A GGC CAG GGT ACG TGA A
A GAG CAC A TT CTT GCG GTC TTC
P AGG AAC TTA CCT ACC A G A  CTG
Murine skeletal a-actin S GAG CGT GGC TAT TCC TTC GT
A CAC A TA  GCA CAG CTT CTC TTT GAT
P CGC GCA CAA TCT CAC GTT CAG CTG
Murine p-actin S CGT G A A  A AG  ATG ACC CAG ATC A
A CAC AGC CTG GAT GGC TAC GT
P TTG A G A  CCT TCA ACA CCC CAG CCA TG
Murine P 3 11 S CAG CCA AGA ACC GTT TGC AT
A CAC TTC CTT AGG CAC GGG A A
P TTC CCT TAA  T A A  GAC CTC CCT CCA TTT CCT TG
S, sense; A , antisense; P, TaqMan probe. A ll probes were 5 ’ labelled with 6-carboxyfluoresceln (FAM), 
and 3 ’ labelled with 6 -carboxytetramethylrhodamine(TAM RA). Murine M yHC 2a was also labelled 
with Minor Groove Binder (M O B) to increase stability.
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Table 4.2. RT-PCR primer concentration and values of standard curve.
G ene P rim er concentration  o f  
5 ’ :3’(pmoI/tiI)
S tandard  curve value
Porcine P 311 900:900 T: 0.026
S: -3.357
Y: 12.360
Murine M yHC slow 900:900 T: 0.009
S: -4.241
Y: 13.583
Murine M yHC 2a 900:900 T: 0.006
S: -3.993
Y: 16.785
Murine M yHC 2x 900:900 T: 0.014
S : -3.831
Y: 13.018
Murine M yHC 2b 900:900 T: 0.012
S: -3.943
Y: 9.928
Murine M yf5 900:900 T: 0.011
S: -3.495
Y: 17.831
Murine M yHC embryonic 900:900 T: 0.011
S: -3.900
Y: 12.229
Murine M yHC perinatal 900:900 T: 0.007
S: -3.600
Y: 16.063
Murine skeletal a-actin 300:50 T: 0.017
S: -4.335
Y: 7.98
Murine p-actin 300:900 T: 0.017
S: -3.859
Y: 13.563
Murine P311 900:900 T: 0.023
S: -3.023
Y: 20.895
T, threshold; S, slope; Y , y-intercept.
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4.3. Results
4.3.1. P311 cDNA cloning and sequencing
The cDNA of porcine P311 was previously isolated in the Molecular Medicine 
Laboratory. In vector pBK-CMV, a series of multiple restriction digestions, followed 
by DNA electrophoresis were performed to determine the insert size of the P311 
cDNA (Fig. 4.3). The construct was digested with 8 different combinations of 
enzymes. (1) EcoR. I, (2) Xho I, (3) Xho I +EcoK I, (4) Pst I, (5) BamH I, (6) Hind III, 
(7) Xba I and (8) Sma I (Fig.4.3.A). Digestion results show that the P311 fragment 
was 2.2 kb, with an internal Xba I restriction site (Fig.4.3.B). Xba I restriction 
enzyme was used to digest the pBK-CMV-P311 into 2 fragments, which were 1.0 kb 
and 5.7 kb in size. The smaller insert (1.0 kb) fragment was cloned into pBluescript II 
SK(+) (Stratagene), and the remaining fragment, housing the remaining 1.2 kb of 
PS 11 insert was self-ligated (Fig. 4.4).
The full-length of a P5/7  cDNA was sequenced with primers T3 and T7 (ABI Prism 
3100 Genetic analyzer). The full-length o f P311 cDNA was 2.2 kb and the deduced 
coding sequence was 0.3 kb in length. The full DNA sequence result is shown in 
Figure 4.5. Basic nucleotide alignment search tool (BLAST) showed that porcine 
P311 was 85% homologous to human P31L  The deduced amino acid sequence of 
porcine P311 is shown in Figure 4.6. It was 87% homologous to human P31L 
Besides Homo sapiens^ comparisons with other species were also made. The deduced 
amino acid sequence of porcine P311 was 73.4% homologous to mouse P311 and 
52.7% homologous to chicken P577.
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neo/kan
pBK -CM V-Psil
6 6 8 7  b p
pUC origin
CMV promoter
Yma 7 (1025 )  
S w û f/(1027 )  
7(1057 )
Xba I {1015)
P311 
(2.2 kb)
EcoR I {1255) 
BamH I (3262)  
> 5 /7 (3 2 8 4 )
Figure 4.3. R estriction d igestion  of pBK-CMV-P311. (A) Gel electrophoresis of P311 
plasmid in pBK-CMV vector after 2 hours of enzyme digestion. The constructs were 
digested with 8 different combinations of enzymes. (1) EcoR I (2) Xho I (3) Xho I +EcoR I (4) 
Pst I (5) BamH I (6) Hind III (7) Xba I and (8) Sma I. M=marker ladder. (B) The pBK-CMV 
with P311 insert is 6.7 kb. The P311 cDNA was 2.2 kb with an internal Xba I restriction site.
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CMV p r o m o te ^ ^ Z ^ ^ ^ EcoR /(3253)
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Figure 4.4. Sub-cloning of P311. A Xba I restriction enzyme was used to digest the pBK- 
CMV-P311 into 2 fragments, which were 1.0 kb and 5.7 kb in size. The smaller fragment 
was cloned into pBluescript II SK(+) (Stratagene), and the remaining fragment was self­
ligated. Xba I restriction site highlighted in blue.
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GAATTCGGCACGACGCCCAACACTTCACGCTGAGCTGACCCGGAGCCCTTGCTCCCCTGG 6 0 
ATGGATGGTTTGGGAGGAGAGCTGCTTGGGTGGGCTGGTGGGCGGGGGTCCAGGGAGGCA 1 2 0  
CAGGTCCTTTTCCCCAGCCCTTCCTGCCAAAGAAGCAGCACCTGCCCTGGGTCTCCTCTG 1 8 0  
CGACCCTGTGCTGCATGAGCTGGCGTGGTCTGAGTGCTGTCTGCGGGGCTTTTGTCTGTT 24  0 
GCTTGGTCTCCCTGGACTGAAGAGAGGGAGGGTACAAGGCCAAGACTGTTAAGGATTCTC 3 0 0  
AAaJ B g TTTATTACCCAGAGCTTTCTGTCTGGGTCAGTCAAGAACCATTTCCAAACAAG 3 60 
GAAATG5ÂQGGAAGGCTTCCfrAAGG^AAGfclCTTCCCATÇCCAAAGQAAQTGAAC0flC^ ^  4 20  
PSGdATG(S55!^S^PAGGCTGCCTCCCTGACTCCACTCGGCAGCAATGAAAATGAACTC 4 80  
C A C T C C C C A G G A A TC A G TT A C C TC C G C T C rm lH h’CACCTCCATTTGTATTACATATG 5 4 0
CAAGTATAAGAAGAAACTATGGGACTCTGAGCCTTGCTTTAGAGAATTTACAGTGGACAA 6 6 0  
ATAGGTATCATCAAACCAGTTTTTAATCATTCTGACTCAAGTGAAAACGCTCAGAATTTC 7 2 0  
ACACTGTGAATCCACGTTTACAACCCTTACAGGTGGGCCTTCAGGCCTGGTTCGCTACGA 7 8 0  
CGATGTCTTCCACAACTCAAACCCCCAACTGCTCTCACACAACCGGTCCACTTCTGCCTT 84  0 
TTCACTCACACAGCTCCCGACTGCTCCTTGCAGAGGCTGAGAGTCCCCATTTTTTTTTTT 9 0 0  
TTTTCATTTAGATGTAACAAGCCTAGTAGTTTATGTTCATCAATTGTCTGTATATCTCTA 9 6 0  
TATTTTATCCATGTACTCTTTTGATGTATAGAAGTAGTTTGAAACTCATTGTTTCCTTGT 1 0 2 0  
GGTAAGTGACCGAGATGCTGCCACAGGACCTGAGACACTGATGAATGGTGCTATTTTGGA 1 0 8 0
AAGAAGGTGTTGGTACTCTGTTTCCCTGAATGTTGTTCTCTAGACTGGATTGACTTGTTT 1 2 0 0  
TCCTTGTGTCTTCAGTGTGGCTTTCTTCTTCAGCGTTGGAGGTTGAGTAAGTGCCACCTC 1 2 6 0  
TGAGAGCAGACACTCGTCTCAGGGGCCGGCTCTCCCAGACACGCAGTCCCTGTAGCGGGA 1 3 2 0  
GCAATCACAAAACTGTAATTTCCTTACCAGATCTCTTCCTTTCGGTCGCCTCGCCTGCCT 13 8 0 
AACTTAGAGAATGAAAAGCAATAATTTGACAGGCGTTTTTAGGTGTCTCTTTTGGTTCTT 1 4 4  0 
TTCATTTAAAAGAATATTTGGGGAAAAAAAGGGCAAACTGGTTTGGGTTTTTTTGmTT 1 5 0 0
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GTTTTTAATAAATGCCCTCTGGAAAAAAAAAAAAAAAATCCAAAAACTGACGTCTCCGTA 1 5 6 0
GGAACATGAAAATTACACCTTTCCCAAAAATAAGGTTGAAAAAATGTCTTGACAAAATTC 1 6 2 0
1 6 8 0
TAGATTTTACATnTTGTCCTTGCTCCCAATGAAATGGATAAACAAAAATACAATCAGAC 174 0
AATACCATCTACTCATGGAATGTTGTTGTGTTAGCCAGTCTGAAAGCCCACCTTAATTTT 1 8 0 0
TATATAACTGTCTTTTAGCTCTTCCTTTGACAGGGCAGGCTTCGTTCTGAACTGTTCCGC 1 8 6 0
TTCTGACTTAACACATCGACGACGCATGCGCTGCACTTCTTCGTTCTCTTCTTGCTCCCC 1 9 2 0
CATTGGCCTGAGTTTCTTGTGCATCCCCCGCCCCTCCTTTGTTAGAATAGGTATATCCGC 1 9 8 0
TGTGTAAATAGAGCAAGAAAACAGTATTCTGCATCTGTGGCATTTACGTAGAGTTGCAGT 2 0 4  0
TGTGTACTGCTGAATATGCAGGCTTTTGTAACAATGTGATCTTTACCGATGCACTCACGA 2 1 0 0
CAAGTACCCAATGTATTTTAGCTATTTTAGTAGTATTTGTTCAATAAATATGCAAGCTGT 2 1 6 0
ATGGTAAAAAAAAGAAAAAAAAAACTCGAGAGTACTTCTAGA 2 2 0 2
Figure 4.5. Full length nucleotide seq u en ce of porcine P311 cDNA.
I I P311 PCR 5’ and 3' primers 
Start / stop codon 
I H I  P311 real-time RT-PCR 5 and 3’ primers 
P311 real-time RT-PCR probe 
I . . I P311 internal detection 5 and 3’ primers
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* * * 4- * + + . * * * * * + + * + . + . + * * . + . * * + * * + + * * * * * * * . . * + . + * +
pig MVYYPELSVWVSQEPFPNKEMEGRLPKGRLPIPKEVNRKKDGETEAAS
human ( 8 7.0%) MVYYPELFVWVSQEPFPNKDMEGRLPKGRLPVPKEVNRKKNDETNAASmouse ( 73.4%) MVYYPELLVWVSQEPFAYKEMEGGLIKGRLPVPKEVNRKKMEETGAASchicken( 52.7%) MIYQPRQTIWVSQKVFPTSQGDGGFLKGCLPISKEVNRKKESEVEGAC
+ + * . + + . + . . . . + + . + + * * +  * pig LTPLGSNEneLHSPGISYLRSFhuman LTPLGSSE--LRSPRISYLHFF
mouse LTPPGSRE--FTSPATSYLHPFchicken WAPVNGDG--HHFTKINYLYTF
* = hom ologous; + = limited h om ologou s;. =  not hom ologous.
Figure 4.6. Pile-up o f P311 deduced amino acid sequences fo r pig, human, mouse and 
chicken.
PESTfind® software was used to locate the PEST motif in the deduced acid amino 
sequence. PEST motifs are hydrophilic stretches of at least 12 amino acid lengths, 
that contain at least one proline (P), one glutamic acid (E) or aspartate (D) and one 
serine (S) or threonine (T), flanked by lysine (K), arginine (R) or histidine (H) 
residues, without positively charged residues. Results show a region of low 
homology porcine PEST domain, region 40-60 shows a score of +4.85 (score range 
from -50.0 to +50.0, +ve score indicating a possible PEST sequence) (Fig. 4.7). For 
human, mouse and chicken, the possible PEST region score is +0.50, +0.64 and -6.16 
respectively.
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* * * 4- * + + , * * * * * + + * + , + . + * * . + . * * + * * + + * * * * * * * . . * + . + * +
pig ( +4.85) MVYYPELSVWVSQEPFPNKEMEGRLPKGRLPIPKEVNRKKDGETEAAS
human ( +0.50) MVYYPELFVWVSQEPFPNKDMEGRLPKGRLPVPKEVNRKKNDETNAASmouse { +0.64) MVYYPELLVWVSQEPFAYKEMEGGLIKGRLPVPKEVNRKKMEETGAAS
chicken ( -6.16) MIYQPRQTIWVSQKVFPTSQGDGGFLKGCLPISKEVNRKKESEVEGAC
++*.++.+....++.++**+ * pig LTPLGSNEneLHSPGISYLRSFhuman LTPLGSSE--LRSPRISYLHFFmouse LTPPGSRE- -FTSPATSYLHPFchicken WAPVNGDG--HHFTKINYLYTF
(RED -the possible PEST region in porcine P311)(Blue- comparison of possible PEST region among other species)
* = hom ologous; + = limited h om ologou s;. = not hom ologous.
Figure 4.7. Comparison o f PEST dom ains in P311 deduced amino acid sequences fo r 
pig, human, mouse and chicken.
4.3.2. Recombinant P311 adenovirus production
The P311 PCR 5’ and 3’ primers were used to amplify the coding sequence of P i / /  
in PCR. Gel electrophoresis of the 0.5 kb RT-PCR products is shown in Figure 4.8.A. 
T0P0-P311 vector was digested with EcoR I and Xho I restriction enzymes to 
ascertain the P311 insert (Figs. 4.8.B and C). The required DNA insert was excised 
and cloned into pDNR-CMV for recombinant adenovirus production. pDNR-CMV- 
P311 vector was digested with EcoR I and Xho I restriction enzymes to ascertain the 
clones containing the appropriate P311 insert (Figs. 4.9.A and B).
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P3I1  
0.5 kb 
(Lane 1)
Topo-vector 
3.9 kb
P311 
0.5 kb
P311 
(0.5 kb)
EcoR I (3963)
X h o I ( 4 \ )
f1 origin
pUC origin
TOPO-P3II
4 4 2 6  b p
Kan
Amp
Figure 4.8. C loning o f P311 Into TOPO vector. (A) Gel electrophoresis of the 0.5 kb RT-
PCR products with the use of sense and anti-sense primers (Lane 1). Sense primer with 
template DNA in alone Lane 2 as control; no band was detected. (B) Gel electrophoresis 
after digestion of T0P0-P311 with Xho I and EcoR I; P311 segment (0.5 kb) and topo 
vector (3.9 kb) are shown. (C) TOPO vector with P311 insert. The P311 insert is about 0.5 
kb with EcoR I restriction in 5’ and Xba I restriction site in 3’ ends.
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Figure 4.9. Cloning o f P311 in to pDNR-CMV vector. (A) The pDNR-CMV with P311 
cDNA insert is 8 .6  kb. The P311 fragment is 0.5 kb with EcoR I restriction in 5’ and Xho I 
restriction site in 3’ ends. (B) Digestion of pDNR-CMV-P311 with Xho I and EcoR I. Lanes 
3-5 are clones with the appropriate cloned 0.5 kb insert.
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After the correct pDNR-CMV-P311 clones were identified by restriction mapping, 
gene sequencing was performed to confirm an intact start codon at the 5’ end and a 
FLAG epitope was cloned in frame at the 3’ end. P311 internal 5’ primer (5’ CGG 
TCT CGC CAT CCT TCT T 3’) was used to detect the start codon at the 5’ end. 
Another P311 internal 3’ primer (5’ GAG GGA AGG CCT A AG GG 3’) was used 
to detect FLAG epitope at the 3’ end. The primers used are highlighted in grey in 
Figure 4.5. Sequencing results confirmed that both the start codon and FLAG epitope 
are correctly cloned. The sequence of the FLAG epitope at the 3’ end is shown (Fig. 
4.10).
Nucleotide sequence
TACCTCCGCTCTTTT CTC GAG HAC TAC AAG GAT GAC GAT GAC 
EÎAC GAC GAT GAT AAfll |SAC TAT AAG GAT GAT GAC GAC 
CAATTCCTCGACGACTGCATAGGG
Deduced amino acid sequence
Y L R S F L E > Y K D D D D K l  D Y K D D P 'P ^  b Y K D P C f g l
Q F L D D C I G
Figure 4.10. 3x FLAG and stop codon o f P311 In pDNR-CMV vector. The 3X FLAG 
sequence is highlighted in blue, while the stop codon is highlighted in red.
4.3.3. P311 over-expression in C2C12 cells by adenovirus infection and by stable 
transfection
To assess the function of P311 in muscle cells, P311 was over-expressed in C2C12 
muscle cells by stable transfection with pBK-CMV-P311 plasmid (Fig. 4.3.B) as well 
as by infection with a Pi//-adenovirus construct (Fig. 4.11). Expression of both
158
constructs could be demonstrated by P311 mRNA detection (Fig. 4.11.A), and by 
P311-FLAG fusion protein detection by immunofluorescence (Fig. 4.1 l.B). Cell 
cytotoxicity assays that measured metabolic capacity showed no significant difference 
between infected/transfected cells, and control cells over an extended period of 10 
days differentiation, which indicated similar cell viability (Fig. 4.1 l.C). This finding 
also indicates that over-expression of P311 is not detrimental to C2C12 cells. 
Western blot was performed to detect P311 proteins. P311 is reported to be highly 
labile, with a short half-life (Taylor et al., 2000). 0-phenanthroline and lactacystin 
were added to improve P311 stability. No prominent P311 band sizes were detected 
in Western blotting. The instability of P311 might account for the failure of its 
detection.
Pi//-adenovirus infection
4.0i:
£ 2.5
5 2.0 
« 1.5
-  , n^  I.O 
«  0.5
31 31 3D 31 6D
P i / /-Stable transfection
0.14
0 .1 2
0 .1 0
— #  P311
Plasmid ' "àr"  control
0.08
0.06 1
0.04 r
0 .0 2 I
0
PM DM 3D DM 6D
Figure 4.11. (A) O ve r-exp ress ion  o f  P 311  in  C 2C12 cells. P311 expression, through 
infection with an adenovirus construct and through stable transfection with an expression plasmid 
(Fig. 4.3.B), was determined over a time course. Proliferating cells were infected for 3 days in 
proliferation medium [PM] (31), followed by 3 days in differentiation medium [DM] (31 3D) or 6  days 
in DM (31 6 D). Stably transfected cells were incubated for 3days in PM (PM), followed by 3 days 
in DM (DM 3D) or 6  days in DM (DM 6 D). Results expressed as mean ± standard deviation from 
triplicate samples within the same experiment.
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GFP control adenovirus P i 7 7-adenovirus
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Figure 4.11. (B) P311-FLAG fusion protein detection by immunofluorescence.
Adenovirus-mediated (MOI of 5) expression of P311 in C2C12 cells (infected for 3 
days during proliferation followed by 6  days of differentiation), viewed under 
fluorescence for GFP and immunostained for FLAG. P3ft-infected cells showed 
co-localisation of both proteins.
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Figure 4.11. (0) Cell v iab ility  assay o f P3 If- in fe c te d  and P 3 ff-s tab ly  transfected 
C2C12 cells. The viability of P3ff-infected and P3f t-transfected 02012 cells was 
similar to control cells over an extended culture period, as demonstrated by cell 
cytotoxicity assay (CellTiter-Blue kit, Promega). Results expressed as mean ± standard 
deviation from triplicate samples within the same experiment.
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4.3.4. P311 over-expression increased C2C12 cell proliferation and reduced 
differentiation
Proliferation assays were performed in stably transfected C2C12 cells by quantifying 
cell number with a Neubauer haemocytometer. P311 over-expressed C2C12 cells 
showed significant increase in cell proliferation compared with plasmid control cells 
(Fig. 4.12.A). In addition, 5’-bromo-2’-deoxyuridine (BrdU) assays were performed 
on P311-adenovirus infected and stably transfected C2C12 cells. Both constructs 
promoted proliferation compared with control GFP cells (Fig. 4.12.B). C2C12 cells 
stably transfected with P311 also appeared to give rise to less myotubes as visualised 
by immunostaining for desmin, MyHC fast and MyHC slow proteins (Fig. 4.12.C). 
This observation could be further appreciated quantitatively by determining the fusion 
index of the transfected myotubes, which showed that P311 over-expression produced 
fewer myotubes than control (Fig. 4.12.D).
4.3.5. Muscle gene expression in P311- adenovirus infected C2C12 cells
No obvious differences in MyHC expression were detected between f 3 / /-infected 
and control C2C12 cells during the early stages (31 and 31 3D) of development (Fig
4.13.). However, at the later stage of differentiation (31 6D), there was the suggestion 
of reduced expression of MyHC embryonic, MyHC 2b, Myf-5 and a-actin in P3IÎ-  
infected C2C12 myotubes (Fig. 4,13), with the notable exception of MyHC slow 
which showed raised expression. The overall results of extended P31I over­
expression indicated a trend towards reduction in the expression of a number 
regulatory and structural muscle genes, which was consistent with reduced muscle
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differentiation. P311 appeared to associate with increased proliferation (Fig. 4.12.A), 
and reduced differentiation and myotube formation (Figs. 4.12.C and D to 4.13). 
P311 was also examined to see if it could be down-regulated by the over-expression 
of constitutively active calcineurin (Cn), a key mediator of skeletal muscle 
differentiation (Bassel-Duby and Olson, 2003; Michel et al., 2004). Indeed, 
endogenous expression o f P311 was down-regulated a few days after Cn infection, 
regardless of the developmental stage of the C2C12 cells (Fig. 4.14). Hence, in the 
promotion of muscle differentiation, Cn down-regulated P311 expression.
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Figure 4.12. O ver-expression of P311 en h an ced  C2C12 cell proliferation. (A) P311 over­
express C2C12 cells showed significant increased in cell proliferation compared with plasmid 
control cells . (B) BrdU assay  was performed on -infected and adenovirus-GFP control cells, 
as well as P3ff-stably transfected and vector only-transfected cells. For both approaches, P311 
over-expression significantly increased cell proliferation. Results were analysed with SAS 
software, differences between pair-wise combinations of the least square m eans were tested for 
significance (*p<0.05). Error bars were standard error, n=3 replicates from 3 independent 
experiments.
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Figure 4.12. (C) Immunostaining of P3f t-stably transfected C2C12 cells.
P3ff-stably transfected C2C12 myotubes (differentiated for 9 days) were 
separately immunostained for desmin, MyHC fast and MyHC slow, along with 
DAPI nuclei staining. Under immunofluorescence, myotubes appeared less 
abundant in P3ff-transfected cells.
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Figure 4.12. (D) Over-expression o f P311 reduced C2C12 cell d ifferentiation. Fusion 
index quantification on immunostained images showed that P3f f-transfected cells resulted 
in less myotubes formation than control cells. Results were analysed with SAS software, 
differences between pair-wise combinations of the least square means were tested for 
significance (*p<0.05). Asterisks indicate statistical significance. Error bars were standard 
error, n=3 replicates from 3 independent experiments.
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Figure 4.13. Muscle gene expression In P31 t-adenovlrus Infected C2C12 cells. Real­
time PCR was performed on cDNAs derived from infected cells over a time course as 
detailed in Fig. 4.11. No dramatic difference in MyHC expression between P3f f-infected 
and control C2C12 cells was seen during the early infection time points (31 and 31 3D). 
Reduction in expression of MyHC embryonic, MyHC 2b, Myf-5 and a-actin in P3ff-infected 
02012 myotubes was noticeable at the last time point (31 60). Results expressed as mean 
± standard deviation from triplicate samples within the same experiment.
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Figure 4.14. Effect o f calcineurin over-expression on endogenous P311 expression in 
C2C12 cells. (A) Cells were infected with a constitutively active calcineurin (Cn) or GFP- 
control adenoviral construct in PM for 2 days (21), or for 3 days (31), followed by 1 day DM (31 
1D), or 3 days in DM (31 3D), or 6  days in DM (31 6 D). (B) Cells were also infected as myotubes 
(at 4 days in DM) for 2 days, followed by a further 2 days in DM (4+4), or 5 days in DM (4+7), or 
7 days in DM (4+9). In both series (A and B), extended expression of Cn led to a reduction of 
P311 expression. Results expressed as mean ± standard deviation from triplicate samples 
within the same experiment.
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4,4. Discussion
A full-length porcine P311 cDNA clone was sequenced and molecularly characterised 
(Accession. N-. EF416570). The full-length porcine P311 cDNA was 2.2 kb and the 
coding sequence was 0.3 kb in length. The deduced amino acid sequence of porcine 
P311 is 87% homologous to human P311. P311 does not belong to any known family 
of proteins, and its cellular function remains largely unclear. To investigate the 
function o f P311 in skeletal muscle, it is necessary to ascertain its effects in muscle in 
the context of cell proliferation, differentiation and phenotype determination. In this 
study, P311 over-expression led to raised C2C12 cell proliferation and reduced 
myotube formation (Figs. 4.12.B and C). Consistent with reduced myotube formation, 
expression of several muscle genes {MyHC embryonic, MyHC 2h, a-actin and myf-5) 
was down-regulated in late differentiation of 77-over-expressed C2C12 cells (Fig.
4.13.). Myf-5, like MyoD, is transcriptionally active in proliferating myoblasts; its 
exogenous expression can cause non-myogenic cells to differentiate and fuse into 
myotubes (Ishibashi et al., 2005). No P311 protein was detected with Western 
blotting because of its highly lability and short half life. However, P311-FLAG 
fusion protein was detected by immunofluorescence with o-phenanthroline and 
lactacystin added. To improve P311 protein detection, immunoprécipitation with 
rabbit polyclonal anti-P311 raise against the synthetic peptide might be useful (Pan et 
ah, 2002).
At present, it is not certain if  PCS-associated fibre atrophy is also accompanied by 
fibre hypoplasia. Given that P311 expression was down-regulated in PCS muscles 
(Fig. 3.10.B) and P311 promoted cell proliferation (Figs. 4.12.A and B), it may have 
an active role in promoting muscle growth tluough raised myoblast number. The
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aetiology and pathogenesis of PCS remain unknown, but it seems likely that the 
development of clinical PCS is a function of fibre size and, possibly, fibre number at 
birth, such that below a certain fibre threshold, the newborn would no longer be able 
to properly support its own weight. However, there are wide variations in muscle 
fibre numbers between piglets (Stickland and Handel, 1986).
Previously, P311 was shown to be involved in glioblastoma cell migration and 
fibroblast cell proliferation (Mariani et al., 2001; Pan et al., 2002). Moreover, 
differentiation of neural cells was related to loss of P311 expression (Taylor et al., 
2000). tience, P311 may play an active part in the determination of muscle mass 
through the promotion of myoblast proliferation. The endogenous expression of P311 
was suppressed by Cn over-expression (Fig. 4.14). As Cn is a key mediator of muscle 
differentiation (Bassel-Duby and Olson, 2003; Michel et al., 2004) it would suggest 
that P311 could also have an effect of limiting muscle differentiation.
Recently, expression of P311 was found to be down-regulated in human lung samples 
with emphysema and impaired alveolar formation. P311 was suggested to be 
involved in protection against injury or it might play a role in the repair or 
regeneration of damaged lungs (Zhao et al., 2006). Consistently, P311 expression 
was found to be down-regulated in almost all PCS muscles (Fig. 3.10). P311 might 
be essential for protection, repair or regeneration of damaged skeletal muscles. On 
the other hand, the reduced P311 expression could be consequence of muscle atrophy. 
Clearly, more work is needed to evaluate the P311 potential in regeneration or repair. 
In future, to investigate the P311 potential in regeneration or repair, it will be 
interesting to study the expression of MAFbx, a major atrophy marker, in P311 over­
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expressed cells. Synthetic glucocorticoid dexamethasone could be used to induce 
atrophy in C2C12 muscle cells (Thompson et al., 1999). The expression of murine 
MAFbx in P311 over-expressed cells under atrophic condition over a time-comse 
study could then be determined.
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Chapter 5
Functional studies of 
SPARCL-1
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5.1. Introduction
SPARC like-1 (SPARCL-1), also knowii as MAST9/hevin/SCl, is a matricellular 
secreted glycoprotein that belongs to the SPARC family. SPARCL-1 was originally 
cloned from a rat brain expression library by screening with a polyclonal antibody 
raised against a synaptic junction glycoprotein (Johnston et al., 1990). SPARCL-1 
contains a follistatin-like domain (FS) and an extracellular calcium binding domain 
(ES), which are the hallmarks of the SPARC family.
SPARCL-1 was highlighted in PCS skeletal muscle and could be a candidate gene 
involved in PCS pathogenesis (Maak et a l, 2001). It has shown to be a negative 
regulator of cell proliferation (Claeskens et al., 2000), and down-regulated in many 
types of cancer cells (Bendik et al., 1998). To investigate the function of SPARCL-1 
in skeletal muscle, it would be necessary to study its effects on muscle cell 
proliferation, differentiation and phenotype determination. The aims of this study 
were to first characterise the full-length SPARCL-1 cDNA clone, and then to apply it 
on over-expression functional studies.
5.2. Materials and methods
All the commonly used techniques in this section have been previously described in 
the Materials and Methods Chapter (Sections 2.3, 2.4, 2.5 and 2.6),
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5.2.1. SPARCL-1 cDNA cloning and sequencing
The cDNA of porcine SPARCL-1 gene was previously isolated in the Molecular 
Medicine Laboratory, Faculty of Veterinary Medicine, University of Glasgow. The 
SPARCL-1 cDNA was housed in a pBK-CMV vector (Stratagene). A series of 
restriction digestions (Section 2.3.3), followed by DNA electrophoresis (Section 2.3.4) 
was performed to determine the insert size of SPARCL-1. After restriction mapping, 
SPARCL-1 cDNA insert was sub-cloned as 2 fragments and sequenced (Section 5.3.1. 
for details). pBK-CMV vector (Stratagene) and pBluescript II SK(+) vector 
(Stratagene) were used for the sub-cloning. The sequencing was performed on the 
SPARCL-1 cDNA insert with the T3 and T7 primers promoters (as described in 
Section 2.5).
Open reading frame finder (ORF finder, NCBI) was used to locate the possible 
starting codon and stop codon within SPARCL-1. To amplify the coding region of 
SPARCL-1 without the stop codon, the following set of SPARCL-1 PCR primers was 
used. An EcoK I and ^.Xho I restriction digestion site were engineered into the 5’ and 
3’ primers respectively. The primers are shown below, with the highlighted 
restriction digestion sites.
SPARCL-1 PCR 5’ (sense primer)
5’ AA ETA'A TTCXrTT GAC AGA GCA GCA GAA TTT 3’ 
EcoK I
SPARCL-1 PCR 3’ (anti-sense primer)
5’ A A E E S I  AAA CAO GAG ATT TTC ATC TAT GT 3’ 
Xho I
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Amplification of the ORF was carried out as in Section 2.4. Next, the PCR products 
were cloned into TOPO- TA cloning vector (Invitrogen) as in Section 2.3.1.2. The 
resulting colonies were selected for DNA miniprep preparation as described in 
Section 2.3.2.1. The insert size of SPARCL-1 was confirmed by digestion with EcoK 
I diïiàXho I. The correct DNA band was excised and directionally cloned into pDNR- 
CMV for recombinant adenovirus production as described in Section 2.6.4.
5.2.2. SPARCL-1 cell cultures, transfections and recombinant adenovirus 
production
C2C12 cells were grown in PM, and replaced by DM when cells reached 80% 
confluence. The C2C12 cell culture methods are described in Section 2.6.1. For 
stable transfections, C2C12 cells at 40% confluence in T25 culture flasks were 
transfected with 6.0 pg SPARCL-1 pBK-CMV plasmid, by the use of lipofectamine 
and Opti-MEM, according to manufacturer’s instructions (Invitrogen) as detailed in 
Section 2.6.3. Coding region porcine SPARCL-1 cDNA was cloned into an 
adenovirus vector, using the Adeno-X Expression System 2 (BD Biosciences) as 
described in Section 2.6.4. The SPARCL-1 construct was cloned as a fusion protein, 
which comprised a FLAG epitope at the carboxyl-end (Section 2.6.4.1). For time 
course studies, infection with SPARCL-1 constmcts was used at a multiplicity of 
infection (MCI) of 5. Cells were infected in PM for 3 days (31), followed by 3 days in 
DM (31 3D), or by 6 days in DM (31 6D), or 10 days in DM (31 lOD). Stably 
transfected cells were grown in PM for 3 days (PM), followed by 3 days in DM (DM 
3D), or 6 days in DM (DM 6D).
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5.2.3. SPARCL-1 cell cytotoxicity and Western blotting
For cell cytotoxicity assay, a resazurin-based reduction assay that measured the 
metabolic capacity of cells, was performed according to the manufacturer’s protocol 
(Section 2.6.5). Western blotting was performed as in Section 2.8 with the use of 
primary anti-FLAG M2 monoclonal antibody (Sigma).
5.2.4. SPARCL-1 cell proliferation, fusion index and BrdU assay
Thirty thousand C2C12 cells were plated on each 25 cm^ flask (three flasks for each 
SPARCL-1 pBK-CMV plasmid and pBK-CMV empty plasmid as control), and were 
grown for up to 5 days in PM. The cell proliferation assay was based on stably 
transfected cells as described in Section 2.6.6. For fusion index assays, after 9 days in 
DM, transfected cells were fixed and stained as detailed in Section 2.6.7. BrdU 
assays on C2C12 cells, infected with S'PXTîCZ-i-adenovirus and stably transfected 
with SPARCL-1 plasmid construct, were performed as previously described (Section 
2.6.8).
5.2.5. SPARCL-1 quantitative real-time RT-PCR
TaqMan quantitative real-time RT-PCR (Applied Biosystems) was performed on a 
number of murine genes: MyHC slow, MyHC 2a, MyHC 2x, MyHC 2b, Myf5, MyHC 
embryonic, MyHC perinatal, a-actin, fl-actin, and porcine SPARCL-1. The TaqMan
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real-time PCR primer and probe set for SPARCL-1 were designed using Primer 
Express v 2.0 software (Applied Biosystems) as in Section 2.7.4. The primers and 
probe sequences are shown (Table 4.1 and Table 5.1). A relative standard curve 
method, normalised to p-actin, was used in the quantification of expression. The 
primer concentration used and the values of the standard curve calculations are shown 
(Table 4.2 and Table 5.2).
Table 5.1. Sequences of porcine SPARCL-1 primers and TaqMan probe.
P rim er Sequence 5 ’->  3 ’
S TGG GTC GAG CCA CCT ACC T
A TCT GCA GTT G A A  AGC CTG GTT T
P A AG  GTA TTC A A G  GTC ACC CCG GAG GA
S, sense; A, antisense; P, TaqMan probe. A ll probes were 5 ’ labelled with 6-carboxyfluorescein (FAM), 
and 3 ’ labelled with 6 -carboxytetramethylrhodamine (TAM RA).
Table 5.2. Porcine SPARCL-1 RT-PCR primer concentration and vaines of 
standard curve.
P rim er concentration  o f  
5 ’;3 ’(pmol/p,l)
Standard curve value
300:300 T: 0.018
S: -3.255
Y; 14.190
T, threshold; S, slope; Y, y-intercept.
5.2.6. SPARCL-1 expression in PCS muscle
Muscle collection and TaqMan quantitative real-time RT-PCR (Applied Biosystems) 
were performed as described in Section 3.2.3.
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5.3. Results
5.3.1. SPARCL-1 cDNA cloning and sequencing
The cDNA of SPARCL-1 was previously isolated in the Molecular Medicine 
Laboratory. In vector pBK-CMV, a series of multiple restriction digestions, followed 
by DNA electrophoresis were performed to determine the insert size of the SPARCL-1 
cDNA (Fig. 5.1). The construct was digested with 8 different combinations of 
enzymes. (1) EcoK I, (2) Xho I, (3) Xho I +EcoR I, (4) Pst I, (5) BamH I, (6) BamH I 
+Xho I, (7) EcoR I +BamH I and (8) Xho I +EcoR I (Fig.5.1.A). Digestion results 
show that the SPARCL-1 fragment was 2.8 kb, with an internal BamH I restriction site 
(Fig.5.1.B). A BamH I restriction enzyme was used to digest the pBK-CMV- 
SPARCL-1 into 2 fragments, which were 1.0 kb and 6.3 kb in size. The smaller insert 
(1.0 kb) fragment was cloned into pBluescript II SK(+) (Stratagene), and the 
remaining fragment, housing the remaining 1.8 kb of SPARCL-1 insert was self­
ligated (Fig. 5.2).
The full-length of SPARCL-1 cDNA was sequenced with primers T3 and T7 (ABI 
Prism 3100 Genetic analyzer). The full-length SPARCL-1 cDNA was 2.8 kb and the 
deduced coding sequence was 2.0 kb in length. The full DNA sequence result is 
shown in Figure 5.3. Basic nucleotide alignment search tool (BLAST) had shown 
that porcine SPARCL-1 was 75.2% homologous to human SPARCL-1. The deduced 
amino acid sequence of porcine SPARCL-1 is shown in Figure 5.4. It was 76% 
homologous to human SPARCL-1. Besides Homo sapiens, comparisons with other 
species were also made. The deduced amino acid sequence of porcine SPARCL-1 was 
66% homologous to mouse SPARCL-1 and 68% homologous to rat SPARCL-1.
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Figure 5.1. Restriction digestion o f pBK-CMV-SPARCL-1. (A) Gel electrophoresis of 
SPARCL-1 plasmid in pBK-CMV vector after 2 hours of enzyme digestion. The constructs 
were digested with 8  different combinations of enzymes. (1) EcoR I (2) Xho I (3) Xho I 
+EcoR I (4) PSt I (5) BamH I (6 ) BamH I + Xho I. (7) EcoR I +BamH I and (8 ) Xho I +EcoR I 
M=marker ladder. (B) The pBK-CMV with SPARCL-1 insert, 7.3 kb. The SPARCL-1 cDNA 
was 2.8 kb with an internal BamH I restriction site within.
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F1 orig in
neo/kan ^
pBK-CMV-SPARCL-1 
7272 bp
pUC origin
CMV prom oter
A '/xi/(1057)
SPARCL-1  
(2.8 kb)
EcoRHmS)
1 D igestion with BamH I
Cloned into vector pBII sk(+) Self-ligated
17
^  rfig/wir/r2oi]
/ i f 167311
pBII Sk(+)-SPARCL-il 
3914 bp
SPARCL-1 
(1.0 kb)
Xha I(\6»5)
T7
pBK-CMV-SPARCL-1 
6319 bp
SPARCL-1  
(1.8 kb)
Figure 5.2. Sub-cloning of SPARCL-1. A BamH I restriction enzyme was used to digest 
the pBK-CMV-SPARCL-1 into 2 fragments, which were 1.0 kb and 6.3 kb in size. The 
smaller fragment was cloned into pBluescript 11 SK(+) (Stratagene), and the remaining 
fragment was self-ligated. BamH I restriction sites highlighted in blue.
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GTGATCCAAAGAATTCGGCACGAGACAGCCTGAAATACGTCCCAGTGCCAACCTCCAAAT 60
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
TCATCTGTCACCTCAGACCCTGACTAGTTGACAGAGCAGCAGAATTTCAACTCCAATAGA 1 2 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CCTGAATGTGTTTCTGGGCAAAGAAGCAGAGCTAACGAGGAAAGAGATATATAGAGTATT 1 8 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GGGTATTTGTCAAACTTTTATTTTCTGGCTGTGTGCAAAGAGAAGATTCAACTTCAATTT 24 0 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CCTGCCAAGGCTC]gg0 g ^ g g 0 ^gpAAGGTATTC|_______________
* * * * * * * * * * * *  *  *  * * * * * * * * * * * * * * * * * * * * * * * * * * *
3 0 0
AAAACCAGGCTTTCAACTGCAGATGGATGCTGCGGATACTACAACCAGGAGGGCTAGAAA 3 6 0
r * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
G^0AAGACTCTGCTTTTTCTCCTGTACATTTTGGGAACGGCAGCTGCAGTCCCGACACA 4 2 0
* * * * * * * * * * 1 r * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AGCCAGGTTCCCATCTGATCATTCCAACCCAACTGCTGCTTCCTTAAGTTCCTTCCAGCA 4 80  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GGCTGAAACGTTGGTAACAGCGGAGCAGACTGCAACCCCCACTGGAAGGGTTGAAGATGC 54 0 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AGAAAAGGAAAAGGAACCAGCAGTGTCCCTAGAAGAGCATCCCTATCATAAGGCTGAAAA 6 0 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
ATCTTCAGTACTAAAGTCAAAGCAGGAAGACCATGAAGAGTCAGCAGACCAGGACCAGAG 6 6 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CTACAGCCAAAACCTGGGATCACAGGAACATGAGAAAAGTGAAAGAGACTTAATTGAGAA 7 2 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CTCCGAGTATATGCCAACTGAAGGTACATTGGACCTAAAAGAAGATATGACTGAACCTCA 7 8 0
AAAGGAAAAATTCCCAGAGAGCATTGATTCCCTTGGTCATGATGACAGTTCCATTGTAGA
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
8 4 0
TTCTAACCAACAAGAAAGTATCACAAAAGCAGAGGAAAACCAAGACTCACATCCTCAACT
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
9 0 0
GAACGGGAGCAGTAAACATAGCCCAGATCTAAGTGACCGAGGAAACCAAGGGCAGGATCC
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
9 6 0
AGATAGTCCAACTGGAGAAGAGGAAGGGGAAAAAGAGCCACATGAAGTTGATACCCTCTT 1 0 2 0  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CGACAACCAAGAAGAGGAGAGAGAAGTGCTCCAGGAGCAGTCTAACAGCGAGCAGGAAGA 1 0 8 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AGACAGTACCCGATCAGATGACATCTTGGAAGAGTCTTACCAACCAACTCAAGCAAGCAA 11 4  0 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GATGCAGAAAGATGAATTTGAGCAGGGTAATCAAGGACGAGAAGAGGAAAACGCCAATGC 1 2 0 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AGAAACAGAAGAGGAAACTGCCTCAAAAATCACTAAGCCCAATCAAGAAAGAGAATGGCA 1 2 6 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GAGCCCAGAAGGAAAGCCTGGCCTTGAAGTTATCAGCAACCACGAGGAGATGGATAAAAA 1 3 2 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GACCCTTGCTAAGCCTTTGTTGGTGGAGCCTACTGATGATGATAACGTCATGCCCAGAAA 1 3 8 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
TCACGGGGCCGATGATGACAGTGATGATGATGATGAACACAACGCAAGTGAGGACGCCTT 14 4 0 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CAACCCAAGTGAGGCTTATCTGGAGCGTGAAAGAGCTCCATCCAATTACTACCACACCAA 1 5 0 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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ATACGAGGAGCAAAGAGAAAAAGCACATGAGGGTGAGAATGTAGATACCAGCGAAGCTGC 15 60* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AGAAAACCAAGGGGCCAAGAAAGCAGAGGGCTCACCAAATGAAGATGACAGTTCAACTGA 1 6 2 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AGGCACCACGAGGGGGCACAGTGTTGATTCTTGCATGAGCTTCCAGTGTAAAAGAGGACA 1 6 8 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CATCTGCAAGGCTGATCAACAGGGAAAACCCCACTGTGTTTGCCAAGACCCAGTGACATG 17 40 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
TCCTCCTACAAAACTCCTTGACCAAGTTTGTGGCACTGACAATCAGACCTATGCCAGCTC 1 8 0 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CTGTCATCTCTTTGCTACCAAGTGCAGACTGGAGGGGACGAAAAAGGGGCACCAACTGCA 1 8 6 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GCTGGATTACTTTGGAGCCTGCAAATCTATTCCTGCTTGTACGGACTTTGAAGTGACCCA 1 9 2 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GTTTCCTCTAAGGATGAGAGACTGGCTCAAGAATATCCTCATGCAGCTTTATGAGCCTAA 1 9 8 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CCCTGAACATGCTGGATATCTAAATGAGAAGCAGAGAAATAAAGTCAAGAAAATTTACCT 2 0 4  0 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GGATGAAAAGAGGCTCTTGGCTGGGGACCATTCCATCGACCTTCTCTTAAGGGACTTTAA 2 1 0 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GAAAAACTACCACATGTATGTGTATCCCGTGCACTGGCAGTTCAGTGAGCTTGACCAACA 2 1 6 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
TCCGCGGGACAGAGTCCTGACCCACtÜTGAGCTCStggmgCGAGCATCGCTGGTGCC 2 2 2 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CATGGAACACTGCATAACACGCTTCTTTGGAGAGTGTGACCCCAACAAGGATAAGCACAT 2 2 8 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CACCCTGAAGGAGTGGGGCCGCTGCTTTGAAATTAAAGAAGAAGACATAGATGAAAATCT 2 3 4  0 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
C C T G T T T B B a TTAAGATTTGAAAGAACTCAAACTTTTCTGCATCCTCCTGTTTTGATCA 24  00  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CTTCTCAAGCATATGCAACGTGATACTTATAGATTTATATTTAGCAAAATGCTTGCATGT 24  60
CTAAGACAATGAGAGTAACTGCTTGATAACAGTATGTACACCAGGCATTTAACATTAACT 2 5 2 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
TTGGAAATACAACGTTTAAATTAAGTAAAGTCAGTATTTGCAAAATACTATACACTGTGA 2 5 8 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
ACAGTTTAACTCCTCACTCCCTGCACCCATTCACAAAATACTTAGATTATAACATCCCCC 2 6 4 0
CCAAAAAAATACATTCATTTTGTCCATTATATCATGTGCACTTCAAAAAAGTGAAATAAT 2 7 0 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
GTTCCTTGTTGCTGATGTGTTTTCAATATCTTAATATTCTAATAAAATCTATAAAAATCT 2 7 6 0  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
AAAAAAAAAAAAAAAAAATCTCGAG 2 7 8 5  
* * * * * * * * * * * * * * * * * * * * * * * * *
Figure 5.3. Full length nucleotide sequence of porcine SPARCL-1 cDNA.
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I 1 SPARCL-1 PCR 5’ and 3' primers 
Start / stop codon 
H I SPARCL-1 real-time RT-PCR 5 and 3" primers 
HI SPARCL-1 real-time RT-PCR probe 
I 1 SPARCL-1 internal detection 5 and 3' primers
* * + . . +  + * . . * * * ★  + * + * * . . + + . + * * *  + * * + +  * + + + . + + + +  + * .  . . + * .  .
p i g  ( 1 )  MKTLLFLLYILGTAAAVPTQARFPSDHSNPTAAslssfqqaeTLVTAEQTATPTGRVEDA
h u m a n  7 6 . 0 % ( 1 )  MKTGPFFLCLLGTAAAIPTNARLLSDHSKPTAE------------------- T-VAPDNTAIPSLWAEAE
m o u s e  6 6 . 0 % ( 1 )  MKAVLLLLCALGTAVAIPTSTRFLFDHSNPTTA------------------- TLVTPEDATVPIAGVEAT
r a t  6 8 .0 %  ( 1 )  MKAVLLLLYALGIAAAVPT— TFLSDHSNPTSA------------------- TLPTLEDATVPTVPAEAA
p i g  ( 6 1 )  EKEKEPAVSLEEHPYHKAEKSSVLKSKQEDHEESADQDQSYSQNLGSQEHEKSERDLIEN
hu m an  ( 5 1 )  ENEKETAVSTEDDSHHKAEKSSVLKSKEESHEQSAEQGKSSSQELGLKDQEDSDGHLSVN
m o u s e  ( 5 2 )  A ----------------- DIENHPNDKAEKPSALNSEEETHEQSTEQDKTYSFEVDLKDEEDGDGDL-----
r a t  ( 5 0 )  A ----------------- DIEKHPNHKAEKPSALNSEEEAHEQSTEQDKTYSFEVDLKDEEDGDGDL-----
' + + *+..* ** + + + + + ’ . + * + * * + + .
p i g  ( 1 2 1 )  SEYMPTEG— TLDLKEDMTEPQKEKFPESIDSLGHDDSSIVDSNQQESITKAEENQD-------
h u m a n  ( 1 1 1 )  LEYAPTEG— TLDIKEDMIEPQEKKLSENTDFLAPGVSSFTDSNQQESITKREENQEQPR
m o u s e  ( 1 0 2 )  SVD-PTEGtlTLDLQEGTSEPQQKSLPENGDFPATVSTSYVDPNQRANITKGKESQEQPV
r a t  ( 1 0 0 )  SVD-PTER--TLDLQEGTSEPQQKRLPENADFPATVSTPFVDSDQPANITKGEESQEQPV
. . **.*.*.*+*++++. . .+.++ ***. .++.................. *+*+*+**.+*++..****+
p i g  ( 1 7 6 )  — SHPQLNGSSKHSPDLSDRGNQGQDPDSPT------------------- GEEEGEKEPHEVDTLFDNQEE
h u m an  ( 1 6 9 )  NYSHHQLNRSSKHSQGLRDQGNQEQDPNISN-------------------GEEEEEKEPGEVGTHNDNQER
m o u s e  ( 1 6 1 )  SDSHQQPNESSKQTQDLKAEESQTQDPDIPNeeeeeeedEEEEEEEEPEDIGAPSDNQEE
r a t  ( 1 5 7 )  SDSHQQQDESGKQTQDSMTEESHKQDPGIPN------------------- EEKEEEEDPEDVGAPSDNQEE
p i g  ( 2 2 6 )  EREVLQEQSNSEQEEDSTRSDDILEESYQPTQASKMQKDEFEQGNQGrEEENANAETEEE
hu m an  ( 2 2 1 )  KTELPREHANSKQEEDNTQSDDILEESDQPTQVSKMQEDEFDQGNQE-QEDNSNAEMEEE
m o u s e  ( 2 2 1 )  GKEPLEEQPTSKWEGNREQSDDTLEESSQPTQISKTEKHQSEQGNQG-QESDSEAEGEDK
r a t  ( 2 0 9 )  EKEPPEEQPTSKWEGNGDQSEDILQESSQPTQISKT-KNDFEQGSQG-QEGDSNAEGEDK
. * + .  . . + + . + +  + * * *  . + + * + * + + + + ’
p i g  ( 2 8 6 )  TASKITKPNQEREWQSPEGKPGLEVISNHEEMD-KKTLAKPLLVEPTDDDNVMPRNHGA-
hu m an  ( 2 8 0 )  NASNVNKHIQETEWQSQEGKTGLEAISNHKETE-EKTVSEALLMEPTDDGNTTPRNHGVd
m o u s e  ( 2 8 0 )  AAGS-KEHIPHTEQQDQEGKAGLEAIGNQKDTD-EKAVS TEPTDAA-VVPRSHGG-
r a t  ( 2 6 7 )  AAGS-KEHLPHTEWQGQEGRAGLDAIGNRKDTDeEKAVS TEPTDAA-VVPRNHGA-
. . + + + + ’ . . + * + * + * * + * ' + * + . . . * + ..............
p i g  ( 3 4 4 )  ------- DDDSDD------DD-EHNASEDAFNPSEAYLERERAPSNYYHTKY— EEQREKAHEGENV
hu m an  ( 3 3 9 )  dDGDDDGDDggtDGpRHSASDDYFIPSQAFLEAERAQSIAYHLKI— EEQREKVHENENI
m o u s e  ( 3 3 2 )  -AGDNGGGD------DS-KHGAGDDYFIPSQEFLEAERMHSLSYYLKYggGEET-TTGESEN-
r a t  ( 3 2 0 )  — SDNGGGD------DS-KHGASDDYFIPSQEFLEAERMHSLSYYLKY— GEET— PDESEN-
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Jr +4-*******  + ** + *+ + *******  *
pig (395) DTSEAAENQGAKKAEGSPNEDDSSTEGTTRGHSVDSCMSFQCKRGHICKADQQGKPHCVC
human (397) GTTEPGEHQEAKKAENSSNEEETSSEGNMRVHAVDSCMSFQCKRGHICKADQQGKPHCVC
mouse (385) -RREAADNQEAKKAESSPNAEPSD-EGNSREHSAGSCTNFQCKRGHICKTDPQGKPHCVC
rat (369) -RSEAGDNQGAKKAESSPNAEPSD-EGNSRGHSADSCMNFQCKRGHTCKTDQHGKPHCVC
* * * -k -k -k -k -^ -k k'k-k^ 'k-k-k'k'k'kk'k'kkkk-k'k'k'k'k'k'k. '^k'k'k'k'kk'k-k-k'kk'k'k-k'k'k'k'k'k'k'k'k^ -k'k
pig (455) QDPVTCPPTKLLDQVCGTDNQTYASSCHLFATKCRLEGTKKGHQLQLDYFGACKSIPACT
human (457) QDPVTCPPTKPLDQVCGTDNQTYASSCHLFATKCRLEGTKKGHQLQLDYFGACKSIPTCT
mouse (443) QDPETCPPAKILDQACGTDNQTYASSCHLFATKCRLEGTKKGHQLQLDYFGACKSIPACT
rat (427) QDPETCPPAKILDQACGTDNQTYASSCHLFATKCMLEGTKKGHQLQLDYFGACKSIPACT
k  k  k  -k k k k k k k k k k k k k k k k k k k k ^ k . ^ ^ k . ^ k k k k k k k k . ^ k k k k k k k k k k k k k k k k k ^ k ^ k
pig (515) DFEVTQFPLRMRDWLKNILMQLYEPNPEHAGYLNEKQRNKVKKIYLDEKRLLAGDHSIDL
human (517) DFEVIQFPLRMRDWLKNILMQLYEANSEHAGYLNEKQRNKVKKIYLDEKRLLAGDHPIDL
mouse (503) DFEVAQFPLRMRDWLKNILMQLYEPNPKHGGYLNEKQRSKVKKIYLDEKRLLAGDHPIEL
rat (487) DFEVAQFPLRMRDWLKNILMQLYEPNPKHGGYLNEKQRSKVKKIYLDEKRLLAGDHPIEL
k k k k k k k k k k k k k k k k k k k k . j . k k k k k k ^ k k k k k k k k k k k k k k k k k k k k k k k k k k k . ] . k k k k
pig (575) LLRDFKKNYHMYVYPVHWQFSELDQHPRDRVLTHSELAPLRASLVPMEHCITRFFGECDP
human (577) LLRDFKKNYHMYVYPVHWQFSELDQHPMDRVLTHSELAPLRASLVPMEHCITRFFEECDP
mouse (563) LLRDFKKNYHMYVYPVHWQFNELDQHPADRILTHSELAPLRASLVPMEHCITRFFEECDP
rat (547) LLRDFKKNYHMYVYPVHWQFNELDQHPADRILTHSELAPLFLASLVPMEHCITRFFEECDP
k k k k k k k k k k k k k k k . ^ k k k k k k k k k k k k
pig (635) NKDKHITLKEWGRCFEIKEEDIDENLLF
human (637) NKDKHITLKEWGHCFGIKEEDIDENLLF
mouse (523) NKDKHITLKEWGHCFGIKEEDIDENLLF
rat (607) NKDKHITLKEWGHCFGIKEEDIDENLLF
* = hom ologous; +  = limited h om ologou s;. =  not hom ologous.
Figure 5.4. Pile-up o f SPARCL-1 deduced amino acid sequences fo r pig, human, 
mouse and rat.
Only 76% homology amino acid sequence was found between porcine and human 
SPARCL-1. However, when compared the FS domain and EC domain, it shows 100% 
and 98.6% similarity between the 2 species (Fig. 5.5). Moreover, porcine and mouse 
SPARCL-1 also has shown 99.8% and 98.6% similarity for FS domain and EC 
domain. The differences between the species were mainly at Domain I.
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Porcine
SPARCL-1
Human
SPARCL-1
Mouse
SPARCL-1
Acidic FS EC
Acidic FS EC
63.1% 100% 98.6%
Acidic FS EC
49% 99.8% 98.6%
Figure 5.5. Comparison o f SPARCL-1 domain deduced amino acid sequences fo r pig, 
human and mouse.
5.3.2. Recombinant SPARCL-1 adenovirus production
The SPARCL-1 PCR 5’ and 3’ primers were used to amplify the coding sequence of 
SPARCL-1 in PCR. Gel electrophoresis of the 2.2 kb RT-PCR products is shown in 
Figure 5.6.A. TOPO-SPARCL-1 vector was digested with EcoK I and Xho I 
restriction enzymes to ascertain the SPARCL-1 insert (Figs. 5.6.B and C). The 
required DNA insert was excised and cloned into pDNR-CMV for recombinant 
adenovirus production. pDNR-CMV-SPARCL-1 vector was digested with EcoK I 
and Xho I restriction enzymes to ascertain the clones containing the appropriate 
SPARCL-1 insert (Figs. 5.7.A and B).
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SPARCL-1 
2.2 kb 
(Lane 2)
4
Topo-vector 
3.9 kb
SPARCL-I 
2.2 kb
X h o I{A \)
f1 origin
SPARCL-1 
(2.2 kb)
BamH I (4837)
EcoR I (3963) 
f ia m //7 (3932)
Topo-SPARCL-1
6 1 8 9  b p
Kan
pUC origin
Figure 5.6. Cloning of SPARCL-1 into TOPO vector. (A) Gel electrophoresis of the 2.2
kb RT-PCR with the use of sense  and anti-sense primers (Lane 2). S ense primer with 
template DNA alone in Lane 1 as control; no band was detected. (B) Gel electrophoresis 
after digestion of TOPO-SPARCL-1 with Xho I and EcoR I; SPARCL-1 segm ent (2.2 kb) and 
topo vector (3.9 kb) were shown. (C) TOPO vector with SPARCL-1 insert. The SPARCL-1 
insert is about 2.2 kb with EcoR I restriction in 5’ and Xba I restriction site in 3' ends.
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CMV promoter
pUC origin loxP beta-globin intron
£co/? 7(1260)
SacB
pDNR-CMV-SPARCL-1
10324 bp
hrGFP
SPARCL-1 
(2.2 kb)
Xho1(3527)
3x FLAG
hGH polyA
B pDNR-CMV 
vector 
8.1 kb
•4-----
SPARCL-1 
2.2 kb 
(Lanes 1-5)
Figure 5.7. Cloning of SPARCL-1 into pDNR-CMV vector. (A) The pDNR-CMV with 
SPARCL-1 cDNA insert is 10.3 kb. The SPARCL-1 fragment is 2.2 kb with EcoR I restriction 
in 5’ and Xho I restriction site in 3’ ends. (B) Digestion of pDNR-CMV-SPARCL-1 with Xho I 
and EcoR I. Lanes 1-5 are clones with the appropriate cloned 2.2 kb insert.
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After the correct pDNR-CMV-SPARCL-1 clones were identified by restriction 
mapping, gene sequencing was performed to confirm an intact start codon at the 5’ 
end and a FLAG epitope was cloned in frame at the 3’ end. SPARCL-1 internal 5’ 
primer (5’ TGG GTC GAG CCA CCT ACC T 3’) was used to detect the start codon 
at the 5’ end. Another SPARCL-1 internal 3’ primer (5’ CAC TCT GAG CTC GCT 
CCT TTG 3’) was used to detect FLAG epitope at the 3’ end. These primers used 
are highlighted in grey in Figure 5.3. Sequencing results confirmed that both the start 
codon and the FLAG epitope are correctly cloned. The sequence of the FLAG 
epitope at the 3’ end is shown (Fig. 5.8).
Nucleotide sequence
GAAAATCTCCTGTTT CTC GAG fiAC TAC AAG GAT GAC GAT GAC AA^ 
Ba g GAC GAT GAT AAgj RÂC TAT AAG GAT GAT GAC GAC ÀÂ3
CAATTCCTCGACGACTGCATAGGG
Deduced amino acid sequence
E N L L F L E p Y K D D D D i a  D Y K D D p Y K D P D P K
Q F L D D C I G
Figure 5.8. 3x FLAG and  s to p  codon  of SPARCL-1 in pDNR-CMV vector. The 3X
FLAG sequence is highlighted in blue, while the stop codon is highlighted in red.
5.3.3. SPARCL-1 over-expression in C2C12 cells by adenovirus infection and by 
stable transfection
To assess the function of SPARCL-1 in muscle cells, SPARCL-1 was over-expressed 
in C2C12 muscle cells by stable transfection with pBK-CMV-SPARCL-1 plasmid 
(Fig. 5.7.A) as well as by infection with a SPARCL-1-adenovirus construct (Fig. 5.9).
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Expression of both constructs could be demonstrated by SPARCL-1 mRNA detection 
(Fig. 5.9.A). Cell cytotoxicity assays that measured metabolic capacity showed no 
significant difference between infected/transfected cells, and control cells over an 
extended period of 10 days differentiation, which indicated similar cell viability (Fig.
5.9.B). This finding also indicates that over-expression of SPARCL-1 is not 
detrimental to C2C12 cells. Western blot was performed to detect SPARCL-1 
proteins. SPARCL-1 is a secreted matricellular protein. However, no prominent 
SPARCL-1 bands were detected with anti-FLAG primary antibody (Sigma) (data not 
shown). The secretion of SPARCL-1 might account for the failure of its detection by 
conventional Western analysis.
-adenovirus infection SPARCL-I-^Xdih\Q transfection
= 4.00I
g- 3.0 
S 2.01I 1.0 ?as 0.5
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3.5 0.030
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S p a r ( , . i  00:0
GFP 0.005
Sparcl-1
Plasmid control
31 31 3D 31 6D DM  3DPM DM  6D
Figure 5.9. (A) Over-expression of S P A R C L -1  in C 2C 12  cells. SPARCL-1 expression, 
through infection with an adenovirus construct and through stable transfection with an expression 
plasmid (Fig.S.I.B), was determined over a time course. Proliferating cells were infected for 3 
days in proliferation medium [PM] (31), followed by 3 days in differentiation medium [DM] (31 3D) or 
6 days in DM (31 6D). Stably transfected cells were incubated for 3days in PM (PM), followed by 3 
days in DM (DM 3D) or 6 days in DM (DM 6D). Results expressed as mean ± standard deviation 
from triplicate sam ples within the sam e experiment.
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Figure 5.9. (B) Cell viability a ssa y  of SPA/?CL-f-Infected and  SPARCL-1-stably 
transfec ted  C2C12 cells. The viability of SPARCL-f-infected and SPARCL-1- 
transfected 02 0 1 2  cells was similar to control cells over an extended culture period, as 
demonstrated by cell cytotoxicity assay  (OellTiter-Blue kit, Promega). Results expressed 
as  mean ± standard deviation from triplicate sam ples within the sam e experiment.
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5.3.4. SPARCL-1 over-expression decreased C2C12 cell proliferation but did not 
affect fusion
Proliferation assays were performed in stably transfected C2C12 cells by quantifying 
cell number with a Neubauer haemocytometer. SPARCL-1 over-expressed C2C12 
cells showed significant decreases in cell proliferation compared with plasmid control 
cells (Fig. 5.10.A). In addition, BrdU assays were performed on SPARCL-1 
adenovirus infected and stably transfected C2C12 cells. Both constructs showed a 
decrease in proliferation compared with control GFP cells (Fig. 5.10.B). SPARCL-1- 
stably transfected C2C12 myotubes (differentiated for 9 days) were separately 
immunostained for desmin, MyHC fast and MyHC slow, along with DAPI nuclei 
staining (Fig. 5.10.C). Fusion index quantification on immunostained images showed 
no significant difference between SP^i?CZ.-7-transfected and control cells (Fig.
5.10.D).
5.3.5. SPARCL-1- over-expression depressed expression of muscle genes
No obvious differences in MyHC expression were detected between SPARCL-1- 
infected and control C2C12 cells at the early infection time point (31) (Fig. 5.11). 
However, reductions in the expression of all skeletal MyHC isoforms, Myf-5 and a- 
actin in SPARCL-l-mÏQoXQd C2C12 myotubes were noticeable at the later stages of 
differentiation (31 3D and 31 6D). The overall results of extended SPARCL-1 over­
expression indicated a reduction in the expression of regulatory and structural muscle 
genes.
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GFP or Control 
SPARCL-1
Adenovirus-Infected Stably transfected
Figure 5.10. O ver-expression of SPARCL-1 reduced  C2C12 cell proliferation. (A) SPARCL- 
1 over-express C2C12 cells showed significant reduce in cell proliferation compared with plasmid 
control cells. (B) BrdU assay  was performed on SPARCL-f-infected and adenovirus-GFP 
control cells, as well as  SPARCL-f-transfected and vector only-transfected cells. For both 
approaches, SPARCL-1 over-expression significantly reduced cell proliferation. Results were 
analysed with SAS software, differences between pair-wise combinations of the least square 
m eans were tested for significance (*p<0.05). Error bars were standard error, n=3 replicates 
from 3 independent experiments.
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Control SPARCL-1-stdibXy transfected
desmin
MyHC fast
MyHC slow
Figure 5.10. (C) Immunostalning of SPARCL-f-stably transfected C2C12 
cells. SPARCL-1-siab\y transfected C2C12 myotubes (differentiated for 9 days) 
were separately immunostained for desmin, MyHC fast and MyHC slow, along 
with DAPI nuclei staining.
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Figure 5.10. (D) O ver-expression of SPARCL-1 on C2C12 cell differentiation. Results 
showed no significant difference between SPARCL-f-transfected and control cells. 
Results were analysed with SAS software, differences between pair-wise combinations of 
the least square m eans were tested for significance (*p<0.05). Asterisks indicate 
statistical significance. Error bars were standard error, n=3 replicates from 3 independent 
experiments.
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Figure 5.11. Muscle gene expression in SP>)RCL-f-adenovirus infected C2C12 cells.
Real-time PCR was performed on cDNAs derived from infected cells over a time course as 
detailed in Fig. 5.9. No dramatic difference in MyHC expression between SPARCL-1- 
infected and control 02 0 1 2  cells was seen during the early infection (31). However in the 
later time point (3I3D and 3I6D), reductions in expression of all MyHC  isoforms, Myf-5 and 
a-actin in SPARCL-1-infected 02 0 1 2  myotubes were noticeable. Results expressed as 
m ean ± standard deviation from triplicate sam ples within the sam e experiment.
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5.3.6. SPARCL-1 expression in PCS muscles, and interactions between SPARCL- 
1 and P311
SPARCL-1 was previously suggested as differentially expressed in PCS (Maak et al., 
2001). The relative expression of porcine SPARCL-1 in affected and normal muscles 
was determined. No significant difference in SPARCL-1 expression was found 
between affected and normal piglets, which suggest that SPARCL-1 is not associated 
with PCS (Fig. 5.12).
To assess the interaction of SPARCL-1 with P311, C2C12 cells were infected with 
SPARCL-1-adenovirus construct as described in Section 5.2.2 over a time course. No 
difference of P311 endogenous expression in SPARCL-1 over-expressed cells was 
detected (Fig. 5.13). These results indicate that over-expression of SPARCL-1 has no 
apparent effect on endogenous expression o f P311.
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Figure 5.12. Q uantitative PCR perform ed for SPARCL-1 exp ression . No significant difference 
was found between normal and PCS piglets for the combined results of 4 sets of 2-day-old PCS 
piglets. Results of each litter are expressed as  mean ± standard deviation from triplicate sam ples 
within the sam e experiment. Combined results of 4 sets of PCS piglets were also tested for 
significance (*p<0.05) in differences between pair-wise combinations of the least square means. 
Norm= normal; PCS= porcine congenital splayleg.
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Figure 5.13. E xpression  in teraction  betw een SPARCL-1 and P311. Real-time 
PCR was performed on cDNAs derived from infected cells over a time course as 
detailed in Fig. 5.9. No difference of P311 endogenous expression in SPARCL-1 
over-expressed cells. There are no apparent linkage between SPARCL-1 and P311 
at RNA level. Results expressed as  mean ± standard deviation from triplicate 
sam ples within the sam e experiment.
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5.4. Discussion
A full-length porcine SPARCL-l cDNA clone was sequenced and molecularly 
characterised (Accession. N-. EF416571). The full-length porcine SPARCL-1 cDNA 
was 2.8 kb and the coding sequence was 2.0 kb in length. Although the deduced 
amino acid sequence of porcine SPARCL-1 is only 76% homologous to human 
SPARCL-1, the FS domain and EC domains showed 100% and 98.6% similarity 
respectively, between the 2 species (Fig. 5.5). These two domains are the hall-marks 
of SPARC family proteins. The FS domain is involved in the inhibition of activin, 
and thereby inliibits release of follicle stimulating hormone, while EC domain is 
involved in binding both calcium and collagen (Pottgiesser et ah, 1994). The acidic 
domain of porcine SPARCL-1 only showed 63.1% similarity to human SPARCL-1 
(Fig. 5.5); it is the most divergent portion among the family of SPARC-like proteins. 
No direct link of the domains function with skeletal muscles has been reported.
Although SPARCL-1 was previously highlighted in a PCS paper (Maak et ah, 2001), 
no significant difference in expression between affected and normal piglets was 
detected (Fig. 5.12). Hence, SPARCL-1 is unlikely to be linked to PCS. In addition, 
there is no apparent expression interaction between SPARCL-1 and P311 at the RNA 
level (Fig. 5.13). No SPARCL-1 protein could be detected by Western blotting. 
Given that cells transfected or infected with SPARCL-1 showed biological effects of 
reduced proliferation and reduced muscle gene expression, it was likely that the 
protein product was translated. Since SPARCL-1 is a matricellular secreted 
glycoprotein, protein levels could be higher in culture supernatants. By generating rat 
anti-SPARCL-1 monoclonal antibodies and the use of immunoprécipitation, 
SPARCL-1 protein was successfully detected (Brekken et ah, 2004). In future, to
2 0 1
improve on SPARCL-1 protein detection, cell culture supernatants could be collected 
along with cell lysate for detection.
As far as can be determined, there is no information about function of SPARCL-l in 
skeletal muscle. In this study, SPARCL-1 over-expression in C2C12 skeletal muscle 
cells led to the reduction in cell proliferation (Fig. 5.10) and down-regulation of 
MyHC isoforms expression during late differentiation (Fig. 5.11.). SPARCL-1 is 
reported as a negative regulator of cell proliferation and cell differentiation when 
over-expressed in HeLa 3S cells (human uterine cervical cells) (Claeskens et ah, 
2000). Moreover, smooth muscle cells isolated from SPARC-null mice exhibited a 
higher rate of proliferation relative to their wild-type counterparts (Bradshaw et al.,
1999). Hence, SPARCL-1 might act as a negative regulator of cell proliferation and 
cell differentiation in skeletal muscle.
Among the SPARC family members, SPARCL-1 displays the highest amino acid 
similarity with SPARC^ sharing 55.6% identity at FS domain and 61.4% identity at EC 
domain. Given their structural similarities, SPARCL-1 could exhibit similar function 
as SPARC, such as the anti-adhesive properties in endothelial cell culture (Girard and 
Springer, 1996). However, the functions of SPARC and SPARCL-1 could be tissue 
specific (Framson and Sage, 2004). The expression of SPARCL-1 endogenous level 
during myoblast differentiation is unknown, but SPARC endogenous expression was 
reported to be highly up-regulated during differentiation of C2C12 cells (Cho et ah,
2000). SPARC was suggested to play a role in fusion during myoblast differentiation 
(Cho et ah, 2000). Given that SPARCL-1 displays high amino acid similarity with 
SPARC, SPARCL-1 could exhibit similar function to SPARC. Endogenous
2 0 2
expression may be required for myoblast differentiation, but over-expression could 
lead to the down-regulation of muscle genes in late differentiation. Although 
SPARCL-1 was not related to PCS, over-expression of this gene demonstrated its 
important role in regulating skeletal muscle proliferation and differentiation. Clearly, 
more work is needed to further investigate its potential in skeletal muscle.
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Chapter 6
General discussion
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The aim of this study is to investigate the cellular and molecular changes in skeletal 
muscles of PCS. This project is the first to detail the histological, biochemical and 
molecular changes that take place in muscles of PCS. Results showed that PCS 
piglets had smaller fibre size and higher fibre density in the semitendinosus (ST), 
longissimus dorsi (LD) and gastrocnemius (G) muscles. PCS associated atrophy was 
not accompanied by significant changes in fibre type composition as determined by 
immunohistochemistry. However, the expression of MyHC slow, MyHC 2x and 
MyHC 2b gene was significantly reduced, as demonstrated by real-time RT-PCR. 
MAFhx, a marker of muscle atrophy, was highly expressed in all PCS muscles. 
Conversely, expression of P311, a novel 8-kDa protein with a conserved PEST 
domain, was down-regulated in all PCS muscles tested.
Full-length porcine P311 (Accession. N°. EF416570) and SPARCL-1 (Accession. N~. 
EF416571) cDNA clones were sequenced and characterised in this project. The 
coding sequence for porcine P311 and SPARCL-1 cDNA was 0.3 kb and 2.0 kb in 
length respectively. The deduced amino acid sequence of porcine P311 and 
SPARCL-1 was 87% and 76% homologous to their human counterpart. P311 over­
expression led to raised C2C12 cell proliferation and reduced myotuhe formation. 
Consistent with reduced myotube formation, expression of several muscle genes 
{MyHC embryonic, MyHC 2b, a-actin and myf-5) was down-regulated in late 
differentiation of Rdf 7-over-expressed C2C12 cells. In contrast, SPARCL-1 over­
expression led to reduction in C2C12 cell proliferation. No difference in fusion index 
was found, but -over-expressed C2C12 cells down-regulated MyHC
isoforms, Myf-5 and a-actin expression during late differentiation. SPARCL-1 might 
act as a negative regulator of cell proliferation and differentiation. SPARC
205
endogenous expression was reported to be highly up-regulated during differentiation 
of C2C12 cells (Cho et ah, 2000). Given that SPARCL-1 displays high amino acid 
similarity with SPARC, SPARCL-1 may have similar functions to SPARC. 
Endogenous SPARCL-1 expression may be required for myoblast differentiation, but 
its over-expression could lead to the down-regulation of muscle genes in late 
differentiation.
Stickland and Handel (1986) have showed that there are variations in muscle fibre 
numbers between piglets. In PCS muscles, reduced P311 expression could 
conceivably mediate fibre atrophy tlirough reduced cell proliferation, leading to 
reduced availability of total myoblast number in the formation of muscle fibres. 
Moreover, reduced myoblast number could potentially lead to the formation of less 
muscle fibres, hence myofibre hypoplasia. Future work will require detailed total 
fibre counting to determine if myofibre hypoplasia is also a feature of PCS muscles. 
Although SPARCL-1 was previously highlighted in a PCS paper (Maak et ah, 2003), 
no significant difference in expression between PCS affected and normal piglets was 
detected. In addition, there is no apparent expression interaction between SPARCL-1 
and P31L
Currently, the precise aetiology and pathogenesis of PCS remain unknown, but PCS is 
believed to be a multifactorial condition which involves environmental and genetic 
factors. The environmental factors could include sow management, the 
administration of various drugs and my cotoxins (reviewed in Chapter 1). A 
combination of history and management evaluation can be used to identify the 
possible involvement of such factors. In this project, the PCS samples collected did
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not show any apparent evidence of strong environmental factors. Proper sow 
management by the provision of adequate bedding and a dry floor in farrowing crate 
ruled out the possibility of PCS due to slippery floor. Administration of certain drugs 
such as glucocorticoids, pyrimethamine and prostaglandin in pregnant sow have been 
shown to lead to PCS (Jirmanova, 1983; Ohnishi et ah, 1989; Bolcskei et ah, 1996). 
None of the drugs were in use on the farm where the PCS affected piglets originated. 
All pregnant sows in the farm from which the piglets came were on the same diet. 
Consumption of mycotoxins could be expected to extensively affect all litters in a 
herd. However, all PCS samples collected were sporadic and isolated cases. 
Interestingly, all the PCS affected piglets collected for this study were male, which 
may suggest that males are more susceptible to PCS, which is in line with previous 
reports (Vogt et ah, 1984; Van Der Heyde et ah, 1989). The lack of obvious 
environmental factors in the farm of origin suggests that PCS is connected to genetic 
factors. The mixture of semen from several boars in artificial insemination hinders 
the identification of any possible sire involvement. Parental and sibling genotyping 
could establish the parental linkage of affected individuals.
PCS can be easily identified from the clinical signs, however there are some piglets 
that may be sub-clinically affected. The sub-clinical condition may not be life 
thi'eatening as is clinical PCS. Since PCS might be genetically determined, it is useful 
to detect sub-clinically affected PCS piglets in order to remove them from breeding 
programmes to reduce the genetic predisposition. Sub-clinical PCS might exhibit 
similar expression of MAFbx and P311 as clinical PCS. Muscle biopsy of suspected 
piglets accompanied by real time RT-PCR of P311 and MAFbx could be used to 
detect the sub-clinical PCS condition, but the diagnostic procedure is costly and
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laborious. To explore the potential of MAFbx and P311 as biomarkers in the 
diagnosis of sub-clinical PCS, more research work is needed. In future, a larger 
sample size of PCS and normal piglets could be obtained to determine the consistency 
and repeatability of the expression pattern. Moreover, comparisons between PCS and 
other myopathies, such as arthrogryposis, could be made in relation to MAFbx and 
P311 expression. The detection of P311 protein as a potential biomarker is limited by 
its high lability and short half life. In future, with improved protein preservation and 
detection methods, P311 and MAFbx proteins could be used in clinical practice as 
protein markers to distinguish sub-clinically PCS affected piglets from normal piglets. 
Such an application will be of the greatest value in nucleus herd breeding programmes.
The total number of skeletal muscle fibres (hyperplasia) in pig is virtually fixed 
before birth (Wigmore and Stickland, 1983). Postnatal muscle growth continues by 
muscle fibre hypertrophy. This means that any manipulation of muscle fibre number 
must be undertaken prenatally. In pigs, the primary fibre and secondary fibre 
formations occur around 30-50 days and 50-90 days of gestation respectively 
(Wigmore and Stickland, 1983). However, it is impossible to diagnose PCS affected 
piglets at present merely based on the visualisation of foetuses. PCS affected piglets 
can only be identified and assessed after birth. Muscle fibre number is an important 
determinant of postnatal growth. Littermates with higher fibre number tend to 
outgrow other littermates (Dwyer et ah, 1993). At present, it is not certain if PCS- 
associated fibre atrophy is also accompanied by fibre hypoplasia. Even though 50% 
of the PCS affected piglets may recover within a week, it may not he economical to 
attend to affected piglets. PCS affected piglets might not grow as efficiently as the 
healthy littermates.
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Porcine muscle satellite cells could be collected from PCS and normal piglets as an in 
vitro approach in the future. Porcine muscle satellite cells have been successfully 
isolated to study IGF-1 expression, proliferation and differentiation (Fligger et al., 
1998; Mesires and Doumit, 2002). PCS muscle satellite cells may exhibit different 
gene expression patterns compared with normal muscle satellite cells. It would be 
interesting to determine the relative expression of P311 and MAFbx in PCS and 
normal satellite cells over a time-course.
Study on muscle iimeiwation was not done in this project. Previously, smaller size 
and irregularly distribution of motor endplates were found in PCS muscles compared 
to normal muscles (Hanzlikova, 1980). In future, it will be interesting to investigate 
the nerve supply of PCS muscles. Sciatic nerve would be a prime start, since it 
supplies some of the hindlimb muscles, a region commonly affected in PCS. 
Morphological, biochemical characteristic and neuromuscular transmission could be 
measured in both PCS affected and normal piglets to identify possible involvement of 
neuropathy in PCS (Lindstrom et ah, 1976; Somasekhar et ah, 1996).
A porcine skeletal muscle cDNA microarray, which comprised 5500 clones from two 
developmentally distinct cDNA libraries developed at the Molecular Medicine 
Laboratory (Bai et al., 2003) and several publicly and commercially porcine 
microarrays (from Ark-Genomics and Affymetrix) are readily available. Such arrays 
could be used to identify differentially expressed genes that could be involved in PCS. 
Genes that are up-regulated or down-regulated could be involved in PCS pathogenesis. 
However, PCS is a multifactorial condition and wide variation in endogenous gene
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expression between pigs might occur (Chang et ah, 2003). The challenge to any 
investigator is to identify the correct genes and demonstrate their functional 
significance in the pathogenesis of PCS.
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